



US00RE48060E

(19) **United States**
 (12) **Reissued Patent**
Bhanot et al.

(10) **Patent Number:** **US RE48,060 E**
 (45) **Date of Reissued Patent:** **Jun. 23, 2020**

(54) **ANTISENSE MODULATION OF PTP1B EXPRESSION** 2001/0053519 A1 12/2001 Fodor et al.
 2002/0055479 A1 5/2002 Cowser et al. A61K 48/00
 514/44 A

(71) Applicant: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US) 2002/0198203 A1 12/2002 Robert Vitou et al.
 2003/0108883 A1 6/2003 Rondinone et al.
 2003/0220282 A1 11/2003 Cowser et al.
 2003/0228597 A1 12/2003 Cowser et al.

(72) Inventors: **Sanjay Bhanot**, Carlsbad, CA (US); 2004/0005618 A1 1/2004 Yu et al.
Susan M. Freier, San Diego, CA (US) 2004/0009946 A1 1/2004 Lewis et al.
 2004/0019001 A1 1/2004 McSwiggen
 2005/0070497 A1 3/2005 McSwiggen et al.

(73) Assignee: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US) 2005/0095710 A1 5/2005 Cowser et al.
 2006/0025372 A1 2/2006 Bhanot et al.
 2006/0089325 A1 4/2006 Bhanot et al.

(21) Appl. No.: **15/183,700** 2007/0031844 A1 2/2007 Khvorova et al.
 2008/0015162 A1 1/2008 Bhanot et al.
 2008/0097092 A1 4/2008 Khvorova et al.

(22) Filed: **Jun. 15, 2016** 2009/0036355 A1 2/2009 Bhanot et al.
 2009/0124009 A1 5/2009 Bhanot et al.
 2009/0318532 A1 12/2009 Bhanot et al.
 2009/0318536 A1 12/2009 Freier et al.
 2010/0105134 A1 4/2010 Quay et al.
 2010/0197773 A1 8/2010 Bramlage et al.
 C12N 15/1137
 514/44 R

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **9,034,842**
 Issued: **May 19, 2015**
 Appl. No.: **14/152,896**
 Filed: **Jan. 10, 2014**

U.S. Applications:

(62) Division of application No. 13/446,763, filed on Apr. 13, 2012, now Pat. No. 8,658,783.

(60) Provisional application No. 61/474,981, filed on Apr. 13, 2011.

(51) **Int. Cl.**

A61K 48/00 (2006.01)
C07H 21/02 (2006.01)
C07H 21/04 (2006.01)
C12N 15/113 (2010.01)
A61K 31/7088 (2006.01)

(52) **U.S. Cl.**

CPC **C12N 15/1137** (2013.01); **A61K 31/7088** (2013.01); **C12Y 301/03048** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/322** (2013.01); **C12N 2310/3231** (2013.01); **C12N 2310/3341** (2013.01); **C12N 2310/34** (2013.01); **C12N 2310/341** (2013.01); **C12N 2310/346** (2013.01); **C12N 2320/30** (2013.01)

(58) **Field of Classification Search**

CPC A61K 48/00; C07H 21/02; C07H 21/04; C12N 15/113
 See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,726,027 A 3/1998 Olefsky
 5,801,154 A 9/1998 Baracchini et al.
 6,261,840 B1 7/2001 Cowser et al.
 6,261,849 B1 7/2001 Lee
 6,506,559 B1 1/2003 Fire et al.
 6,582,908 B2 6/2003 Fodor et al.
 6,602,857 B1 8/2003 Cowser et al.
 7,179,796 B2 2/2007 Cowser et al.
 7,427,672 B2 9/2008 Imanishi et al.
 7,563,884 B2 7/2009 Cowser et al.
 7,687,616 B1 3/2010 Bentwich et al.
 7,834,170 B2 11/2010 Khvorova et al.
 8,017,760 B2 9/2011 Bhanot et al.
 8,039,608 B1 10/2011 Bentwich

FOREIGN PATENT DOCUMENTS

WO WO 97/32595 9/1997
 WO WO 98/20024 5/1998
 WO WO 01/05954 1/2001
 WO WO 01/07655 1/2001
 WO WO 01/16312 3/2001
 WO WO 01/30801 5/2001
 WO WO 01/53528 7/2001

(Continued)

OTHER PUBLICATIONS

Abrahamson, "Clinical use of thiazolidinediones: Recommendations" *The American Journal of Medicine* (2003) 115:116S-120S.
 Adjei et al., "A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer" *Clinical Cancer Research* (2003) 9:115-123.

Agrawal et al., "Antisense Therapeutics: Is It as Simple as Complementary Base Recognition?" *Molecular Medicine Today* (2000) 6(2):72-81.

Ahmad et al., "Improved Sensitivity to Insulin in Obese Subjects Following Weight Loss is Accompanied by Reduced Protein-Tyrosine Phosphatases in Adipose Tissue" *Metabolism* (1997) 46:1140-1145.

(Continued)

Primary Examiner — Sharon Turner

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57)

ABSTRACT

Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

37 Claims, 3 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 02/59137	1/2002
WO	WO 02/10378	2/2002
WO	WO 02/44321	6/2002
WO	WO 02/064840	8/2002
WO	WO 02/092772	11/2002
WO	WO 03/007951	1/2003
WO	WO 03/070881	8/2003
WO	WO 03/099227	12/2003
WO	WO 2004/016735	2/2004
WO	WO 2004/046161	6/2004
WO	WO 2004/071407	8/2004
WO	WO 2005/021572	3/2005
WO	WO 2006/044531	4/2006
WO	WO 2007/131237	11/2007
WO	WO 2007/146511	12/2007
WO	WO 2008/109470	9/2008
WO	WO 2009/046141	4/2009
WO	WO 2010/089221	8/2010

OTHER PUBLICATIONS

- Arregui et al., "Impaired integrin-mediated adhesion and signaling in fibroblasts expressing a dominant-negative mutant PTP1B" *J. Cell. Biol.* (1998) 143:861-873.
- Asante-Appiah et al., "Protein tyrosine phosphatase: the quest for negative regulators of insulin action" *Am. J. Physiol. Endocrinol. Metab.* (2003) 284:E663-E670.
- Balsamo et al., "The nonreceptor protein tyrosine phosphatase PTP1B binds to the cytoplasmic domain of N-cadherin and regulates the cadherin-actin linkage" *J. Cell. Biol.* (1998) 143:523-532.
- Bhanot et al., "A Novel PTP-1B Antisense Inhibitor (ISIS 113715) Improves Insulin Sensitivity in Obese Hyperinsulinemic Rhesus Monkeys" *ADA Annual Meeting* (2003) Abstract 477-P.
- Branch et al., "A good antisense molecule is hard to fin" *TIBS* (1998) 23:45-50.
- Brand et al., "Dual PPAR alpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats" *American Journal of Physiology—Endocrinology and Metabolism* (2003) 284:E841-854.
- Brown-Shimer et al., "Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene" *Cancer Res.* (1992) 52:478-482.
- Cheatham et al., "Novel targets for the treatment of obesity: a review of progress" *Drug Discovery Today: Therapeutic Strategies* (2004) 1:227-235.
- Chen et al., "A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells" *Biochemistry* (1999) 38:384-389.
- Chen et al., "Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells" *J. Biol. Chem.* (1997) 272:8026-8031.
- Chernoff et al., "Cloning of a cDNA for a Major Human Protein-Tyrosine-Phosphatase" *Proc. Natl. Acad. Sci. USA* (1990) 87:2735-2739.
- Chin, "On the preparation and Utilization of Isolated and Purified Oligonucleotides" Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
- Clampit et al., "Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells" *Biochem. Biophys. Res. Commun.* (2003) 300:261-267.
- Cox et al., "Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans" *Drug Metabolism and Disposition* (2000) 28:772-780.
- Crooke et al., "Basic Principles of Antisense Therapeutics" *Antisense Research and Application* (1998) Chapter 1:1-50.
- Crooke, "Antisense therapeutics" *Biotechnology & Genetic Engineering Reviews* (1998) 15:121-157.
- Crystal et al., "Transfer of genes to humans: early lessons and obstacles to success" *Science* (1995) 270:404-410.
- Day, "Thiazolidinediones: a new class of antidiabetic drugs" *Diabetic Medicine* (1999) 16:179-192.
- Desmarais et al., "Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides" *Arch. Biochem. Biophys.* (1998) 354:225-231.
- Elchebly et al., "Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene" *Science* (1999) 283:1544-1548.
- Ferber, "New Clues Found to Diabetes and Obesity" *Science* (1999) 283:1423-1424.
- Friedmann et al., "Overcoming the Obstacles to gene therapy" *Scientific American* (1997) 276:96-101.
- Geary et al., "Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2'-methoxyethyl) modified antisense oligonucleotide: comparison across species" *Drug Metabolism and Disposition* (2003) 31:1419-1428.
- Goldstein et al., "Regulation of the insulin signalling pathway by ceullular protein-tyrosine phosphatases" *Mol. Cell. Biochem.* (1998) 182:91-99.
- Goldstein et al., "Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2 Diabetes Mellitus, Obesity and Related States of Insulin Resistance" *Curr. Drug Targets—Immun. Endocrin. Metab. Disorders* (2001) 1:265-275.
- Goldstein, "Protein-tyrosine phosphatases: Emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance" *The Journal of Clinical Endocrinology & Metabolism* (2002) 87:2474-2480.
- Goldstein et al., "Tests of Glycemia in Diabetes" *Diabetes Care* (2004) 27:1761-1773.
- Graham et al., "In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotides Within Rat Liver after Intravenous Administration" *J. Pharm. Exp. Ther.* (1998) 286:447-458.
- Guan et al., "Cloning and Expression of Protein-Tyrosine-Phosphatase" *Proc. Natl. Acad. Sci. USA* (1990) 87:1501-1505.
- Gum et al., "Antisense Protein Tyrosine Phosphatase 1B Reverses Activation of p38 Mitogen-Activated Protein Kinase in Liver of ob/ob Mice" *Molecular Endocrin.* (2003) 17:1131-1143.
- Gum et al., "Reduction of Protein Tyrosine Phosphatase 1B Increases Insulin-Dependent Signaling in ob/ob Mice" *Diabetes* (2003) 52:21-28.
- Ham et al., "Selective inactivation of protein tyrosine phosphatase PTP1B by sulfone analogue of naphthoquinone" *Bioorg. Med. Chem. Lett.* (1999) 9:185-186.
- Hassid et al., "Antisense oligonucleotides against protein tyrosine phosphatase 1B increase focal adhesion protein phosphorylation and migration in rat aortic smooth muscle cells" in Supplement to Circulation, Journal of the American Heart Association, Abstracts from 71st Scientific Sessions (1998) Abstract No. 1733.
- Hassid et al., "NO Alters Cell Shape and Motility in Aortic Smooth Muscle Cells via Protein Tyrosine Phosphatase 1B Activation" *Am. J. Phys.* (1999) 277:H1014-1026.
- Hassid et al., "Role of PTP1B in Aortic Smooth Muscle Cell Motility and Tyrosine Phosphorylation of Focal Adhesion Proteins" *Am. J. Phys.* (1999) 277:H192-198.
- Henry et al., "Toxicology and Pharmacokinetic Properties of Chemically Modified Antisense Oligonucleotide Inhibitors of PKC-Alpha and C-Raf Kinase" *Anti-Cancer Drug Design* (1997) 12:409-420.
- Ho et al., "Mapping or RNA Accessible Sites for Antisense Experiments with Oligonucleotide Libraries" *Nature Biotech.* (1998) 16:59-63.
- Hormes et al., "The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells" *Nucleic Acids Res.* (1997) 25:769-775.
- Huang et al., "Antisense to protein tyrosine phosphatase 1B increases Tyrosine Phosphorylation of Focal Adhesion Protein in Aortic Smooth Muscle Cells of Rats" *FASEB* (1998) 12:A188, Abstract No. 1099.
- James et al., "Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes" *Antiviral Chem. and Chemotherapy* (1991) 2:191-214.

(56)

References Cited

OTHER PUBLICATIONS

- Koizumi et al., "In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides." *Nucleic Acids Symp. Ser.* (2007) 51:111-112.
- Kjems et al., "Increased Insulin Sensitivity in Humans by Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibition-Evaluation of ISIS 113715, an Antisense Inhibitor of PTP-1B" *San Diego ADA Annual Meeting* (2005) Abstract 2201-PO.
- Ko et al., "The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus" *Metabolism* (2003) 52:731-734.
- Lamontagne et al., "Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells" *Proc. Natl. Acad. Sci. USA* (1998) 95:14094-14099.
- Lee et al., "Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor" *J. Biol. Chem.* (1998) 273:15366-15372.
- Liu et al., "Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor" *Biochem. J.* (1997) 327:139-145.
- Liu et al., "Protein tyrosine phosphatase 1B negatively regulates integrin signaling" *Curr. Biol.* (1998) 8:173-176.
- Liu et al., "Transformation suppression by protein tyrosine phosphatase 1B requires a functional SH3 ligand" *Mol. Cell. Biol.* (1998) 18:250-259.
- Liu et al., "Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and Type II diabetes" *Curr. Opin. Invest. Drugs* (2002) 3:1608-1616.
- Liu, "Technology evaluation: ISIS-113715, Isis," *Curr. Opin. Mol. Therap.* (2004) 6:331-336.
- Madsbad et al., "Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a week, double-blind, randomized, controlled trial" *Diabetes Care* (2004) 27:1335-1342.
- Mani et al., "Phase I clinical and pharmacokinetic study of protein kinase C- α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer" *Clinical Cancer Research* (2002) 8:1042-1048.
- Mauvais-Jarvis et al., "Therapeutic perspectives for type 2 diabetes mellitus: Molecular and clinical insights" *Diabetes & Metabolism* (2001) 27:415-423.
- McKay et al., "Effects of a Novel PTP-1B Antisense Oligonucleotide Inhibitor (ISIS 113715) on PTP-1B Expression in Different Liver Cell Types" *ADA Annual Meeting* (2003) Abstract 611-P.
- Meriden, "Progress with thiazolidinediones in the management of type 2 diabetes mellitus" *Clinical Therapeutics* (2004) 26:177-190.
- Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" *Nature* (1997) 15:537-541.
- Moller et al., "Protein tyrosine phosphatases (PTPs) as drug targets: Inhibitors of PTP1B for the treatment of diabetes" *Curr. Opin. Drug Discov. Dev.* (2000) 3:527-540.
- Monia, "Protein Phosphatases" *FASEB Summer Conference presentation on Protein Phosphatases in Colorado*, Jul. 23-28, 2000, poster presentation, 14 pages.
- Monia, "Protein Phosphatases" *FASEB Summer Conference presentation on Protein Phosphatases in Colorado*, Jul. 23-28, 2000, oral presentation, 20 pages.
- Murray et al., "Additive Glucose Lowering Effects of a Novel PTP-1B Antisense Oligonucleotide (ISIS 113715) with Rosiglitazone and Metformin in ZDF Rats" *San Diego ADA Annual Meeting* (2005) Abstract 1545-P.
- New England Biolabs 1998/1999 Catalog, cover page, pp. 121 and 284.
- Nuss et al., "Effects of Protein Tyrosine Phosphatase 1B (PTP1B) Antisense Oligonucleotide (ASO) Treatment on Fat Volume Using MRI in Zucker Fatty Rats" *Diabetes* (2001) 50:A377.
- Palu et al., "In Pursuit of new developments for gene therapy of human disease" *J. Biotech.* (1999) 68:1-13.
- Parker, "Preclinical studies and clinical trials for diabetes—second annual forum: Identify emerging therapies and improve trial efficacy" *Idrugs* (2004) 7:37-39.
- Peracchi et al., "Prospects for antiviral ribozymes and deoxyribozymes" *Rev. in Med.* (2004) 14:47-64.
- Pihl-Carey, "Isis to Restructure as Crohn's Disease Drug Fails in Phase III" *BioWorld Today (The Daily Biotechnology Newspaper)* (1999) 10:1-2.
- Reynolds et al., "Rational siRNA design for RNA interference" *Nature Biotechnology* (2004) 22(3):326-330.
- Roller et al., "Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT)" *Bioorg. Med. Chem. Lett.* (1998) 8:2149-2150.
- Rondinone et al., "Inhibition of PTP1B Induces Differential Expression of PI3-Kinase Regulatory Subunit (p85 α) Isoforms" *Diabetes* (2001) 50:A400.
- Rondinone et al., "Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in Lipogenesis" *Diabetes* (2002) 51:2405-2411.
- Sanghvi et al., "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides" *Antisense Research and Applications* (1993) pp. 273-288.
- Schievella et al., "Protein tyrosine phosphatase 1B undergoes mitosis-specific phosphorylation on serine" *Cell. Growth Differ.* (1993) 4:239-246.
- Schofield et al., "Non-viral approaches to gene therapy" *Brit. Med. Bull.* (1995) 51:56-71.
- Seely et al., "Protein tyrosine phosphatase 1B interacts with the activated insulin receptor" *Diabetes* (1996) 45:1379-1385.
- Sell et al., "Insulin-inducible changes in the relative ratio of PTP1B splice variants" *Mol. Genet. Metab.* (1999) 66:189-192.
- Shifrin et al., "Growth factor-inducible alternative splicing of nontransmembrane phosphotyrosine phosphatase PTP1B pre-mRNA" *J. Biol. Chem.* (1993) 268:25376-25384.
- Skorey et al., "How does alendronate inhibit protein-tyrosine phosphatases?" *J. Biol. Chem.* (1997) 272:22472-22480.
- Skrumsager et al., "Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR α and γ agonist in healthy subjects and patients with type 2 diabetes" *Journal of Clinical Pharmacology* (2003) 43:1244-1256.
- Standl et al., "Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy" *Diabetes, Obesity and Metabolism* (1999) 1:215-220.
- Stein et al., "Antisense oligonucleotides as therapeutic agents—is the bullet really magical?" *Science* (1993) 261:1004-1012.
- Stull et al., "An In Vitro Messenger RNA Binding Assay as a Tool for Identifying Hybridization-Competent Antisense Oligonucleotides" *Antisense & Nucleic Acid Drug Development* (1996) 6:221-228.
- Strickland et al., "Antisense RNA Directed Against the 3' Noncoding Region Prevents Dormant mRNA Activation in Mouse Oocytes" *Science* (1988) 241:680-684.
- Taing et al., "Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B" *Biochemistry* (1999) 38:3793-3803.
- Taylor et al., "Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B [published erratum appears in *Bioorg Med Chem Nov. 1998;6(11):2235*]" *Bioorg. Med. Chem.* (1998) 6:1457-1468.
- Tonks et al., "Characterization of the major protein-tyrosine-phosphatases of human placenta" *J. Biol. Chem.* (1998) 263:6731-6737.
- Tonks et al., "Purification of the major protein-tyrosine-phosphatases of human placenta" *J. Biol. Chem.* (1998) 263:6722-6730.
- Van Huijsduijn et al., "Selecting protein tyrosine phosphatases as drug targets" *DDT* (2002) 7(19): 1013-1019.
- Verma et al., "Gene Therapy: promises, problems and prospects" *Nature* (1997) 389:239-242.
- Vickers et al., "Efficient reduction of target RNAs by small interfering RNA and Rnase H-dependent antisense agents" *The Journal of Biological Chemistry* (2003) 278:7108-7118.

(56)

References Cited

OTHER PUBLICATIONS

Wagner, "Early clinical development of pharmaceuticals for type 2 diabetes mellitus: From preclinical models to human investigation" *The Journal of Clinical Endocrinology & Metabolism* (2002) 87:5362-5366.

Walczak, "Diabetes Technology News" *Diabetes Technology & Therapeutics* (2001) 3:307-331.

Wang et al., "Naphthalenebis [alpha, alpha-difluoromethylenephosphonates] as potent inhibitors of protein tyrosine phosphatases" *Bioorg. Med. Chem. Lett.* (1998) 8:345-350.

Wang et al., "Mechanism of inhibition of protein-tyrosine phosphatases by disodium aurothiomalate" *Biochem. Pharmacol.* (1997) 54:703-711.

Waring et al., "PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat" *Mol. Cell. Endocrin.* (2003) 203:155-168.

Wiener et al., "Overexpression of the Protein Tyrosine Phosphatase PTP1B in Human Breast Cancer: Association with p185 Protein Expression" *J. Nat. Cancer Inst.* (1994) 86:372-378.

Wiener et al., "Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas" *Am. J. Obstet. Gynecol.* (1994) 170:1177-1183.

Wu et al., "Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats" *Br. J. Pharm.* (2005) 146:234-243.

Yao et al., "Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors" *Bioorg. Med. Chem.* (1998) 6:1799-1810.

Yu et al., "Abstract of International Patent Publication No. WO-02/59137" published Aug. 1, 2002.

Zhang et al., "Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis" *Crit. Rev. Biochem. Mol. Biol.* (1998) 33:1-52.

Zinker et al., "PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice" *PNAS* (2002) 99:11357-11362.

International Search Report for PCT/US12/33588 dated Aug. 31, 2012.




Figure 1

**Comparison of Key Tolerability Parameters for 409826, 404173
and 142082**

40 mpk/week		Walk		Fold over Saline		
ISIS #	Chemistry	Position	Spleen Wt	Kidney Wt	Liver Wt	
409826	5-10-5	4518	2.5	1.4	1.7	
142082	5-10-5	4522	3.0	2.1	1.7	
404173	5-10-5	4521	1.6	1.5	1.5	

40 mpk/week		Fold Change vs Baseline			
ISIS #	C3	CRP	MCP1	IL-1	
Saline	-0.05	0.23	-0.29	-0.44	
409826	-0.30	3.90	2.31	2.37	
142082	-0.16	14.52	5.36	1.64	
404173	-0.18	-0.48	0.82	0.09	

* 1 animal very high at day 93; otherwise fold-increase was ~3-4 fold

Figure 2

ISIS-404173 - a More Potent Inhibitor
Preclinical Studies Demonstrate up to Five-Fold Greater Potency




Figure 3

ANTISENSE MODULATION OF PTP1B EXPRESSION

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 13/446,763, filed Apr. 13, 2012, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/474,981, filed Apr. 13, 2011, each of which are herein incorporated by reference in their entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0149USD1SEQ.txt created Jan. 10, 2014, which is 112 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD

Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful, for example, to treat, prevent, delay or ameliorate diseases associated with metabolic disorders, particularly disorders associated with diabetes.

BACKGROUND

Protein tyrosine phosphatase 1B (PTP1B) is a member of a family of PTPs (Barford, et al., Science 1994. 263: 1397-1404) and is a cytosolic enzyme (Neel and Tonks, Curr. Opin. Cell Biol. 1997. 9: 193-204). PTP1B is expressed ubiquitously including tissues that are key regulators of insulin metabolism such as liver, muscle and fat (Goldstein, Receptor 1993. 3: 1-15), where it is the main PTP enzyme.

PTP1B is considered to be a negative regulator of insulin signaling. PTP1B interacts with and dephosphorylates the insulin receptor, thus attenuating and potentially terminating the insulin signaling transduction (Goldstein et al., J. Biol. Chem. 2000. 275: 4383-4389). The physiological role of PTP1B in insulin signaling has been demonstrated in knock-out mice models. Mice lacking the PTP1B gene were protected against insulin resistance and obesity (Elchebly et al., Science 1999. 283: 1544-1548). PTP1B-deficient mice had low adiposity, increased basal metabolic rate as well as total energy expenditure and were protected from diet-induced obesity. Insulin-stimulated glucose uptake was elevated in skeletal muscle, whereas adipose tissue was unaffected providing evidence that increased insulin sensitivity in PTP1B-deficient mice was tissue-specific (Klaman et al., Mol. Cell. Biol. 2000. 20: 5479-5489). These mice were phenotypically normal and were also resistant to diet-induced obesity, insulin resistance and had significantly lower triglyceride levels on a high-fat diet. Therefore, inhi-

bition of PTP1B in patients suffering from Type II diabetes, metabolic syndrome, diabetic dyslipidemia, or related metabolic diseases would be beneficial.

Antisense inhibition of PTP1B provides a unique advantage over traditional small molecule inhibitors in that antisense inhibitors do not rely on competitive binding of the compound to the protein and inhibit activity directly by reducing the expression of PTP1B. Antisense technology is emerging as an effective means for reducing the expression of certain gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of PTP1B.

There is a currently a lack of acceptable options for treating metabolic disorders. It is therefore an object herein to provide compounds and methods for the treatment of such diseases and disorder.

All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

SUMMARY

Provided herein are methods, compounds, and compositions for modulating expression of PTP1B and treating, preventing, delaying or ameliorating diseases associated with metabolic disorders, particularly disorders associated with diabetes and/or a symptom thereof.

BRIEF DESCRIPTION OF THE FIGURES

The numerous objects and advantages of the present invention can be better understood by those skilled in the art by reference to the accompanying figures, in which:

FIG. 1 shows a western blot of PTP1B antisense oligonucleotides, ISIS 404173 and ISIS 142082, decreasing PTP1B protein expression at 8 mgk/week demonstrating potency of the compounds. See Table 47.

FIG. 2 is a summary table of key tolerability studies in cynomolgus monkeys (see Example 17).

FIG. 3 is a graphical representation reduction of human PTP1B mRNA in a dose response preclinical study. Treatment with ISIS 404173 was compared with that of ISIS 113715, the previous clinical candidate. As shown here, dosing with ISIS 404173 was more potent and caused significant reduction in PTP1B mRNA levels compared to dosing with ISIS 113715. Particularly, at 0.3 μ M dose, there was a five-fold decrease in PTP1B mRNA levels with ISIS 404173 compared to ISIS 113715.

DETAILED DESCRIPTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the

subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

Definitions

Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical synthesis, and chemical analysis. Where permitted, all documents, or portions of documents, cited in this application, including, but not limited to, all patents, applications, published applications and other journal publications, GENBANK Accession Numbers and associated sequence information obtainable through databases such as National Center for Biotechnology Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical synthesis, and chemical analysis. Where permitted, all patents, applications, published applications and other publications, GENBANK Accession Numbers and associated sequence information obtainable through databases such as National Center for Biotechnology Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Unless otherwise indicated, the following terms have the following meanings:

“2'-O-methoxyethyl” (also 2'-MOE and 2'-O(CH₂)₂—OCH₃) refers to an O-methoxy-ethyl modification of the 2' position of a furfuryl ring. A 2'-O-methoxyethyl modified sugar is a modified sugar.

“2'-O-methoxyethyl nucleotide” means a nucleotide comprising a 2'-O-methoxyethyl modified sugar moiety.

“3' target site” refers to the nucleotide of a target nucleic acid which is complementary to the 3'-most nucleotide of a particular antisense compound.

“5' target site” refers to the nucleotide of a target nucleic acid which is complementary to the 5'-most nucleotide of a particular antisense compound.

“5-methylcytosine” means a cytosine modified with a methyl group attached to the 5' position. A 5-methylcytosine is a modified nucleobase.

“About” means within $\pm 10\%$ of a value. For example, if it is stated, “a marker may be increased by about 50%”, it is implied that the marker may be increased between 45%-55%.

“Active pharmaceutical agent” means the substance or substances in a pharmaceutical composition that provide a therapeutic benefit when administered to an individual. For example, in certain embodiments an antisense oligonucleotide targeted to PTP1B is an active pharmaceutical agent.

“Active target region” or “target region” means a region to which one or more active antisense compounds is tar-

geted. “Active antisense compounds” means antisense compounds that reduce target nucleic acid levels or protein levels.

“Adipogenesis” means the development of fat cells from preadipocytes. “Lipogenesis” means the production or formation of fat, either fatty degeneration or fatty infiltration.

“Adiposity” or “Obesity” refers to the state of being obese or an excessively high amount of body fat or adipose tissue in relation to lean body mass. The amount of body fat includes concern for both the distribution of fat throughout the body and the size and mass of the adipose tissue deposits. Body fat distribution can be estimated by skin-fold measures, waist-to-hip circumference ratios, or techniques such as ultrasound, computed tomography, or magnetic resonance imaging. According to the Center for Disease Control and Prevention, individuals with a body mass index (BMI) of 30 or more are considered obese. The term “Obesity” as used herein includes conditions where there is an increase in body fat beyond the physical requirement as a result of excess accumulation of adipose tissue in the body. The term “obesity” includes, but is not limited to, the following conditions: adult-onset obesity; alimentary obesity; endogenous or inflammatory obesity; endocrine obesity; familial obesity; hyperinsular obesity; hyperplastic-hypertrophic obesity; hypogonadal obesity; hypothyroid obesity; lifelong obesity; morbid obesity and exogenous obesity.

“Administered concomitantly” refers to the co-administration of two agents in any manner in which the pharmacological effects of both are manifest in the patient at the same time. Concomitant administration does not require that both agents be administered in a single pharmaceutical composition, in the same dosage form, or by the same route of administration. The effects of both agents need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive.

“Administering” means providing an agent to an animal, and includes, but is not limited to, administering by a medical professional and self-administering.

“Agent” means an active substance that can provide a therapeutic benefit when administered to an animal. “First Agent” means a therapeutic compound provided herein. For example, a first agent can be an antisense oligonucleotide targeting PTP1B. “Second agent” means a second therapeutic compound of the invention (e.g. a second antisense oligonucleotide targeting PTP1B) and/or a non-PTP1B therapeutic compound.

“Amelioration” refers to a lessening of at least one indicator, sign, or symptom of an associated disease, disorder, or condition. The severity of indicators can be determined by subjective or objective measures, which are known to those skilled in the art.

“Animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

“Antisense activity” means any detectable or measurable activity attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid.

“Antisense compound” means an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.

“Antisense inhibition” means reduction of target nucleic acid levels or target protein levels in the presence of an

antisense compound complementary to a target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound.

“Antisense oligonucleotide” means a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.

“Bicyclic sugar” means a furosyl ring modified by the bridging of two non-geminal ring atoms. A bicyclic sugar is a modified sugar.

“Bicyclic nucleic acid” or “BNA” refers to a nucleoside or nucleotide wherein the furanose portion of the nucleoside or nucleotide includes a bridge connecting two carbon atoms on the furanose ring, thereby forming a bicyclic ring system.

“Cap structure” or “terminal cap moiety” means chemical modifications, which have been incorporated at either terminus of an antisense compound.

“Chemically distinct region” refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2'-O-methoxyethyl nucleotides is chemically distinct from a region having nucleotides without 2'-O-methoxyethyl modifications.

“Chimeric antisense compound” means an antisense compound that has at least two chemically distinct regions.

“Co-administration” means administration of two or more agents to an individual. The two or more agents can be in a single pharmaceutical composition, or can be in separate pharmaceutical compositions. Each of the two or more agents can be administered through the same or different routes of administration. Co-administration encompasses parallel or sequential administration.

“Cholesterol” is a sterol molecule found in the cell membranes of all animal tissues. Cholesterol must be transported in an animal's blood plasma by lipoproteins including very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and high density lipoprotein (HDL). “Plasma cholesterol” refers to the sum of all lipoproteins (VDL, IDL, LDL, HDL) esterified and/or non-esterified cholesterol present in the plasma or serum.

“Cholesterol absorption inhibitor” means an agent that inhibits the absorption of exogenous cholesterol obtained from diet.

“Complementarity” means the capacity for pairing between nucleobases of a first nucleic acid and a second nucleic acid.

“Contiguous nucleobases” means nucleobases immediately adjacent to each other.

“Deoxyribonucleotide” means a nucleotide having a hydrogen at the 2' position of the sugar portion of the nucleotide. Deoxyribonucleotides may be modified with any of a variety of substituents.

“Diabetes mellitus” or “diabetes” is a syndrome characterized by disordered metabolism and abnormally high blood sugar (hyperglycemia) resulting from insufficient levels of insulin or reduced insulin sensitivity. The characteristic symptoms are excessive urine production (polyuria) due to high blood glucose levels, excessive thirst and increased fluid intake (polydipsia) attempting to compensate for increased urination, blurred vision due to high blood glucose effects on the eye's optics, unexplained weight loss, and lethargy.

“Diabetic dyslipidemia” or “type 2 diabetes with dyslipidemia” means a condition characterized by Type 2 diabetes, reduced HDL-C, elevated triglycerides, and elevated small, dense LDL particles.

“Diluent” means an ingredient in a composition that lacks pharmacological activity, but is pharmaceutically necessary or desirable. For example, the diluent in an injected composition can be a liquid, e.g. saline solution.

“Dyslipidemia” refers to a disorder of lipid and/or lipoprotein metabolism, including lipid and/or lipoprotein overproduction or deficiency. Dyslipidemias may be manifested by elevation of lipids such as cholesterol and triglycerides as well as lipoproteins such as low-density lipoprotein (LDL) cholesterol.

“Dosage unit” means a form in which a pharmaceutical agent is provided, e.g. pill, tablet, or other dosage unit known in the art. In certain embodiments, a dosage unit is a vial containing lyophilized antisense oligonucleotide. In certain embodiments, a dosage unit is a vial containing reconstituted antisense oligonucleotide.

“Dose” means a specified quantity of a pharmaceutical agent provided in a single administration, or in a specified time period. In certain embodiments, a dose can be administered in one, two, or more boluses, tablets, or injections. For example, in certain embodiments where subcutaneous administration is desired, the desired dose requires a volume not easily accommodated by a single injection, therefore, two or more injections can be used to achieve the desired dose. In certain embodiments, the pharmaceutical agent is administered by infusion over an extended period of time or continuously. Doses can be stated as the amount of pharmaceutical agent per hour, day, week, or month.

“Effective amount” or “therapeutically effective amount” means the amount of active pharmaceutical agent sufficient to effectuate a desired physiological outcome in an individual in need of the agent. The effective amount can vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the individuals to be treated, the formulation of the composition, assessment of the individual's medical condition, and other relevant factors.

“Fully complementary” or “100% complementary” means each nucleobase of a nucleobase sequence of a first nucleic acid has a complementary nucleobase in a second nucleobase sequence of a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense compound and a target nucleic acid is a second nucleic acid.

“Gapmer” means a chimeric antisense compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region can be referred to as a “gap segment” and the external regions can be referred to as “wing segments.”

“Gap-widened” means a chimeric antisense compound having a gap segment of 12 or more contiguous 2'-deoxyribonucleosides positioned between and immediately adjacent to 5' and 3' wing segments having from one to six nucleosides.

“Glucose” is a monosaccharide used by cells as a source of energy and inflammatory intermediate. “Plasma glucose” refers to glucose present in the plasma.

“HMG-CoA reductase inhibitor” means an agent that acts through the inhibition of the enzyme HMG-CoA reductase, such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin.

“Hybridization” means the annealing of complementary nucleic acid molecules. In certain embodiments, comple-

mentary nucleic acid molecules include an antisense compound and a target nucleic acid.

“Hyperlipidemia” or “hyperlipemia” is a condition characterized by elevated serum lipids or circulating (plasma) lipids. This condition manifests an abnormally high concentration of fats. The lipid fractions in the circulating blood are cholesterol, low density lipoproteins, very low density lipoproteins and triglycerides.

“Hypertriglyceridemia” means a condition characterized by elevated triglyceride levels.

“Identifying” or “selecting an animal with metabolic” means identifying or selecting a subject having been diagnosed with a metabolic disease, or a metabolic disorder; or, identifying or selecting a subject having any symptom of a metabolic disease, including, but not limited to, metabolic syndrome, hyperglycemia, hypertriglyceridemia, hypertension increased insulin resistance, decreased insulin sensitivity, above normal body weight, and/or above normal body fat or any combination thereof. Such identification may be accomplished by any method, including but not limited to, standard clinical tests or assessments, such as measuring serum or circulating (plasma) blood-glucose, measuring serum or circulating (plasma) triglycerides, measuring blood-pressure, measuring body fat, measuring body weight, and the like.

“Immediately adjacent” means there are no intervening elements between the immediately adjacent elements.

“Individual” or “subject” or “animal” means a human or non-human animal selected for treatment or therapy.

“Inhibiting the expression or activity” refers to a reduction or blockade of the expression or activity of a RNA or protein and does not necessarily indicate a total elimination of expression or activity.

“Insulin resistance” is defined as the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of insulin and glucose due to insulin resistance often leads to metabolic syndrome and type 2 diabetes.

“Insulin sensitivity” is a measure of how effectively an individual processes glucose. An individual having high insulin sensitivity effectively processes glucose whereas an individual with low insulin sensitivity does not effectively process glucose.

“Internucleoside linkage” refers to the chemical bond between nucleosides.

“Intravenous administration” means administration into a vein.

“Linked nucleosides” means adjacent nucleosides which are bonded together.

“Lipid-lowering therapy” or “lipid lowering agent” means a therapeutic regimen provided to a subject to reduce one or more lipids in a subject. In certain embodiments, a lipid-lowering therapy is provided to reduce one or more of ApoB, total cholesterol, LDL-C, VLDL-C, IDL-C, non-HDL-C, triglycerides, small dense LDL particles, and Lp(a) in a subject. Examples of lipid-lowering therapy include statins, fibrates, and MTP inhibitors.

“Major risk factors” refers to factors that contribute to a high risk for a particular disease or condition. In certain embodiments, major risk factors for coronary heart disease include, without limitation, cigarette smoking, hypertension,

low HDL-C, family history of coronary heart disease, age, and other factors disclosed herein.

“Metabolic disease” or “metabolic disorder” refers to a condition characterized by an alteration or disturbance in metabolic function. “Metabolic” and “metabolism” are terms well known in the art and generally include the whole range of biochemical processes that occur within a living organism. Metabolic diseases or disorders include, but are not limited to, obesity, diabetes, hyperglycemia, prediabetes, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulin resistance, diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof.

“Metabolic syndrome” means a condition characterized by a clustering of lipid and non-lipid cardiovascular risk factors of metabolic origin. In certain embodiments, metabolic syndrome is identified by the presence of any 3 of the following factors: waist circumference of greater than 102 cm in men or greater than 88 cm in women; serum triglyceride of at least 150 mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure of at least 130/85 mmHg; and fasting glucose of at least 110 mg/dL. These determinants can be readily measured in clinical practice (JAMA, 2001, 285: 2486-2497).

“Mismatch” or “non-complementary nucleobase” refers to the case when a nucleobase of a first nucleic acid is not capable of pairing with the corresponding nucleobase of a second or target nucleic acid.

“Mixed dyslipidemia” means a condition characterized by elevated cholesterol and elevated triglycerides.

“Modified internucleoside linkage” refers to a substitution or any change from a naturally occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).

“Modified nucleobase” refers to any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).

“Modified nucleoside” means a nucleoside having, independently, a modified sugar moiety or modified nucleobase.

“Modified nucleotide” means a nucleotide having, independently, a modified sugar moiety, modified internucleoside linkage, or modified nucleobase. A “modified nucleoside” means a nucleoside having, independently, a modified sugar moiety or modified nucleobase.

“Modified oligonucleotide” means an oligonucleotide comprising at least one modified nucleotide.

“Modified sugar” refers to a substitution or change from a natural sugar.

“Motif” means the pattern of chemically distinct regions in an antisense compound.

“MTP inhibitor” means an agent inhibits the enzyme, microsomal triglyceride transfer protein.

“Naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage.

“Natural sugar moiety” means a sugar found in DNA (2'-H) or RNA (2'-OH).

“Non-alcoholic fatty liver disease” or “NAFLD” means a condition characterized by fatty inflammation of the liver that is not due to excessive alcohol use (for example, alcohol consumption of over 20 g/day). In certain embodiments, NAFLD is related to insulin resistance and the metabolic syndrome. NAFLD encompasses a disease spectrum ranging from simple triglyceride accumulation in hepatocytes (hepatic steatosis) to hepatic steatosis with inflammation (steatohepatitis), fibrosis, and cirrhosis.

“Nonalcoholic steatohepatitis” (NASH) occurs from progression of NAFLD beyond deposition of triglycerides. A

“second hit” capable of inducing necrosis, inflammation, and fibrosis is required for development of NASH. Candidates for the second-hit can be grouped into broad categories: factors causing an increase in oxidative stress and factors promoting expression of proinflammatory cytokines

“Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, double-stranded nucleic acids, small interfering ribonucleic acids (siRNA), and microRNAs (miRNA). A nucleic acid can also comprise a combination of these elements in a single molecule.

“Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid.

“Nucleobase sequence” means the order of contiguous nucleobases independent of any sugar, linkage, or nucleobase modification.

“Nucleoside” means a nucleobase linked to a sugar.

“Nucleoside mimetic” includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo or tricyclo sugar mimetics e.g. non furanose sugar units.

“Nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

“Nucleotide mimetic” includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by $-N(H)-C(=O)-O-$ or other non-phosphodiester linkage).

“Oligomeric compound” or “oligomer” refers to a polymeric structure comprising two or more sub-structures and capable of hybridizing to a region of a nucleic acid molecule. In certain embodiments, oligomeric compounds are oligonucleosides. In certain embodiments, oligomeric compounds are oligonucleotides. In certain embodiments, oligomeric compounds are antisense compounds. In certain embodiments, oligomeric compounds are antisense oligonucleotides. In certain embodiments, oligomeric compounds are chimeric oligonucleotides.

“Oligonucleotide” means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another.

“Parenteral administration” means administration through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intrathecal or intracerebroventricular administration. Administration can be continuous, or chronic, or short or intermittent.

“Peptide” means a molecule formed by linking at least two amino acids by amide bonds. Peptide refers to polypeptides and proteins.

“Pharmaceutical agent” means a substance that provides a therapeutic benefit when administered to an individual. For example, in certain embodiments, an antisense oligonucleotide targeted to PTP1B is pharmaceutical agent.

“Pharmaceutical composition” means a mixture of substances suitable for administering to an individual. For example, a pharmaceutical composition can comprise one or more active agents and a sterile aqueous solution.

“Pharmaceutically acceptable carrier” means a medium or diluent that does not interfere with the structure of the oligonucleotide. Certain, of such carries enable pharmaceutical compositions to be formulated as, for example, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspension and lozenges for the oral ingestion by a subject. For example, a pharmaceutically acceptable carrier can be a sterile aqueous solution.

“Pharmaceutically acceptable derivative” encompasses pharmaceutically acceptable salts, conjugates, prodrugs or isomers of the compounds described herein.

“Pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts of antisense compounds, i.e., salts that retain the desired biological activity of the parent oligonucleotide and do not impart undesired toxicological effects thereto.

“Phosphorothioate linkage” means a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate linkage is a modified internucleoside linkage.

“Portion” means a defined number of contiguous (i.e. linked) nucleobases of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of an antisense compound.

“Prevent” refers to delaying or forestalling the onset or development of a disease, disorder, or condition for a period of time from minutes to indefinitely. Prevent also means reducing risk of developing a disease, disorder, or condition.

“Prodrug” means a therapeutic agent that is prepared in an inactive form that is converted to an active form within the body or cells thereof by the action of endogenous enzymes or other chemicals or conditions.

“Protein tyrosine phosphatase 1B” or “PTP1B” (also known as PTPN1; protein tyrosine phosphatase, non-receptor type 1; PTP-1B; RKPTP) means any nucleic acid or protein of PTP1B.

“PTP1B expression” means the level of mRNA transcribed from the gene encoding PTP1B or the level of protein translated from the mRNA. PTP1B expression can be determined by art known methods such as a Northern or Western blot.

“PTP1B nucleic acid” means any nucleic acid encoding PTP1B. For example, in certain embodiments, a PTP1B nucleic acid includes a DNA sequence encoding PTP1B, a RNA sequence transcribed from DNA encoding PTP1B (including genomic DNA comprising introns and exons), and a mRNA sequence encoding PTP1B. “PTP1B mRNA” means a mRNA encoding a PTP1B protein.

“Side effects” means physiological responses attributable to a treatment other than the desired effects. In certain embodiments, side effects include injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system abnormalities, myopathies, and malaise. For example, increased aminotransferase levels in serum can indicate liver toxicity or liver function abnormality. For example, increased bilirubin can indicate liver toxicity or liver function abnormality.

“Single-stranded oligonucleotide” means an oligonucleotide which is not hybridized to a complementary strand.

“Specifically hybridizable” refers to an antisense compound having a sufficient degree of complementarity between an antisense oligonucleotide and a target nucleic acid to induce a desired effect, while exhibiting minimal or

no effects on non-target nucleic acids under conditions in which specific binding is desired, i.e. under physiological conditions in the case of in vivo assays and therapeutic treatments.

“Statin” means an agent that inhibits the activity of HMG-CoA reductase.

“Subcutaneous administration” means administration just below the skin.

“Targeting” or “targeted” means the process of design and selection of an antisense compound that will specifically hybridize to a target nucleic acid and induce a desired effect.

“Target nucleic acid,” “target RNA,” and “target RNA transcript” all refer to a nucleic acid capable of being targeted by antisense compounds.

“Target segment” means the sequence of nucleotides of a target nucleic acid to which an antisense compound is targeted. “5' target site” refers to the 5'-most nucleotide of a target segment. “3' target site” refers to the 3'-most nucleotide of a target segment.

“Therapeutically effective amount” means an amount of an agent that provides a therapeutic benefit to an individual.

“Therapeutic lifestyle change” means dietary and lifestyle changes intended to lower fat/adipose tissue mass and/or cholesterol. Such change can reduce the risk of developing heart disease, and may include recommendations for dietary intake of total daily calories, total fat, saturated fat, polyunsaturated fat, monounsaturated fat, carbohydrate, protein, cholesterol, insoluble fiber, as well as recommendations for physical activity.

“Triglyceride” or “TG” means a lipid or neutral fat consisting of glycerol combined with three fatty acid molecules.

“Type 2 diabetes,” (also known as “type 2 diabetes mellitus” or “diabetes mellitus, type 2”, and formerly called “diabetes mellitus type 2”, “non-insulin-dependent diabetes (NIDDM)”, “obesity related diabetes”, or “adult-onset diabetes”) is a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency, and hyperglycemia.

“Treat” refers to administering a pharmaceutical composition to an animal to effect an alteration or improvement of a disease, disorder, or condition.

“Unmodified nucleotide” means a nucleotide composed of naturally occurring nucleobases, sugar moieties, and internucleoside linkages. In certain embodiments, an unmodified nucleotide is an RNA nucleotide (i.e. β -D-ribose nucleosides) or a DNA nucleotide (i.e. β -D-deoxyribose nucleoside).

Certain Embodiments

Certain embodiments provide methods, compounds, and compositions for inhibiting PTP1B expression.

Certain embodiments provide antisense compounds targeted to a PTP1B nucleic acid. In certain embodiments, the PTP1B nucleic acid is any of the sequences set forth in GENBANK Accession No. NM_002827.2 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NT_011362.9 truncated from nucleotides 14178000 to 14256000 (incorporated herein as SEQ ID NO: 2); and a concatenation of sequences from exons 1-9, intron 9 and exon 10 of the rhesus monkey PTP1B scaffold (incorporated herein as SEQ ID NO: 3).

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 10 to 30 nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein can consist of 10 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 4-32 or 100-111.

In certain embodiments, the compounds or compositions provided herein can consist of 10 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 26 or 44.

In certain embodiments, the compounds or compositions provided herein can consist of 10 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of ISIS NOs: 404173, 410002, 438373, 438383, 438445, 438454, 438463, or 438472.

In certain embodiments, the compounds or compositions provided herein can consist of 10 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of ISIS NO: 404173.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 15 to 30 nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 15 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein can consist of 15 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 4-32 or 100-111.

In certain embodiments, the compounds or compositions provided herein can consist of 15 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 26 or 44.

In certain embodiments, the compounds or compositions provided herein can consist of 15 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of ISIS NOs: 404173, 410002, 438373, 438383, 438445, 438454, 438463, or 438472.

In certain embodiments, the compounds or compositions provided herein can consist of 15 to 30 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of ISIS NO: 404173.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 18 to 21 nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3.

In certain embodiments, the compounds or compositions provided herein consist of 20 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or contiguous nucleobases of SEQ ID NOs: 4-32.

In certain embodiments, the compounds or compositions provided herein consist of 20 linked nucleosides and have a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or contiguous nucleobases of SEQ ID NO: 26.

In certain embodiments, the compounds or compositions provided herein consist of any of ISIS NOs: 404173, 410002, 438373, 438383, 438445, 438454, 438463, or 438472.

In certain embodiments, the compounds or compositions provided herein consist of ISIS NO: 404173.

In certain embodiments, the compounds or compositions provided herein consist of SEQ ID NO: 26.

In certain embodiments, the compounds or compositions provided herein comprise a salt of the modified oligonucleotide.

In certain embodiments, the compounds or compositions provided herein further comprise a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to any one of SEQ ID NOs: 1-3 as measured over the entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NO: 4-32 or 39-50, as measured over the entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NO: 26 or 44, as measured over the entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one ISIS NOs: 404173, 410002, 438373, 438383, 438445, 438454, 438463, or 438472 as measured over the entirety of the modified oligonucleotide.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to ISIS NO: 404173 as measured over the entirety of the modified oligonucleotide.

In certain embodiments, the compound provided herein consists of a single-stranded modified oligonucleotide.

In certain embodiments, the modified oligonucleotide consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 linked nucleosides. In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides. In certain embodiments, the modified oligonucleotide consists of 18 linked nucleosides.

In certain embodiments, at least one internucleoside linkage of the modified oligonucleotide is a modified inter-

nucleoside linkage. In certain embodiments, each internucleoside linkage is a phosphorothioate internucleoside linkage.

In certain embodiments, at least one nucleoside of said modified oligonucleotide comprises a modified nucleobase. In certain embodiments, the modified nucleobase is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide comprises: a) a gap segment consisting of linked deoxynucleosides; b) a 5' wing segment consisting of linked nucleosides; and c) a 3' wing segment consisting of linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment and each nucleoside of each wing segment comprises a modified sugar.

In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides, the gap segment consisting of ten linked deoxynucleosides, the 5' wing segment consisting of five linked nucleosides, the 3' wing segment consisting of five linked nucleosides, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides, the gap segment consisting of eight linked deoxynucleosides, the 5' wing segment consisting of six linked nucleosides, the 3' wing segment consisting of six linked nucleosides, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides, the gap segment consisting of thirteen linked deoxynucleosides, the 5' wing segment consisting of two linked nucleosides, the 3' wing segment consisting of five linked nucleosides, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 18 linked nucleosides, the gap segment consisting of eight linked deoxynucleosides, the 5' wing segment consisting of five linked nucleosides, the 3' wing segment consisting of five linked nucleosides, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 18 linked nucleosides having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of any of SEQ ID NOs: 1-3, wherein the modified oligonucleotide comprises: a) a gap segment consisting of eight linked deoxynucleo-

sides; b) a 5' wing segment consisting of six linked nucleosides; and c) a 3' wing segment consisting of six linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 19 contiguous nucleobases of SEQ ID NOs: 4-32, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 19 contiguous nucleobases of SEQ ID NO: 26, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having the nucleobase sequence of SEQ ID NO: 26, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 19 contiguous nucleobases of SEQ ID NO: 26 or 44, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine. In certain embodiments, the compound or composition comprises the compound of any of ISIS NOs: 404173, 410002, 438383, 438445, 438454, 438463, or 438472.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase

sequence comprising at least 20 contiguous nucleobases of SEQ ID NOs: 4-32, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 20 contiguous nucleobases of SEQ ID NO: 26, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine.

In certain embodiments, the compounds or compositions provided herein comprise a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence comprising at least 20 contiguous nucleobases of SEQ ID NO: 26, wherein the modified oligonucleotide comprises: a) a gap segment consisting of ten linked deoxynucleosides; b) a 5' wing segment consisting of five linked nucleosides; and c) a 3' wing segment consisting of five linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl modified sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine residue is a 5-methylcytosine. In certain embodiments, the compound or composition comprises the compound ISIS NOs: 404173.

Certain embodiments provide methods, compounds, and compositions for inhibiting PTP1B expression.

Certain embodiments provide a method of reducing PTP1B expression in an animal comprising administering to the animal a compound as described herein. In certain embodiments, the compound comprises a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 35 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 25 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 24 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 23 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 22 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 to 21 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 linked nucleosides in length targeted to PTP1B.

Certain embodiments provide a method of preventing, ameliorating or treating a metabolic disease in an animal comprising administering to the animal a compound as

described herein. In certain embodiments, the compound comprises a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 linked nucleosides in length targeted to PTP1B. Examples of metabolic diseases or disorders include, but are not limited to obesity, diabetes, hyperglycemia, prediabetes, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulin resistance, diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide a method of reducing glucose levels in an animal comprising administering to the animal a compound as described herein. In certain embodiments, the compound comprises a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to PTP1B. In certain embodiments, the compound comprises a modified oligonucleotide 20 linked nucleosides in length targeted to PTP1B. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats a metabolic disease. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats diabetes. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats obesity. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats metabolic syndrome. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats insulin resistance. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats hyperglycemia. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats NAFLD. In certain embodiments, reduction of glucose levels in an animal prevents, ameliorates or treats diabetic dyslipidemia. In certain embodiments, the glucose level is reduced by at least 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

In certain embodiments, PTP1B has the sequence as set forth in any of the GenBank Accession Numbers GENBANK Accession No. NM_002827.2 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NT_011362.9 truncated from nucleotides 14178000 to 14256000 (incorporated herein as SEQ ID NO: 2); and a concatenation of sequences from exons 1-9, intron 9 and exon 10 of the rhesus monkey PTP1B scaffold (incorporated herein as SEQ ID NO: 3). In certain embodiments, PTP1B has the human sequence as set forth in SEQ ID NOs: 1-2. In certain embodiments, PTP1B has the rhesus monkey sequence as set forth in SEQ ID NOs: 3).

In certain embodiments, the compounds or compositions provided herein comprise a salt thereof, and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NOs: 4-32, 50 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 25 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NOs: 4-32, 50 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in

SEQ ID NO: 4-32, 50 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the compounds or compositions provided herein comprise a salt thereof, and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 26 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 25 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 26 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 26 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the compounds or compositions of the invention comprise a salt thereof, and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NOs: 404173, 410002, 438383, 438445, 438454, 438463, or 438472 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 25 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NOs: 404173, 410002, 438383, 438445, 438454, 438463, or 438472 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NOs: 404173, 410002, 438383, 438445, 438454, 438463, or 438472 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

In certain embodiments, the compounds or compositions of the invention comprise a salt thereof, and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NO: 404173 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 to 25 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NO: 404173 or a salt thereof and a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition comprises a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase

sequences recited in ISIS NO: 404173 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

Certain embodiments provide a method for treating an animal with a PTP1B related disease or condition comprising: a) identifying said animal with the PTP1B related disease or condition, and b) administering to said animal a therapeutically effective amount of a compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence at least 90% complementary to any of SEQ ID NOs: 1-3 as measured over the entirety of said modified oligonucleotide. In certain embodiments, the therapeutically effective amount of the compound administered to the animal treats or reduces the PTP1B related disease or condition, or a symptom thereof, in the animal. In certain embodiments, the PTP1B related disease or condition is diabetes.

Certain embodiments provide a method for treating an animal with a PTP1B related disease or condition comprising: a) identifying said animal with the PTP1B related disease or condition, and b) administering to said animal a therapeutically effective amount of a compound comprising a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence at least 100% complementary to any of SEQ ID NOs: 1-3 as measured over the entirety of said modified oligonucleotide. In certain embodiments, the therapeutically effective amount of the compound administered to the animal treats or reduces the PTP1B related disease or condition, or a symptom thereof, in the animal. In certain embodiments, the PTP1B related disease or condition is diabetes.

Certain embodiments provide methods of treating, preventing, or ameliorating a metabolic disease. In certain embodiments the metabolic disease is obesity, diabetes, hyperglycemia, prediabetes, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, insulin resistance, diabetic dyslipidemia, or hypertriglyceridemia or a combination thereof.

Certain embodiments provide methods of treating, preventing, or ameliorating a hyperproliferative disorder.

Certain embodiments provide methods comprising administering to an animal a compound as described herein to an animal. In certain embodiments, the method comprises administering to an animal a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NOs: 4-32 or 50. Certain embodiments provide methods comprising administering to an animal a compound as described herein to an animal. In certain embodiments, the method comprises administering to an animal a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 26.

Certain embodiments provide methods comprising administering to an animal a compound as described herein to an animal. In certain embodiments, the method comprises administering to an animal a modified oligonucleotide consisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NOs: 404173, 410002, 438383, 438445, 438454, 438463, or 438472.

Certain embodiments provide methods comprising administering to an animal a compound as described herein to an animal. In certain embodiments, the method comprises administering to an animal a modified oligonucleotide con-

sisting of 20 to 35 linked nucleosides and having a nucleobase sequence comprising at least 20 contiguous nucleobases of a nucleobase sequence selected from among the nucleobase sequences recited in ISIS NO: 404173.

In certain embodiments, the animal is a human.

In certain embodiments, the administering prevents, treats, ameliorates, or slows progression of a metabolic disease as described herein.

In certain embodiments, the administering prevents, treats, ameliorates, or slows progression of diabetes as described herein.

In certain embodiments, the compound is co-administered with a second agent.

In certain embodiments, the compound and the second agent are administered concomitantly.

In certain embodiments, the administering is parenteral administration.

Certain embodiments further provide a method to reduce PTP1B mRNA or protein expression in an animal comprising administering to the animal a compound or composition as described herein to reduce PTP1B mRNA or protein expression in the animal. In certain embodiments, the animal is a human. In certain embodiments, reducing PTP1B mRNA or protein expression prevents, treats, ameliorates, or slows progression of metabolic disease. In certain embodiments, the metabolic disease or condition is diabetes.

Certain embodiments provide a method for treating a human with a metabolic disease comprising identifying the human with the disease and administering to the human a therapeutically effective amount of a compound or composition as described herein. In certain embodiments, the treatment reduces a symptom selected from the group consisting of metabolic syndrome, hyperglycemia, hypertriglyceridemia, hypertension, increased glucose levels, increased insulin resistance, decreased insulin sensitivity, above normal body weight, and/or above normal body fat or any combination thereof.

Certain embodiments provide a method for treating a human with diabetes comprising identifying the human with the disease and administering to the human a therapeutically effective amount of a compound or composition as described herein. In certain embodiments, the treatment reduces a symptom selected from the group consisting of metabolic syndrome, hyperglycemia, hypertriglyceridemia, hypertension, increased glucose levels, increased insulin resistance, decreased insulin sensitivity, above normal body weight, and/or above normal body fat or any combination thereof.

Further provided is a method for reducing or preventing metabolic disease comprising administering to a human a therapeutically effective amount compound or composition as described herein, thereby reducing or preventing metabolic disease.

Further provided is a method for reducing or preventing diabetes comprising administering to a human a therapeutically effective amount compound or composition as described herein, thereby reducing or preventing diabetes.

Further provided is a method for ameliorating a symptom of metabolic disease, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 20 to 35 linked nucleosides, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby ameliorating a symptom of metabolic disease in the human.

Further provided is a method for ameliorating a symptom of diabetes, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein said

modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby ameliorating a symptom of diabetes in the human.

Further provided is a method for ameliorating a symptom of diabetes, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby ameliorating a symptom of diabetes in the human.

Further provided is a method for reducing the rate of progression of a symptom associated with metabolic disease, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby reducing the rate of progression a symptom of metabolic disease in the human.

Further provided is a method for reducing the rate of progression of a symptom associated with diabetes, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 20 to 35 linked nucleosides, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby reducing the rate of progression a symptom of diabetes in the human.

Further provided is a method for reducing the rate of progression of a symptom associated with diabetes, comprising administering to a human in need thereof a compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO: 1, 2, or 3, thereby reducing the rate of progression a symptom of diabetes in the human.

Also provided are methods and compounds for the preparation of a medicament for the treatment, prevention, or amelioration of metabolic disease.

Also provided are methods and compounds for the preparation of a medicament for the treatment, prevention, or amelioration of diabetes.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, ameliorating, or preventing metabolic disease.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, ameliorating, or preventing diabetes.

Certain embodiments provide a compound as described herein for use in treating, preventing, or ameliorating metabolic disease as described herein by combination therapy with an additional agent or therapy as described herein. Agents or therapies can be co-administered or administered concomitantly.

Certain embodiments provide a compound as described herein for use in treating, preventing, or ameliorating diabetes as described herein by combination therapy with an additional agent or therapy as described herein. Agents or therapies can be co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, preventing, or ameliorating metabolic disease as described herein by combination therapy with an additional agent or therapy as described herein. Agents or therapies can be co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, preventing, or ameliorating diabetes as described

herein by combination therapy with an additional agent or therapy as described herein. Agents or therapies can be co-administered or administered concomitantly.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, preventing, or ameliorating metabolic disease as described herein in a patient who is subsequently administered an additional agent or therapy as described herein.

Certain embodiments provide the use of a compound as described herein in the manufacture of a medicament for treating, preventing, or ameliorating diabetes as described herein in a patient who is subsequently administered an additional agent or therapy as described herein.

Certain embodiments provide a kit for treating, preventing, or ameliorating metabolic disease as described herein wherein the kit comprises:

- (i) a compound as described herein; and alternatively
- (ii) an additional agent or therapy as described herein.

Certain embodiments provide a kit for treating, preventing, or ameliorating diabetes as described herein wherein the kit comprises:

- (i) a compound as described herein; and alternatively
- (ii) an additional agent or therapy as described herein.

A kit as described herein may further include instructions for using the kit to treat, prevent, or ameliorate metabolic disease as described herein by combination therapy as described herein. In certain embodiments, the metabolic disease is diabetes.

Antisense Compounds

Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense oligonucleotides, and siRNAs. An oligomeric compound may be "antisense" to a target nucleic acid, meaning that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.

In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, an antisense compound targeted to a PTP1B nucleic acid is 10 to 30 nucleotides in length. In other words, antisense compounds are from 10 to 30 linked nucleobases. In other embodiments, the antisense compound comprises a modified oligonucleotide consisting of 8 to 80, 10 to 50, 15 to 30, 18 to 21, 20 to 80, 20 to 35, 20 to 30, 20 to 29, 20 to 28, 20 to 27, 20 to 26, 20 to 25, 20 to 24, 20 to 23, 20 to 22, 20 to 21 or 20 linked nucleobases. In certain such embodiments, the antisense compound comprises a modified oligonucleotide consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked nucleobases in length, or a range defined by any two of the above values.

In certain embodiments, the antisense compound comprises a shortened or truncated modified oligonucleotide. The shortened or truncated modified oligonucleotide can have a single nucleoside deleted from the 5' end (5' truncation), or alternatively from the 3' end (3' truncation). A shortened or truncated oligonucleotide may have two nucleosides deleted from the 5' end, or alternatively may

have two subunits deleted from the 3' end. Alternatively, the deleted nucleosides may be dispersed throughout the modified oligonucleotide, for example, in an antisense compound having one nucleoside deleted from the 5' end and one nucleoside deleted from the 3' end.

When a single additional nucleoside is present in a lengthened oligonucleotide, the additional nucleoside may be located at the 5' or 3' end of the oligonucleotide. When two or more additional nucleosides are present, the added nucleosides may be adjacent to each other, for example, in an oligonucleotide having two nucleosides added to the 5' end (5' addition), or alternatively to the 3' end (3' addition), of the oligonucleotide. Alternatively, the added nucleoside may be dispersed throughout the antisense compound, for example, in an oligonucleotide having one nucleoside added to the 5' end and one subunit added to the 3' end.

It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with 1 or 3 mismatches.

Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti-tumor activity in vivo.

Maier and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

Antisense Compound Motifs

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid have chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds properties such as enhanced inhibitory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by in vivo nucleases.

Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound may optionally serve as a substrate for the cellular endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA duplex.

Antisense compounds having a gapmer motif are considered chimeric antisense compounds. In a gapmer an internal region having a plurality of nucleotides that supports RNaseH cleavage is positioned between external regions

having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments comprise modified nucleosides. In certain embodiments, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments include β -D-ribonucleosides, β -D-deoxyribonucleosides, 2'-modified nucleosides (such as 2'-modified nucleosides may include 2'-MOE and 2'-O-CH₃, among others), and bicyclic sugar modified nucleosides (such as bicyclic sugar modified nucleosides may include those having a constrained ethyl). In certain embodiments, wings may include several modified sugar moieties, including, for example 2'-MOE and constrained ethyl. In certain embodiments, wings may include several modified and unmodified sugar moieties. In certain embodiments, wings may include various combinations of 2'-MOE nucleosides, constrained ethyl nucleosides, and 2'-deoxynucleosides.

Each distinct region may comprise uniform sugar moieties, variant, or alternating sugar moieties. The wing-gapmer motif is frequently described as "X-Y-Z", where "X" represents the length of the 5'-wing, "Y" represents the length of the gap, and "Z" represents the length of the 3'-wing. "X" and "Z" may comprise uniform, variant, or alternating sugar moieties. In certain embodiments, "X" and "Y" may include one or more 2'-deoxynucleosides. "Y" may comprise 2'-deoxynucleosides. As used herein, a gapmer described as "X-Y-Z" has a configuration such that the gap is positioned immediately adjacent to each of the 5'-wing and the 3' wing. Thus, no intervening nucleotides exist between the 5'-wing and gap, or the gap and the 3'-wing. Any of the antisense compounds described herein can have a gapmer motif. In certain embodiments, "X" and "Z" are the same, in other embodiments they are different. In certain embodiments, "Y" is between 8 and 15 nucleosides. X, Y, or Z can be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more nucleosides.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid possess a 5-10-5 gapmer motif.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid possess a 6-8-6 gapmer motif.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid possess a 5-8-5 gapmer motif.

In certain embodiments, an antisense compound targeted to a PTP1B nucleic acid has a gap-widened motif.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid possess a 2-13-5 gap-widened motif Target Nucleic Acids, Target Regions and Nucleotide Sequences

In certain embodiments, the PTP1B nucleic acid is any of the sequences set forth in GENBANK Accession No. NM_002827.2 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NT_011362.9 truncated from nucleotides 14178000 to 14256000 (incorporated herein as SEQ ID NO: 2); and a concatenation of sequences from exons 1-9, intron 9 and exon 10 of the rhesus monkey PTP1B scaffold (incorporated herein as SEQ ID NO: 3).

It is understood that the sequence set forth in each SEQ ID NO in the Examples contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage,

or a nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a combination of nucleobase sequence and motif.

In certain embodiments, a target region is a structurally defined region of the target nucleic acid. For example, a target region may encompass a 3' UTR, a 5' UTR, an exon, an intron, an exon/intron junction, a coding region, a translation initiation region, translation termination region, or other defined nucleic acid region. The structurally defined regions for PTP1B can be obtained by accession number from sequence databases such as NCBI and such information is incorporated herein by reference. In certain embodiments, a target region may encompass the sequence from a 5' target site of one target segment within the target region to a 3' target site of another target segment within the same target region.

Targeting includes determination of at least one target segment to which an antisense compound hybridizes, such that a desired effect occurs. In certain embodiments, the desired effect is a reduction in mRNA target nucleic acid levels. In certain embodiments, the desired effect is reduction of levels of protein encoded by the target nucleic acid or a phenotypic change associated with the target nucleic acid.

A target region may contain one or more target segments. Multiple target segments within a target region may be overlapping. Alternatively, they may be non-overlapping. In certain embodiments, target segments within a target region are separated by no more than about 300 nucleotides. In certain embodiments, target segments within a target region are separated by a number of nucleotides that is, is about, is no more than, is no more than about, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides on the target nucleic acid, or is a range defined by any two of the preceding values. In certain embodiments, target segments within a target region are separated by no more than, or no more than about, 5 nucleotides on the target nucleic acid. In certain embodiments, target segments are contiguous. Contemplated are target regions defined by a range having a starting nucleic acid that is any of the 5' target sites or 3' target sites listed herein.

Suitable target segments may be found within a 5' UTR, a coding region, a 3' UTR, an intron, an exon, or an exon/intron junction. Target segments containing a start codon or a stop codon are also suitable target segments. A suitable target segment may specifically exclude a certain structurally defined region such as the start codon or stop codon.

The determination of suitable target segments may include a comparison of the sequence of a target nucleic acid to other sequences throughout the genome. For example, the BLAST algorithm may be used to identify regions of similarity amongst different nucleic acids. This comparison can prevent the selection of antisense compound sequences that may hybridize in a non-specific manner to sequences other than a selected target nucleic acid (i.e., non-target or off-target sequences).

There may be variation in activity (e.g., as defined by percent reduction of target nucleic acid levels) of the antisense compounds within an active target region. In certain embodiments, reductions in PTP1B mRNA levels are indicative of inhibition of PTP1B expression. Reductions in levels of a PTP1B protein are also indicative of inhibition of target mRNA expression. Further, phenotypic changes are indicative of inhibition of PTP1B expression. In certain embodiments, reduced glucose levels, reduced lipid levels, and reduced body weight can be indicative of inhibition of

PTP1B expression. In certain embodiments, amelioration of symptoms associated with metabolic disease can be indicative of inhibition of PTP1B expression. In certain embodiments, amelioration of symptoms associated with diabetes can be indicative of inhibition of PTP1B expression. In certain embodiments, reduction of insulin resistance is indicative of inhibition of PTP1B expression. In certain embodiments, reduction of diabetes biomarkers can be indicative of inhibition of PTP1B expression.

Hybridization

In some embodiments, hybridization occurs between an antisense compound disclosed herein and a PTP1B nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain embodiments, the antisense compounds provided herein are specifically hybridizable with a PTP1B nucleic acid.

Complementarity

An antisense compound and a target nucleic acid are complementary to each other when a sufficient number of nucleobases of the antisense compound can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., antisense inhibition of a target nucleic acid, such as a PTP1B nucleic acid).

An antisense compound may hybridize over one or more segments of a PTP1B nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the antisense compounds provided herein, or a specified portion thereof, are, or are at least, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a PTP1B nucleic acid, a target region, target segment, or specified portion thereof. Percent complementarity of an antisense compound with a target nucleic acid can be determined using routine methods.

For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403-410; Zhang and Madden, *Genome Res.*, 1997, 7, 649-656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix,

Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482 489).

In certain embodiments, the antisense compounds provided herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, antisense compound may be fully complementary to a PTP1B nucleic acid, or a target region, or a target segment or target sequence thereof. As used herein, "fully complementary" means each nucleobase of an antisense compound is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid. For example, a 20 nucleobase antisense compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the antisense compound. Fully complementary can also be used in reference to a specified portion of the first and/or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase antisense compound can be "fully complementary" to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase oligonucleotide is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the antisense compound. At the same time, the entire 30 nucleobase antisense compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense compound are also complementary to the target sequence.

The location of a non-complementary nucleobase may be at the 5' end or 3' end of the antisense compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.

In certain embodiments, antisense compounds that are, or are up to 12, 13, 14, 15, 16, 17, 18, 19, or nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a PTP1B nucleic acid, or specified portion thereof.

In certain embodiments, antisense compounds that are, or are up to 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a PTP1B nucleic acid, or specified portion thereof.

The antisense compounds provided herein also include those which are complementary to a portion of a target nucleic acid. As used herein, "portion" refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A "portion" can also refer to a defined number of contiguous nucleobases of an antisense compound. In certain embodiments, the antisense compounds, are complementary to at least an 8 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 12 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 13 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are comple-

mentary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 15 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 16 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 17 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 18 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 19 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 20 nucleobase portion of a target segment. Also contemplated are antisense compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion of a target segment, or a range defined by any two of these values.

Identity

The antisense compounds provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific Isis number, or portion thereof. As used herein, an antisense compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the antisense compounds described herein as well as compounds having non-identical bases relative to the antisense compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense compound. Percent identity of an antisense compound is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.

In certain embodiments, the antisense compounds, or portions thereof, are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.

Modifications

A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Conse-

quently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleoside Linkages

The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiester, phosphotriester, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

Modified Sugar Moieties

Antisense compounds provided herein can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise a chemically modified ribofuranose ring moiety. Examples of chemically modified ribofuranose rings include, without limitation, addition of substituent groups (including 5' and 2' substituent groups); bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA); replacement of the ribosyl ring oxygen atom with S, N(R), or C(R1)(R2) (R=H, C₁-C₁₂ alkyl or a protecting group); and combinations thereof. Examples of chemically modified sugars include, 2'-F-5'-methyl substituted nucleoside (see, PCT International Application WO 2008/101157, published on Aug. 21, 2008 for other disclosed 5',2'-bis substituted nucleosides), replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see, published U.S. Patent Application US2005/0130923, published on Jun. 16, 2005), or, alternatively, 5'-substitution of a BNA (see, PCT International Application WO 2007/134181, published on Nov. 22, 2007, wherein LNA is substituted with, for example, a 5'-methyl or a 5'-vinyl group).

Examples of nucleosides having modified sugar moieties include, without limitation, nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'-F, 2'-OCH₃, and 2'-O(CH₂)₂OCH₃ substituent groups. The substituent at the 2' position can also be selected from allyl, amino, azido, thio, O-allyl, O-C₁-C₁₀ alkyl, OCF₃, O(CH₂)₂SCH₃, O(CH₂)₂-O-N(Rm)(Rn) and O-CH₂-C(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.

As used herein, "bicyclic nucleosides" refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include, without limitation, nucleo-

sides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides wherein the bridge comprises a 4' to 2' bicyclic nucleoside. Examples of such 4' to 2' bicyclic nucleosides, include, but are not limited to, one of the formulae: 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4'-CH(CH₃)—O-2' and 4'-CH(CH₂OCH₃)—O-2', and analogs thereof (see, U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4'-C(CH₃)(CH₃)—O-2', and analogs thereof (see, published PCT International Application WO2009/006478, published Jan. 8, 2009); 4'-CH₂—N(OCH₃)-2', and analogs thereof (see, published PCT International Application WO2008/150729, published Dec. 11, 2008); 4'-CH₂—O—N(CH₃)-2' (see, published U.S. Patent Application US2004/0171570, published Sep. 2, 2004); 4'-CH₂—N(R)—O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see, U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4'-CH₂—C(H)(CH₃)-2' (see, Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH₂—C(=CH₂)-2', and analogs thereof (see, published PCT International Application WO 2008/154401, published on Dec. 8, 2008). Also see, for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S. A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 6,670,461, 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 7,399,845; published PCT International applications WO 2004/106356, WO 94/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent Publication Nos. US2004/0171570, US2007/0287831, and US2008/0039618; and U.S. patent Ser. Nos. 12/129,154, 60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International Application Nos. PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922. Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see PCT international application PCT/DK98/00393, published on Mar. 25, 1999 as WO 99/14226).

In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R_a)(R_b)]_n—, —C(R_a)=C(R_b)—, —C(R_a)=N—, —C(=NR_a)—, —C(=O)—, —C(=S)—, —O—, —Si(R_a)₂—, —S(=O)_x—, and —N(R_a)—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_a and R_b is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)—H), substituted acyl, CN, sulfonyl (S(=O)₂—J₁), or sulfoxyl (S(=O)—J₁); and


35

each J_1 and J_2 is, independently, H, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, acyl ($C(=O)$ -H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C_1 - C_{12} aminoalkyl, substituted C_1 - C_{12} aminoalkyl, or a protecting group.


In certain embodiments, the bridge of a bicyclic sugar moiety is, $-[C(R_a)(R_b)]_n-$, $-[C(R_a)(R_b)]_n-O-$, $-C(R_aR_b)-N(R)-O-$ or $-C(R_aR_b)-O-N(R)-$. In certain embodiments, the bridge is $4'-(CH_2)-2'$, $4'-(CH_2)_2-2'$, $4'-(CH_2)_3-2'$, $4'-CH_2-O-2'$, $4'-(CH_2)_2-O-2'$, $4'-CH_2-O-N(R)-2'$, and $4'-CH_2-N(R)-O-2'$, wherein each R is, independently, H, a protecting group, or C_1 - C_{12} alkyl.

In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a $4'$ - $2'$ methylene-oxy bridge, may be in the α -L configuration or in the β -D configuration. Previously, α -L-methyleneoxy ($4'-CH_2-O-2'$) BNA's have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., *Nucleic Acids Research*, 2003, 21, 6365-6372).


In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) α -L-Methyleneoxy ($4'-CH_2-O-2'$) BNA, (B) β -D-Methyleneoxy ($4'-CH_2-O-2'$) BNA, (C) Ethyleneoxy ($4'-(CH_2)_2-O-2'$) BNA, (D) Aminooxy ($4'-CH_2-O-N(R)-2'$) BNA, (E) Oxyamino ($4'-CH_2-N(R)-O-2'$) BNA, (F) Methyl(methyleneoxy) ($4'-CH(CH_3)-O-2'$) BNA, (G) methylene-thio ($4'-CH_2-S-2'$) BNA, (H) methylene-amino ($4'-CH_2-N(R)-2'$) BNA, (I) methyl carbocyclic ($4'-CH_2-CH(CH_3)-2'$) BNA, and (J) propylene carbocyclic ($4'-(CH_2)_3-2'$) BNA as depicted below.




(A)



(B)




(C)




(D)

36


-continued




(E)




(F)




(G)



(H)



(I)




(J)

wherein Bx is the base moiety and R is, independently, H, a protecting group or C_1 - C_{12} alkyl.

In certain embodiments, bicyclic nucleoside having formula I:

37



wherein:


Bx is a heterocyclic base moiety;

$-Q_a-Q_b-Q_c-$ is $-\text{CH}_2-\text{N}(\text{R}_c)-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{N}(\text{R}_c)-\text{CH}_2-$, $-\text{CH}_2-\text{O}-\text{N}(\text{R}_c)-$, $-\text{CH}_2-\text{N}(\text{R}_c)-\text{O}-$, or $-\text{N}(\text{R}_c)-\text{O}-\text{CH}_2-$;

R_c is C_1-C_{12} alkyl or an amino protecting group; and

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium.

In certain embodiments, bicyclic nucleoside having Formula II:



wherein:


Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

Z_a is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl, substituted C_2-C_6 alkynyl, acyl, substituted acyl, substituted amide, thiol, or substituted thio.

In one embodiment, each of the substituted groups is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, $\text{OJ}_{c'}$, $\text{NJ}_{c'd'}$, $\text{SJ}_{c'}$, N_3 , $\text{OC}(=\text{X})\text{J}_{c'}$, and $\text{NJ}_e\text{C}(=\text{X})\text{NJ}_{c'd'}$, wherein each $\text{J}_{c'}$, $\text{J}_{d'}$, and J_e is, independently, H, C_1-C_6 alkyl, or substituted C_1-C_6 alkyl and X is O or $\text{NJ}_{c'}$.

In certain embodiments, bicyclic nucleoside having Formula III:



38


wherein:

I Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

Z_b is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl, substituted C_2-C_6 alkynyl, or substituted acyl ($\text{C}(=\text{O})-$).

In certain embodiments, bicyclic nucleoside having Formula IV:



IV

25

II wherein:


Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

R_d is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, substituted C_2-C_6 alkenyl, C_2-C_6 alkynyl, or substituted C_2-C_6 alkynyl;

each q_a , q_b , q_c and q_d is, independently, H, halogen, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, substituted C_2-C_6 alkenyl, C_2-C_6 alkynyl, or substituted C_2-C_6 alkynyl, C_1-C_6 alkoxy, substituted C_1-C_6 alkoxy, acyl, substituted acyl, C_1-C_6 aminoalkyl, or substituted C_1-C_6 aminoalkyl;

In certain embodiments, bicyclic nucleoside having Formula V:



V

wherein:

III Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;


q_a , q_b , q_e and q_f are each, independently, hydrogen, halogen, C_1-C_{12} alkyl, substituted C_1-C_{12} alkyl, C_2-C_{12} alkenyl, substituted C_2-C_{12} alkenyl, C_2-C_{12} alkynyl, substituted C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, substituted C_1-C_{12} alkoxy, $\text{OJ}_{j'}$, $\text{SJ}_{j'}$, $\text{SOJ}_{j'}$, $\text{SO}_2\text{J}_{j'}$, $\text{NJ}_{j'k'}$, N_3 , CN , $\text{C}(=\text{O})\text{OJ}_{j'}$, $\text{C}(=\text{O})\text{NJ}_{j'k'}$, $\text{C}(=\text{O})\text{J}_{j'}$, $\text{O}-\text{C}(=\text{O})\text{NJ}_{j'k'}$, $\text{N}(\text{H})\text{C}(=\text{NH})\text{NJ}_{j'k'}$, $\text{N}(\text{H})\text{C}(=\text{O})\text{NJ}_{j'k'}$ or $\text{N}(\text{H})\text{C}(=\text{S})\text{NJ}_{j'k'}$;

or q_e and q_f together are $=C(q_g)(q_h)$;

q_g and q_h are each, independently, H, halogen, C_1 - C_{12} alkyl, or substituted C_1 - C_{12} alkyl.

The synthesis and preparation of the methyleneoxy (4'- CH_2 -O-2') BNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine, and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (see, e.g., Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). BNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226.

Analogues of methyleneoxy (4'- CH_2 -O-2') BNA, methyleneoxy (4'- CH_2 -O-2') BNA, and 2'-thio-BNAs, have also been prepared (see, e.g., Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222). Preparation of locked nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (see, e.g., Wengel et al., WO 99/14226). Furthermore, synthesis of 2'-amino-BNA, a novel conformationally restricted high-affinity oligonucleotide analog, has been described in the art (see, e.g., Singh et al., J. Org. Chem., 1998, 63, 10035-10039). In addition, 2'-amino- and 2'-methylamino-BNA's have been prepared and the thermal stability of their duplexes with complementary RNA and DNA strands has been previously reported. In certain embodiments, bicyclic nucleoside having Formula VI:



VI

wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

each q_i , q_j , q_k and q_l is, independently, H, halogen, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_1 - C_{12} alkoxy, substituted C_1 - C_{12} alkoxy, OJ_j , SJ_j , SOJ_j , SO_2J_j , NJ_jJ_k , N_3 , CN , $C(=O)OJ_j$, $C(=O)NJ_jJ_k$, $C(=O)J_j$, $O-C(=O)NJ_jJ_k$, $N(H)C(=NH)NJ_jJ_k$, $N(H)C(=O)NJ_jJ_k$, or $N(H)C(=S)NJ_jJ_k$; and

q_i and q_j or q_l and q_k together are $=C(q_g)(q_h)$, wherein q_g and q_h are each, independently, H, halogen, C_1 - C_{12} alkyl, or substituted C_1 - C_{12} alkyl.

One carbocyclic bicyclic nucleoside having a 4'-(CH_2)₃-2' bridge and the alkenyl analog, bridge 4'- $CH=CH-CH_2$ -2', have been described (see, e.g., Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379).


As used herein, "4'-2' bicyclic nucleoside" or "4' to 2' bicyclic nucleoside" refers to a bicyclic nucleoside comprising a furanose ring comprising a bridge connecting the 2' carbon atom and the 4' carbon atom.

As used herein, "monocyclic nucleosides" refer to nucleosides comprising modified sugar moieties that are not bicyclic sugar moieties. In certain embodiments, the sugar moiety, or sugar moiety analogue, of a nucleoside may be modified or substituted at any position.

As used herein, "2'-modified sugar" means a furanosyl sugar modified at the 2' position. In certain embodiments, such modifications include substituents selected from: a halide, including, but not limited to substituted and unsubstituted alkoxy, substituted and unsubstituted thioalkyl, substituted and unsubstituted amino alkyl, substituted and unsubstituted alkyl, substituted and unsubstituted allyl, and substituted and unsubstituted alkynyl. In certain embodiments, 2' modifications are selected from substituents including, but not limited to: $O[(CH_2)_nO]_mCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, $OCH_2C(=O)N(H)CH_3$, and $O(CH_2)_nON[(CH_2)_mCH_3]_2$, where n and m are from 1 to about 10. Other 2'-substituent groups can also be selected from: C_1 - C_{12} alkyl; substituted alkyl; alkenyl; alkynyl; aralkyl; aralkyl; O-alkaryl or O-aralkyl; SH; SCH₃; OCN; Cl; Br; CN; CF₃; OCF₃; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving pharmacokinetic properties; and a group for improving the pharmacodynamic properties of an antisense compound, and other substituents having similar properties. In certain embodiments, modified nucleosides comprise a 2'-MOE side chain (see, e.g., Baker et al., J. Biol. Chem., 1997, 272, 11944-12000). Such 2'-MOE substitution have been described as having improved binding affinity compared to unmodified nucleosides and to other modified nucleosides, such as 2'-O-methyl, O-propyl, and O-amino-propyl. Oligonucleotides having the 2'-MOE substituent also have been shown to be antisense inhibitors of gene expression with promising features for in vivo use (see, e.g., Martin, P., Helv. Chim. Acta, 1995, 78, 486-504; Altmann et al., Chimia, 1996, 50, 168-176; Altmann et al., Biochem. Soc. Trans., 1996, 24, 630-637; and Altmann et al., Nucleosides Nucleotides, 1997, 16, 917-926).

As used herein, a "modified tetrahydropyran nucleoside" or "modified THP nucleoside" means a nucleoside having a six-membered tetrahydropyran "sugar" substituted in for the pentofuranosyl residue in normal nucleosides (a sugar surrogate). Modified THP nucleosides include, but are not limited to, what is referred to in the art as hexitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (see Leumann, C J. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), or those compounds having Formula X:

Formula X:



X

wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula X:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound or one of T₃ and T₄ is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5' or 3'-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and

one of R₁ and R₂ is hydrogen and the other is selected from halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(=X)NJ₁, OC(=X)NJ₁J₂, NJ₃C(=X)NJ₁J₂, and CN, wherein X is O, S, or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula X are provided wherein q_m, q_n, q_p, q_r, q_s, q_t, and q_u are each H. In certain embodiments, at least one of q_m, q_n, q_p, q_r, q_s, q_t, and q_u is other than H. In certain embodiments, at least one of q_m, q_n, q_p, q_r, q_s, q_t, and q_u is methyl. In certain embodiments, THP nucleosides of Formula X are provided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ is fluoro and R₂ is H, R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxy and R₂ is H.

As used herein, "2'-modified" or "2'-substituted" refers to a nucleoside comprising a sugar comprising a substituent at the 2' position other than H or OH. 2'-modified nucleosides, include, but are not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring connects the 2' carbon and another carbon of the sugar ring and nucleosides with non-bridging 2' substituents, such as allyl, amino, azido, thio, O-allyl, O-C₁-C₁₀ alkyl, —OCF₃, O-(CH₂)₂-O-CH₃, 2'-O(CH₂)₂SCH₃, O-(CH₂)₂-O-N(R_m)(R_n), or O-CH₂-C(=O)-N(R_m)(R_n), where each R_m and R_n is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl. 2'-modified nucleosides may further comprise other modifications, for example, at other positions of the sugar and/or at the nucleobase.

As used herein, "2'-F" refers to a sugar comprising a fluoro group at the 2' position.

As used herein, "2'-OMe" or "2'-OCH₃" or "2'-O-methyl" each refers to a sugar comprising an —OCH₃ group at the 2' position of the sugar ring.

As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA).

Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be used to modify nucleosides for incorporation into antisense compounds (see, e.g., review article: Leumann, J. C, *Bioorganic & Medicinal Chemistry*, 2002, 10, 841-854). Such ring systems can undergo various additional substitutions to enhance activity.

Methods for the preparations of modified sugars are well known to those skilled in the art.

In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified, or a combination thereof) are maintained for hybridization with an appropriate nucleic acid target.

In certain embodiments, antisense compounds comprise one or more nucleotides having modified sugar moieties. In certain embodiments, the modified sugar moiety is 2'-MOE.

In certain embodiments, the 2'-MOE modified nucleotides are arranged in a gapmer motif. In certain embodiments, the modified sugar moiety is a cEt. In certain embodiments, the cEt modified nucleotides are arranged throughout the wings of a gapmer motif.

Modified Nucleobases

Nucleobase (or base) modifications or substitutions are structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of participating in hydrogen bonding. Such nucleobase modifications may impart nuclease stability, binding affinity or some other beneficial biological property to antisense compounds. Modified nucleobases include synthetic and natural nucleobases such as, for example, 5-methylcytosine (5-me-C). Certain nucleobase substitutions, including 5-methylcytosine substitutions, are particularly useful for increasing the binding affinity of an antisense compound for a target nucleic acid. For example, 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278).

Additional unmodified nucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thio-uracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Nucleobases that are particularly useful for increasing the binding affinity of antisense compounds include 5-substituted pyrimidines, 6-azapyrimidines and N2, N-6 and O-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, antisense compounds targeted to a PTP1B nucleic acid comprise one or more modified nucleobases. In certain embodiments, gap-widened antisense oligonucleotides targeted to a PTP1B nucleic acid comprise one or more modified nucleobases. In certain embodiments, the modified nucleobase is 5-methylcytosine. In certain embodiments, each cytosine is a 5-methylcytosine.

Compositions and Methods for Formulating Pharmaceutical Compositions

Antisense oligonucleotides may be admixed with pharmaceutically acceptable active or inert substance for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

Antisense compound targeted to a PTP1B nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically

acceptable diluent or carrier. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS). PBS is a diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to a PTP1B nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is PBS. In certain embodiments, the antisense compound is an antisense oligonucleotide.

Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

Pharmaceutically acceptable salts of the compounds described herein may be prepared by methods well-known in the art. For a review of pharmaceutically acceptable salts, see Stahl and Wermuth, *Handbook of Pharmaceutical Salts: Properties, Selection and Use* (Wiley-VCH, Weinheim, Germany, 2002). Sodium salts of antisense oligonucleotides are useful and are well accepted for therapeutic administration to humans. Accordingly, in one embodiment the compounds described herein are in the form of a sodium salt.

A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound which are cleaved by endogenous nucleases within the body, to form the active antisense compound.

Conjugated Antisense Compounds

Antisense compounds may be covalently linked to one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides. Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

Antisense compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense compounds to enhance properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense compound having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-terminus (5'-cap), or at the 3'-terminus (3'-cap), or can be present on both termini. Cap structures are well known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5'-stabilizing groups that can be used to cap one or both ends of an antisense compound to impart nuclease stability include those disclosed in WO 03/004602 published on Jan. 16, 2003.

Cell Culture and Antisense Compounds Treatment

The effects of antisense compounds on the level, activity or expression of PTP1B nucleic acids can be tested in vitro in a variety of cell types. Cell types used for such analyses are available from commercial vendors (e.g. American Type Culture Collection, Manassus, Va.; Zen-Bio, Inc., Research Triangle Park, N.C.; Clonetics Corporation, Walkersville, Md.) and cells are cultured according to the vendor's instructions using commercially available reagents (e.g.

Invitrogen Life Technologies, Carlsbad, Calif.). Illustrative cell types include, but are not limited to, HepG2 cells, Hep3B cells, primary hepatocytes, A549 cells, GM04281 fibroblasts and LLC-MK2 cells.

5 In Vitro Testing of Antisense Oligonucleotides

Described herein are methods for treatment of cells with antisense oligonucleotides, which can be modified appropriately for treatment with other antisense compounds.

10 In general, cells are treated with antisense oligonucleotides when the cells reach approximately 60-80% confluence in culture.

One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes the cationic lipid transfection reagent LIPOFECTIN® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotides are mixed with LIPOFECTIN® in OPTI-MEM® 1 (Invitrogen, Carlsbad, Calif.) to achieve the desired final concentration of antisense oligonucleotide and a LIPOFECTIN® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides into cultured cells includes LIPOFECTAMINE 2000® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotide is mixed with LIPOFECTAMINE 2000® in OPTI-MEM® 1 reduced serum medium (Invitrogen, Carlsbad, Calif.) to achieve the desired concentration of antisense oligonucleotide and a LIPOFECTAMINE® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides into cultured cells includes Cytofectin® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotide is mixed with Cytofectin® in OPTI-MEM® 1 reduced serum medium (Invitrogen, Carlsbad, Calif.) to achieve the desired concentration of antisense oligonucleotide and a Cytofectin® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another technique used to introduce antisense oligonucleotides into cultured cells includes electroporation.

40 Cells are treated with antisense oligonucleotides by routine methods. Cells are typically harvested 16-24 hours after antisense oligonucleotide treatment, at which time RNA or protein levels of target nucleic acids are measured by methods known in the art and described herein. In general, when treatments are performed in multiple replicates, the data are presented as the average of the replicate treatments.

The concentration of antisense oligonucleotide used varies from cell line to cell line. Methods to determine the optimal antisense oligonucleotide concentration for a particular cell line are well known in the art. Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM when transfected with LIPOFECTAMINE2000®, Lipofectin or Cytofectin. Antisense oligonucleotides are used at higher concentrations ranging from 625 to 20,000 nM when transfected using electroporation.

RNA Isolation

RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. RNA is prepared using methods well known in the art, for example, using the TRIZOL® Reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's recommended protocols.

Analysis of Inhibition of Target Levels or Expression

65 Inhibition of levels or expression of a PTP1B nucleic acid can be assayed in a variety of ways known in the art. For example, target nucleic acid levels can be quantitated by,

e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or quantitative real-time PCR. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art. Quantitative

real-time PCR can be conveniently accomplished using the commercially available ABI PRISM® 7600, 7700, or 7900 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.

Quantitative Real-Time PCR Analysis of Target RNA Levels
Quantitation of target RNA levels may be accomplished by quantitative real-time PCR using the ABI PRISM® 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. Methods of quantitative real-time PCR are well known in the art.

Prior to real-time PCR, the isolated RNA is subjected to a reverse transcriptase (RT) reaction, which produces complementary DNA (cDNA) that is then used as the

substrate for the real-time PCR amplification. The RT and real-time PCR reactions are performed sequentially in the same sample well. RT and real-time PCR reagents are obtained from Invitrogen (Carlsbad, Calif.). RT, real-time-PCR reactions are carried out by methods well known to those skilled in the art.

Gene (or RNA) target quantities obtained by real time PCR are normalized using either the expression level of a gene whose expression is constant, such as cyclophilin A, or by quantifying total RNA using RIBOGREEN® (Invitrogen, Inc. Carlsbad, Calif.). Cyclophilin A expression is quantified by real time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RIBOGREEN® RNA quantification reagent (Invitrogen, Inc. Eugene, Oreg.). Methods of RNA quantification by RIBOGREEN® are taught in Jones, L. J., et al, (Analytical Biochemistry, 1998, 265, 368-374). A CYTOFLUOR® 4000 instrument (PE Applied Biosystems) is used to measure RIBOGREEN® fluorescence.

Probes and primers are designed to hybridize to a PTP1B nucleic acid. Methods for designing real-time PCR probes and primers are well known in the art, and may include the use of software such as PRIMER EXPRESS® Software (Applied Biosystems, Foster City, Calif.).

Analysis of Protein Levels

Antisense inhibition of PTP1B nucleic acids can be assessed by measuring PTP1B protein levels. Protein levels of PTP1B can be evaluated or quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked immunosorbent assay (ELISA), quantitative protein assays, protein activity assays (for example, caspase activity assays), immunohistochemistry, immunocytochemistry or fluorescence-activated cell sorting (FACS). Antibodies directed to a target can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art. Antibodies useful for the detection of human and rat PTP1B are commercially available.

In Vivo Testing of Antisense Compounds

Antisense compounds, for example, antisense oligonucleotides, are tested in animals to assess their ability to inhibit expression of PTP1B and produce phenotypic changes. Testing may be performed in normal animals, or in experimental disease models. For administration to animals, anti-

sense oligonucleotides are formulated in a pharmaceutically acceptable diluent, such as phosphate-buffered saline. Administration includes parenteral routes of administration. Following a period of treatment with antisense oligonucleotides, RNA is isolated from tissue and changes in PTP1B nucleic acid expression are measured. Changes in PTP1B protein levels are also measured.

Certain Indications

In certain embodiments, provided herein are methods of treating an individual comprising administering one or more pharmaceutical compositions as described herein. In certain embodiments, the individual has metabolic related disease.

As shown in the examples below, compounds targeted to PTP1B, as described herein, have been shown to reduce the severity of physiological symptoms of metabolic related diseases, including metabolic syndrome, diabetes mellitus, insulin resistance, diabetic dyslipidemia, hypertriglyceridemia, obesity and weight gain. In certain of the experiments, the compounds reduced blood glucose levels, e.g., the animals continued to experience symptoms, but the symptoms were less severe compared to untreated animals. In other of the experiments, however, the compounds appear to reduce the symptoms of diabetes; e.g., animals treated for a longer period of time experienced less severe symptoms than those administered the compounds for a shorter period of time. In other of the experiments, however, the compounds appear to inhibit weight gain; e.g., animals treated for a longer period of time experienced less severe symptoms than those administered the compounds for a shorter period of time. In other of the experiments, however, the compounds appear to inhibit hypertriglyceridemia; e.g., animals treated for a longer period of time experienced less severe symptoms than those administered the compounds for a shorter period of time. The ability of the compounds exemplified below to restore function therefore demonstrates that symptoms of the disease may be reversed by treatment with a compound as described herein.

Diabetes mellitus is characterized by numerous physical and physiological symptoms. Any symptom known to one of skill in the art to be associated with Type 2 diabetes can be ameliorated or otherwise modulated as set forth above in the methods described above. In certain embodiments, the symptom is a physical symptom selected from the group consisting of increased glucose levels, increased weight gain, frequent urination, unusual thirst, extreme hunger, extreme fatigue, blurred vision, frequent infections, tingling or numbness at the extremities, dry and itchy skin, weight loss, slow-healing sores, and swollen gums.

In certain embodiments, the symptom is a physiological symptom selected from the group consisting of increased insulin resistance, increased glucose levels, increased fat mass, decreased metabolic rate, decreased glucose clearance, decreased glucose tolerance, decreased insulin sensitivity, decreased hepatic insulin sensitivity, increased adipose tissue size and weight, increased body fat, and increased body weight.

In certain embodiments, the physical symptom is increased weight gain. In certain embodiments, the symptom is frequent urination. In certain embodiments, the symptom is unusual thirst. In certain embodiments, the symptom is extreme hunger. In certain embodiments, the symptom is extreme fatigue. In certain embodiments, the symptom is blurred vision. In certain embodiments, the symptom is frequent infections. In certain embodiments, the symptom is tingling or numbness at the extremities. In certain embodiments, the symptom is dry and itchy skin. In certain embodiments, the symptom is weight loss. In certain embodiments,

the symptom is slow-healing sores. In certain embodiments, the symptom is swollen gums. In certain embodiments, the symptom is increased insulin resistance. In certain embodiments, the symptom is increased fat mass. In certain embodiments, the symptom is decreased metabolic rate. In certain embodiments, the symptom is decreased glucose clearance. In certain embodiments, the symptom is decreased glucose tolerance. In certain embodiments, the symptom is decreased insulin sensitivity. In certain embodiments, the symptom is decreased hepatic insulin sensitivity. In certain embodiments, the symptom is increased adipose tissue size and weight. In certain embodiments, the symptom is increased body fat. In certain embodiments, the symptom is increased body weight.

Liu and Chemoff have shown that PTP1B binds to and serves as a substrate for the epidermal growth factor receptor (EGFR) (Liu and Chemoff, *Biochem. J.*, 1997, 327, 139-145). Furthermore, in A431 human epidermoid carcinoma cells, PTP1B was found to be inactivated by the presence of H₂O₂ generated by the addition of EGF. These studies indicate that PTP1B can be negatively regulated by the oxidation state of the cell, which is often deregulated during tumorigenesis (Lee et al., *J. Biol. Chem.*, 1998, 273, 15366-15372).

Overexpression of PTP1B has been demonstrated in malignant ovarian cancers and this correlation was accompanied by a concomitant increase in the expression of the associated growth factor receptor (Wiener et al., *Am. J. Obstet. Gynecol.*, 1994, 170, 1177-1183).

PTP1B has been shown to suppress transformation in NIH3T3 cells induced by the neu oncogene (Brown-Shimer et al., *Cancer Res.*, 1992, 52, 478-482), as well as in rat 3Y1 fibroblasts induced by v-src, v-src, and v-ras (Liu et al., *Mol. Cell. Biol.*, 1998, 18, 250-259) and rat-1 fibroblasts induced by bcr-abl (LaMontagne et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1998, 95, 14094-14099). It has also been shown that PTP1B promotes differentiation of K562 cells, a chronic myelogenous leukemia cell line, in a similar manner as does an inhibitor of the bcr-abl oncoprotein. These studies describe the possible role of PTP1B in controlling the pathogenesis of chronic myeloid leukemia (LaMontagne et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1998, 95, 14094-14099).

Accordingly, provided herein are methods for ameliorating a symptom associated with hyperproliferative disorders in a subject in need thereof. In certain embodiments, the hyperproliferative disorder is cancer. In certain embodiments, provided herein are methods for ameliorating a symptom associated with cancer. In certain embodiments, provided is a method for reducing the rate of onset of a symptom associated with hyperproliferative disorders. In certain embodiments, provided is a method for reducing the rate of onset of a symptom associated with cancer. In certain embodiments, provided is a method for reducing the severity of a symptom associated with hyperproliferative disorders. In certain embodiments, provided is a method for reducing the severity of a symptom associated with cancer. In such embodiments, the methods comprise administering to an individual in need thereof a therapeutically effective amount of a compound targeted to a PTP1B nucleic acid.

In certain embodiments, provided are methods of treating an individual comprising administering one or more pharmaceutical compositions as described herein. In certain embodiments, the individual has metabolic related disease.

In certain embodiments, administration of an antisense compound targeted to a PTP1B nucleic acid results in reduction of PTP1B expression by at least about 15, 20, 25,

30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values.

In certain embodiments, pharmaceutical compositions comprising an antisense compound targeted to transthyretin are used for the preparation of a medicament for treating a patient suffering or susceptible to metabolic related disease.

In certain embodiments, the methods described herein include administering a compound comprising a modified oligonucleotide having a contiguous nucleobases portion as described herein of a sequence recited in SEQ ID NO: 26 (ISIS 404173).

Administration

In certain embodiments, the compounds and compositions as described herein may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical, pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. The compounds and compositions as described herein can be administered directly to a tissue or organ.

In certain embodiments, the compounds and compositions as described herein are administered parenterally. "Parenteral administration" means administration through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intracerebral administration, intrathecal administration, intraventricular administration, ventricular administration, intracerebroventricular administration, cerebral intraventricular administration or cerebral ventricular administration. Administration can be continuous, or chronic, or short or intermittent.

In certain embodiments, parenteral administration is by injection. The injection can be delivered with a syringe or a pump. In certain embodiments, the injection is a bolus injection. In certain embodiments, the injection is administered directly to a tissue or organ.

In certain embodiments, the compounds and compositions as described herein are administered parenterally.

In certain embodiments, parenteral administration is subcutaneous.

In further embodiments, the formulation for administration is the compounds described herein and saline.

In certain embodiments, an antisense oligonucleotide is delivered by injection or infusion once every month, every two months, every 90 days, every 3 months, every 6 months, twice a year or once a year.

Certain Combination Therapies

In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease, disorder, or condition as the one or more pharmaceutical compositions described herein. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease, disorder, or condition as the one or more pharmaceutical compositions described herein. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired side effect of one or more pharmaceutical compositions as described herein. In certain embodiments, one or more pharmaceutical compositions are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compo-

sitions are co-administered with another pharmaceutical agent to produce a combinational effect. In certain embodiments, one or more pharmaceutical compositions are co-administered with another pharmaceutical agent to produce a synergistic effect.

In certain embodiments, a first agent and one or more second agents are administered at the same time. In certain embodiments, the first agent and one or more second agents are administered at different times. In certain embodiments, the first agent and one or more second agents are prepared together in a single pharmaceutical formulation. In certain embodiments, the first agent and one or more second agents are prepared separately.

In certain embodiments, the second compound is administered prior to administration of a pharmaceutical composition of the present invention. In certain embodiments, the second compound is administered following administration of a pharmaceutical composition of the present invention. In certain embodiments, the second compound is administered at the same time as a pharmaceutical composition of the present invention. In certain embodiments, the dose of a co-administered second compound is the same as the dose that would be administered if the second compound was administered alone. In certain embodiments, the dose of a co-administered second compound is lower than the dose that would be administered if the second compound was administered alone. In certain embodiments, the dose of a co-administered second compound is greater than the dose that would be administered if the second compound was administered alone.

In certain embodiments, the co-administration of a second compound enhances the effect of a first compound, such that co-administration of the compounds results in an effect that is greater than the effect of administering the first compound alone. In certain embodiments, the co-administration results in effects that are additive of the effects of the compounds when administered alone. In certain embodiments, the co-administration results in effects that are supra-additive of the effects of the compounds when administered alone. In certain embodiments, the first compound is an antisense compound. In certain embodiments, the second compound is an antisense compound.

In certain embodiments, second agents include, but are not limited to, a glucose-lowering agent. The glucose lowering agent can include, but is not limited to, a therapeutic lifestyle change, PPAR agonist, a dipeptidyl peptidase (IV) inhibitor, a GLP-1 analog, insulin or an insulin analog, an insulin secretagogue, a SGLT2 inhibitor, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, or a combination thereof. The glucose-lowering agent can include, but is not limited to metformin, sulfonylurea, rosiglitazone, meglitinide, thiazolidinedione, alpha-glucosidase inhibitor or a combination thereof. The sulfonylurea can be acetohexamide, chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or a gliclazide. The meglitinide can be nateglinide or repaglinide. The thiazolidinedione can be pioglitazone or rosiglitazone. The alpha-glucosidase can be acarbose or miglitol.

In some embodiments, the glucose-lowering therapeutic is a GLP-1 analog. In some embodiments, the GLP-1 analog is exendin-4 or liraglutide.

In other embodiments, the glucose-lowering therapeutic is a sulfonylurea. In some embodiments, the sulfonylurea is acetohexamide, chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or a gliclazide.

In some embodiments, the glucose-lowering drug is a biguanide. In some embodiments, the biguanide is met-

formin, and in some embodiments, blood glucose levels are decreased without increased lactic acidosis as compared to the lactic acidosis observed after treatment with metformin alone.

5 In some embodiments, the glucose-lowering drug is a meglitinide. In some embodiments, the meglitinide is nateglinide or repaglinide.

In some embodiments, the glucose-lowering drug is a thiazolidinedione. In some embodiments, the thiazolidinedione is pioglitazone, rosiglitazone, or troglitazone. In some embodiments, blood glucose levels are decreased without greater weight gain than observed with rosiglitazone treatment alone.

10 In some embodiments, the glucose-lowering drug is an alpha-glucosidase inhibitor. In some embodiments, the alpha-glucosidase inhibitor is acarbose or miglitol.

In a certain embodiment, a co-administered glucose-lowering agent is ISIS 113715.

15 In a certain embodiment, glucose-lowering therapy is therapeutic lifestyle change.

In certain embodiments, second agents include, but are not limited to, lipid-lowering agents. The lipid-lowering agent can include, but is not limited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. In certain such embodiments, the lipid-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the lipid-lowering agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the lipid-lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co-administered lipid-lowering agent is the same as the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is lower than the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is greater than the dose that would be administered if the lipid-lowering agent was administered alone.

20 In certain embodiments, a co-administered lipid-lowering agent is a HMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoA reductase inhibitor is a statin. In certain such embodiments the statin is selected from atorvastatin, simvastatin, pravastatin, fluvastatin, and rosuvastatin.

In certain embodiments, a co-administered lipid-lowering agent is a cholesterol absorption inhibitor. In certain such embodiments, cholesterol absorption inhibitor is ezetimibe.

25 In certain embodiments, a co-administered lipid-lowering agent is a co-formulated HMG-CoA reductase inhibitor and cholesterol absorption inhibitor. In certain such embodiments the co-formulated lipid-lowering agent is ezetimibe/simvastatin.

In certain embodiments, a co-administered lipid-lowering agent is a microsomal triglyceride transfer protein inhibitor (MTP inhibitor).

30 In certain embodiments, a co-administered lipid-lowering agent is an oligonucleotide targeted to ApoB.

In certain embodiments, second agents include, but are not limited to an anti-obesity drug or agent. Such anti-obesity agents include but are not limited to Orlistat, Sibutramine, or Rimonabant, and may be administered as described above as adipose or body weight lowering agents. In certain embodiments, the antisense compound may be co-administered with appetite suppressants. Such appetite

suppressants include but are not limited to diethylpropion tenate, mazindol, orlistat, phendimetrazine, phentermine, and sibutramine and may be administered as described herein. In certain embodiment, the anti-obesity agents are CNS based such as, but not limited to, sibutramine or GLP-1 based such as, but not limited to, liraglutide.

Formulations

The compounds provided herein may also be admixed, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds provided herein encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds provided herein: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. The term "pharmaceutically acceptable salt" includes a salt prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic or organic acids and bases. For oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety. Sodium salts have been shown to be suitable forms of oligonucleotide drugs.

The term "pharmaceutically acceptable derivative" encompasses, but is not limited to, pharmaceutically acceptable salts, solvates, hydrates, esters, prodrugs, polymorphs, isomers, isotopically labeled variants of the compounds described herein.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds provided herein. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intracerebral administration, intrathecal administration, intraventricular administration, ventricular administration, intracerebroventricular administration, cerebral intraventricular administration or cerebral ventricular administration.

Parenteral administration, is preferred to target PTP1B expression in the liver and plasma. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and pow-

ders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

Formulations of the present invention include liposomal formulations. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes which are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

In another embodiment, formulations of the present invention include saline formulations. In certain embodiments, a formulation consists of the compounds described herein and saline. In certain embodiments, a formulation consists essentially of the compounds described herein and saline. In certain embodiments, the saline is pharmaceutically acceptable grade saline. In certain embodiments, the

saline is buffered saline. In certain embodiments, the saline is phosphate buffered saline (PBS).

In certain embodiments, a formulation excludes liposomes. In certain embodiments, the formulation excludes sterically stabilized liposomes. In certain embodiments, a formulation excludes phospholipids. In certain embodiments, the formulation consists essentially of the compounds described herein and saline and excludes liposomes.

The pharmaceutical formulations and compositions of the present invention may also include surfactants. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

In one embodiment, the present invention employs various penetration enhancers to affect the efficient delivery of nucleic acids, particularly oligonucleotides. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administration.

Formulations for topical administration include those in which the oligonucleotides provided herein are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

Compositions and formulations for parenteral administration, including intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion, or intracranial may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Certain embodiments provided herein provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds provided herein, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroi-

dal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions provided herein. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions provided herein may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Alternatively, compositions provided herein may contain two or more antisense compounds targeted to different regions of the same nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

Dosing

The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or at desired intervals. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

Certain Compounds

About two hundred and seventy six newly designed antisense compounds of various lengths, motifs and backbone composition were tested for their effect on human PTP1B mRNA *in vitro* in several cell types. The new compounds were compared with about five hundred previously designed compounds including ISIS 107772, ISIS 107831, ISIS 142025, ISIS 142026, ISIS 142027, ISIS 142028, ISIS 142082, ISIS 146908, and ISIS 146909 which have previously been determined to be some of the most potent antisense compounds *in vitro* (see e.g., U.S. Patent Publication No. US 2003/0220282 published Nov. 27, 2003 and PCT Patent Publication No. WO2007/131237 published Nov. 15, 2007). Of the about two hundred and eighty five newly designed and previously designed antisense compounds, about eleven compounds were selected for further study based on *in vitro* potency. The selected compounds were tested for dose dependent inhibition in HuVEC, HepG2, HuVEC, LLC-MK2, and cynomolgus primary hepatocytes. Additional oligonucleotides were designed based on microwalk of ISIS 409826, one of the selected compounds which demonstrated significant reduction of

PTP1B mRNA in all the cell lines tested. The oligonucleotides were tested in HuVEC cells (Example 5) along with gapmers from the earlier screen (Example 1). Several antisense oligonucleotides from the screen in Example 5 were selected and tested for dose-dependent inhibition in HuVEC cells (Example 6) and HepG2 cells (Example 7). Additionally, two oligonucleotides were designed as shortmers to ISIS 1428082, one of the selected compounds. These two shortmers (ISIS 446431 and ISIS 446432), as well as five ISIS oligonucleotides selected from the study described in Examples 6 and 7 were tested in HepG2 cells, LLC-MK2 cells, HuVEC cells, and cynomolgus primary hepatocytes (Examples 8-11). ISIS oligonucleotides that demonstrated dose-dependent reduction of PTP1B mRNA in all cell lines were tested for in vivo tolerability. Two more oligonucleotides ISIS 446433 and ISIS 446434, designed as shortmers to ISIS 409826, were included in the in vivo tolerability studies as well.

The twelve gapmers chosen were tested in a mouse model (see Example 12) and a rat model (Example 13). By virtue of their complementary sequence, the compounds are complementary to the regions 3291-3310, 989-1008, 3290-3309, 3287-3306, 3291-3310, 3288-3307, 3292-3309, 3293-3308, 3288-3305, and 3289-3304 of SEQ ID NO: 1. In the in vivo models, body weights and organ weights, the liver metabolic markers, such as alanine transaminase, aspartate transaminase and bilirubin, kidney metabolic markers, such as BUN and creatinine, plasma glucose levels, cholesterol and triglyceride levels, and inflammatory cytokine levels were measured. Of the twelve compounds tested, five compounds, ISIS 142082, ISIS 404173, ISIS 410003, ISIS 446431, and ISIS 446432 were selected and their viscosity was measured (Example 14). All the five oligonucleotides were considered optimal in their viscosity according to the criteria stated for the study.

Final evaluation of these studies (Examples 12-14), led to the selection of four compounds having a nucleobase sequence of a sequence recited in SEQ ID NO: 27 (ISIS 142082), 46 (ISIS 446431), 26 (ISIS 404173), and 23 (ISIS 409826). By virtue of their complementary sequence, the compounds are complementary to the regions 3291-3310, 3292-3309, 3290-3309, 3287-3306 of SEQ ID NO: 1. In certain embodiments, the compounds targeting the listed regions, as further described herein, comprise a modified oligonucleotide having some nucleobase portion of the sequence recited in the SEQ ID NOs, as further described herein. In certain embodiments, the compounds targeting the listed regions or having a nucleobase portion of a sequence recited in the listed SEQ ID NOs can be of various length, as further described herein, and can have one of various motifs, as further described herein. In certain embodiments, a compound targeting a region or having a nucleobase portion of a sequence recited in the listed SEQ ID NOs has the specific length and motif, as indicated by the ISIS NOs: ISIS 142082, ISIS 446431, ISIS 404173, and ISIS 409826.

Three compounds having a nucleobase sequence of a sequence recited in SEQ ID NO: 27 (ISIS 142082), 23 (ISIS 404173), and 46 (ISIS 446431), were further tested in a long-term, six month tolerability study in a mouse model (See Example 15). The half life in the liver of CD1 mice of all four of the compounds having a nucleobase sequence of a sequence recited in SEQ ID NOs: 53 (ISIS 409826), 27 (ISIS 142082), 26 (ISIS 404173), and 46 (ISIS 446431) was also evaluated (Example 16).

These four compounds were tested for efficacy, pharmacokinetic profile and tolerability in cynomolgus monkeys (Example 17). The inhibition studies in these monkeys

indicated that treatment with some of these compounds caused reduction of PTP1B mRNA in the liver and fat tissues. Specifically, treatment with ISIS 409826, ISIS 142082, ISIS 446431 and ISIS 404173 caused 45%, 48%, 18 and 22% reduction of PTP1B mRNA in liver tissue, respectively compared to the PBS control. Treatment with ISIS 409826, ISIS 142082, ISIS 446431 and ISIS 404173 caused 21%, 28%, 12% and 31% reduction of PTP1B mRNA in fat tissue, respectively compared to the PBS control. It was noted that ISIS 404173 caused similar reduction of PTP1B mRNA compared to ISIS 142082, even though the two oligonucleotides differ from each other by a single base-pair shift of their target region on SEQ ID NO: 1. Protein analysis of liver tissue was also conducted by western blot analysis. PTP1B mRNA reduction using ISIS 409826, ISIS 142082, ISIS 446431 and ISIS 404173 was measured at a maximum dose of 40 mgk/week for efficacy and at a lower dose of 8 mgk/week for potency (See table 45). Protein analysis at a lower dose of 8 mgk/week demonstrated that ISIS 404173 caused greater reduction (33%) of PTP1B protein than ISIS 142082 (20%) demonstrating that ISIS 404173 was more potent than ISIS 142082 (See Table 47 and FIG. 1). Protein analysis at the higher dose of 40 mg/week demonstrated that ISIS 404173 (60% protein reduction) was as efficacious as ISIS 142082 (65% protein reduction). Finally, treatment with ISIS 409826 and ISIS 142082 resulted in 22% decrease in triglyceride levels while treatment with ISIS 404173 resulted in 37% decrease in triglyceride levels compared to the PBS control.

Tolerability studies in cynomolgus monkeys (Example 17) indicated that treatment with ISIS 142082 was not as tolerable to the primates as treatment with ISIS 404173. The levels of C-reactive protein, which is synthesized in the liver and which serves as a marker of inflammation, were measured on day 93. At the higher dose of 40 mg/week, treatment with ISIS 142082 caused a significant increase of CRP levels of 12 mg/L compared to the control level of 1.2 mg/L. Treatment with ISIS 404173 at 40 mg/L caused an increase of CRP levels to 1.6 mg/L. The other compounds tested, ISIS 409826 and ISIS 446431 caused increase of CRP levels to 4.8 mg/L and 6.7 mg/L. Therefore, ISIS 404173 caused the least increase in CRP levels indicating that ISIS 404173 is extremely tolerable and non-proinflammatory. Organ weights were also measured to evaluate the tolerability of ISIS oligonucleotides by the monkeys. Treatment with ISIS 142082 at a dose of 40 mg/L caused increases in kidney and liver weights of 21 g and 18 g respectively, which is two-fold increase over the control (kidney 10 g and liver 10.5 g). Treatment with ISIS 409826 caused a two-fold increase in liver weight (18.5 g vs. 10.5 g of control) and a three-fold increase in spleen weight (6.0 g vs. 2.3 g of control). Treatment with ISIS 446431 caused a four-fold increase in spleen weight (9.6 g vs. 2.3 g control). Treatment with ISIS 404173 caused less than one-fold increase in all organs (kidney 14.8 g; liver 15.5 g; spleen 3.7 g) See (FIG. 2). Hence, treatment with ISIS 142082, ISIS 409826, and ISIS 446431 were not considered tolerable in the monkeys, whereas treatment with ISIS 404173 was tolerable.

Treatment with ISIS 142082 caused increase in organ weights and elevated levels of CRP, indicating an inflammatory state. Treatment with ISIS 409826 also caused elevated levels of CRP and low complement C3 levels, indicating a diseased state. Treatment with ISIS 404173 and ISIS 446431 were considered optimal in terms of their

tolerability profiles in cynomolgus monkeys. However, ISIS 446431 demonstrated less potency compared to ISIS 404173.

In case of the pharmacokinetic profile studies of the oligonucleotides in liver and kidney, none of the ISIS oligonucleotides demonstrated any abnormal ratios in concentration in the liver versus the kidney. ISIS 404173 was a better renal accumulator compared to ISIS 142082, as indicated in the results.

Hence, the in vivo studies, particularly in the cynomolgus monkeys, indicate that ISIS 404173 was just as potent and considerably more tolerable compared to the other compounds. The studies demonstrate that ISIS 142082, although shifted from ISIS 407173 by only one nucleobase, was as efficacious but less potent and tolerable than ISIS 404173, as demonstrated by assays for metabolic and inflammatory markers. Overall, ISIS 404173 was more potent and tolerable compared to any other compound.

Accordingly, provided herein are antisense compounds with any one or more of the improved characteristics. In a certain embodiments, provided herein are compounds comprising a modified oligonucleotide as further described herein targeted to or specifically hybridizable with the region of nucleotides of SEQ ID NO: 1.

Accordingly, provided herein are antisense compounds with any one or more of the improved characteristics. In a certain embodiments, provided herein are compounds comprising a modified oligonucleotide as further described herein targeted to or specifically hybridizable with the region of nucleotides of SEQ ID NO: 2.

In certain embodiments, the compounds as described herein are efficacious by virtue of having at least one of an in vitro IC₅₀ of less than 0.4 μM, less than 0.35 μM, less than 0.3 μM, less than 2.5 μM, less than 2.0 μM, less than 1.5 μM, less than 1.0 μM, when delivered to a cynomolgus monkey hepatocyte cell line using electroporation as described in Example 11. In certain embodiments, the compounds as described herein are highly tolerable, as demonstrated by having at least one of an increase an ALT or AST value of no more than 4 fold, 3 fold, or 2 fold over saline treated animals; or an increase in liver, spleen or kidney weight of no more than 30%, 20%, 15%, 12%, 10%, 5% or 2%.

EXAMPLES

Non-Limiting Disclosure and Incorporation by Reference

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

Example 1

Antisense Inhibition of Human PTP1B mRNA in HuVEC Cells

Antisense oligonucleotides targeted to a human PTP1B nucleic acid were designed and tested for their effect on PTP1B RNA transcript in vitro. ISIS 107772, ISIS 107831, ISIS 142025, ISIS 142026, ISIS 142027, ISIS 142028, ISIS 142082, ISIS 146908, and ISIS 146909, claimed in a previous patent (BIOL001USP2) were included in this assay for comparison. Cultured HuVEC cells at a density of 5,000 cells per well were transfected using LipofectAMINE 2000® with 2 nM antisense oligonucleotide. After approximately 24 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR. PTP1B mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of PTP1B mRNA levels, relative to untreated control cells.

The antisense oligonucleotides in Table 1 are 5-10-5 MOE gapmers or 2-13-5 MOE gapmers. The 5-10-5 MOE gapmers have a gap segment comprising ten 2'-deoxynucleosides and two wing segment comprising five 2'-MOE nucleosides. The 2-13-5 MOE gapmers have a gap segment comprising thirteen 2'-deoxynucleosides, a 5' wing segment comprising two 2'-MOE nucleosides, and a 3' wing segment comprising three 2'-MOE nucleosides. The internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. 'Target start site' indicates the 5'-most nucleotide to which the antisense oligonucleotide is targeted in the human gene sequence. 'Target stop site' indicates the 3'-most nucleotide to which the antisense oligonucleotide is targeted in the human gene sequence. All the antisense oligonucleotides listed in Table 1 target either the mRNA sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_002827.2) or the genomic sequence, designated herein as SEQ ID NO: 2 (GENBANK Accession NT_011362.9 truncated from nucleotides 14178000 to 14256000), or both.

Some of the human oligonucleotides of Table 1 are also fully cross-reactive with rhesus monkey gene sequences. 'n/a' indicates that there were more than 3 base mismatches between the human oligonucleotide and the rhesus monkey gene sequence. The greater the complementarity between the human oligonucleotide and the rhesus monkey sequence, the more likely the human oligonucleotide can cross-react with the rhesus monkey sequence. The human oligonucleotides in Table 1 were compared to SEQ ID NO: 3 (exons 1-9, intron 9 and exon 10 from the rhesus monkey PTP1B scaffold). "Rhesus monkey Target start site" indicates the 5'-most nucleotide to which the gapmer is targeted in the rhesus monkey gene sequence. "Rhesus monkey Target stop site" indicates the 3'-most nucleotide to which the gapmer is targeted rhesus monkey gene sequence.

TABLE 1

Inhibition of human PTP1B RNA transcript in HuVEC cells by antisense oligonucleotides targeting SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3							
ISIS No	Sequence	Motif	% inhibition	Start Site at SEQ ID NO: 1	Start Site at SEQ ID NO: 2	Start Site at SEQ ID NO: 3	SEQ ID NO
142025	TTGTGCATCTGCTCGAACTC	5-10-5	43	190	1989	197	4
142026	GACTTGTCGATCTGCTCGAA	5-10-5	59	193	1992	989	5

TABLE 1-continued

Inhibition of human PTP1B RNA transcript in HuVEC cells by antisense oligonucleotides targeting SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3							
ISIS No	Sequence	Motif	% inhibition	Start Site at SEQ ID NO: 1	Start Site at SEQ ID NO: 2	Start Site at SEQ ID NO: 3	SEQ ID NO
107772	CCCGGACTTGTCGATCTGCT	5-10-5	66	197	1996	3754	6
142027	GCTCCCGGACTTGTCGATCT	5-10-5	55	200	1999	3759	7
142028	CCAGCTCCCGGACTTGTCGA	5-10-5	60	203	2002	4498	8
373125	GGCACCTTCGATCACAGCCA	5-10-5	55	989	70726	4487	9
113715	GCTCCTTCCACTGATCCTGC	5-10-5	50	1035	n/a	4500	10
107831	GGTCATGCACAGGCAGGTTG	5-10-5	70	2360	75039	3753	11
409988	AGGTCATGCACAGGCAGGTT	2-13-5	83	2361	75040	3759	12
409821	GATCAGGTCATGCACAGGCA	5-10-5	86	2365	75044	3575	13
404176	TGATCAGGTCATGCACAGGC	5-10-5	87	2366	75045	4493	14
146908	ACCCTTGGAATGTCTGAGTT	5-10-5	56	2544	75223	3746	15
404169	CCCATACCCTTGGAATGTCT	5-10-5	77	2549	75228	3756	16
409815	TCCCATAACCCTTGGAATGTC	5-10-5	72	2550	75229	3566	17
146909	TTCCCATAACCCTTGGAATGT	5-10-5	43	2551	75230	3569	18
409845	TATTCATGGCCATTGTAAA	5-10-5	23	3283	75962	4485	19
410030	TTATTCATGGCCATTGTAA	2-13-5	24	3284	75963	4486	20
409825	TTTATTCATGGCCATTGTA	5-10-5	34	3285	75964	192	21
409883	GTTTATTCATGGCCATTGT	3-14-3	36	3286	75965	198	22
409999	GGTTTATTCATGGCCATTG	2-13-5	54	3287	75966	190	23
409826	GGTTTATTCATGGCCATTG	5-10-5	73	3287	75966	201	23
410000	TGGTTTATTCATGGCCATT	2-13-5	55	3288	75967	194	24
404172	TGGTTTATTCATGGCCATT	5-10-5	61	3288	75967	192	24
410001	ATGGTTTATTCATGGCCAT	2-13-5	51	3289	75968	198	25
409827	ATGGTTTATTCATGGCCAT	5-10-5	44	3289	75968	195	25
410002	AATGGTTTATTCATGGCCA	2-13-5	0	3290	75969	204	26
404173	AATGGTTTATTCATGGCCA	5-10-5	48	3290	75969	201	26
410003	AAATGGTTTATTCATGGCC	2-13-5	64	3291	75970	193	27
142082	AAATGGTTTATTCATGGCC	5-10-5	52	3291	75970	190	27
410004	AAAATGGTTTATTCATGGC	2-13-5	46	3292	75971	196	28
409828	AAAATGGTTTATTCATGGC	5-10-5	44	3292	75971	194	28
409829	AAAAATGGTTTATTCATGG	5-10-5	36	3293	75972	198	29
404161	GGTCATTCCATGGCCAGAG	2-13-5	78	n/a	73855	3746	31
409975	GGAGGTCATTTCATGGCCA	2-13-5	85	n/a	73858	n/a	32
409976	AGGAGGTCATTTCATGGCC	2-13-5	85	n/a	73859	2379	30

61

Example 2

Dose-Dependent Antisense Inhibition of Human PTP1B mRNA in HuVEC Cells

Several antisense oligonucleotides, which displayed significant antisense inhibition of PTP1B mRNA in the study described in Example 1 were further tested in HuVEC cells at various doses. Cells were plated at a density of 5,000 cells per well and transfected using LipofectAMINE 2000® with 0.9375 nM, 1.875 nM, 3.75 nM, 7.5 nM, 15 nM, and 30 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA transcript levels were measured by quantitative real-time PCR using primer probe set RTS3000 (forward sequence CTGGTTTAACCTCCTATCCTTGGA, designated herein as SEQ ID NO: 33; reverse sequence CAGAGCAGCTCGCTACCTCTCT, designated herein as SEQ ID NO: 34, probe sequence CAGCTGGCTCTCCACCTTGTTACACATTATGT, designated herein as SEQ ID NO: 35). PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 2 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

TABLE 2

Dose-dependent antisense inhibition of human PTP1B in HuVEC cells							
ISIS No	0.9375 nM	1.875 nM	3.75 nM	7.5 nM	15.0 nM	30.0 nM	IC ₅₀ (nM)
113715	0	0	2	11	23	33	>30
404161	1	0	7	29	42	57	17
404169	0	6	17	37	57	72	7
404176	0	0	20	38	68	79	6
409815	0	0	7	30	48	65	12
409821	0	1	17	41	68	82	5
409826	0	0	10	30	47	64	12
409975	0	0	23	50	74	86	4
409976	0	0	21	46	65	82	5
409988	0	0	23	49	70	83	5
410003	0	0	4	16	28	46	>30

Example 3

Dose-Dependent Antisense Inhibition of PTP1B mRNA in LLC-MK2 Cells

The antisense oligonucleotides from the study described in Example 2 are also cross-reactive with rhesus monkey the gene sequence (SEQ ID NO: 3) and were further tested in rhesus monkey LLC-MK2 cells at various doses. Cells were plated at a density of 3,000 cells per well and transfected using Lipofectin with 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, and 100 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS198 (forward sequence GGAGTTCGAGCAGATCGA-CAA, designated herein as SEQ ID NO: 36; reverse sequence GGCCACTCTACATGGGAAGTC, designated herein as SEQ ID NO: 37, probe sequence AGCTGGGCGGCCATTACCAGAT, designated herein as SEQ ID NO: 38). PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 3 as percent inhibition of PTP1B mRNA, relative to untreated control cells. The start and stop sites of

62

each oligonucleotide on rhesus monkey SEQ ID NO: 3 (the concatenation of exons 1-9, intron 9 and exon 10 from the rhesus PTP1B scaffold (gene scaffold 240) are presented in Table 4.

TABLE 3

Dose-dependent antisense inhibition of PTP1B mRNA in LLC-MK2 cells							
ISIS No	3.125 nM	6.25 nM	12.5 nM	25.0 nM	50.0 nM	100.0 nM	IC ₅₀ (nM)
113715	9	18	18	42	71	88	12
404161	18	26	37	49	67	79	9
404169	9	33	36	52	70	85	8
404176	4	21	28	52	73	85	10
409815	19	27	32	51	67	83	9
409821	4	20	37	53	74	85	9
409826	7	31	63	46	62	78	8
409975	13	20	28	43	62	74	15
409976	12	20	37	42	65	77	12
409988	3	20	39	56	73	86	8
410003	16	24	36	43	65	80	11

TABLE 4

Target sites of antisense oligonucleotides targeting PTP1B on rhesus monkey gene sequence (SEQ ID NO: 3)		
ISIS No	Start Site	Stop Site
113715	1035	1054
404161	2385	2404
409975	2388	2407
409976	2389	2408
409988	3566	3585
409821	3570	3589
404176	3571	3590
404169	3754	3773
409815	3755	3774
409826	4491	4510
410003	4495	4514

Example 4

Dose-Dependent Antisense Inhibition of PTP1B mRNA in Cynomolgus Primary Hepatocytes

Some of the antisense oligonucleotides from the study described in Examples 1, 2 and 3 were further tested in cynomolgus primary hepatocytes at various doses. Cells were plated at a density of 35,000 cells per well and transfected using Lipofectin with 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM, and 200 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS198. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 5 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

TABLE 5

ISIS No	Dose-dependent antisense inhibition of PTP1B mRNA in cynomolgus primary hepatocytes						
	6.25 nM	12.5 nM	25.0 nM	50.0 nM	100.0 nM	200.0 nM	IC ₅₀ (nM)
373125	16	4	13	32	48	67	104
404161	7	3	24	40	56	77	72
404169	0	13	27	44	57	77	67
404176	16	17	27	42	64	76	59
409815	0	24	26	40	57	75	69
409821	0	9	25	37	60	73	73
409826	8	28	10	37	56	71	82
409975	13	19	29	38	57	75	67
409976	2	18	13	35	60	80	70
409988	16	22	28	41	59	77	61
410003	17	10	37	46	60	78	56

Example 5

Antisense Inhibition of Human PTP1B mRNA in HuVEC Cells by Oligonucleotides Designed by Microwalk

Additional gapmers were designed based on ISIS 409826 that demonstrated significant inhibition of PTP1B in all cell lines tested. These gapmers were designed by creating gapmers shifted slightly upstream and downstream (i.e. "microwalk") of ISIS 409826. Oligonucleotides were also created with various motifs, e.g. 5-10-5 MOE, 5-8-5 MOE, 2-13-5 MOE, 6-8-6 MOE motifs, or were uniform oligonucleotides with deoxy and MOE units. These gapmers were tested *in vitro*. ISIS oligonucleotides ISIS 142082, ISIS 113715, ISIS 373125, ISIS 404161, ISIS 404172, ISIS 404173, ISIS 404176, ISIS 409825, ISIS 409827, ISIS 409828, ISIS 409829, ISIS 409845, ISIS 409998, ISIS 409999, ISIS 410000, ISIS 410001, ISIS 410002, ISIS 410003, ISIS 410004, and ISIS 410030 (from Example 1), as well as ISIS 399038, ISIS 404159, and ISIS 404174, from a previous application (CORE0061WO15), were also included in the assay for comparison. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 2,000 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR. The human primer probe set RTS3000 was used to measure PTP1B mRNA levels. PTP1B mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of PTP1B mRNA, relative to untreated control cells. The results are presented in Tables 6 and 7.

The 5-10-5 MOE gapmers are 20 nucleotides in length, wherein the central gap segment is comprised of ten 2'-deoxynucleotides and is flanked on both sides (in the 5' and 3' directions) by wings comprising five nucleotides each. The 5-8-5 MOE gapmers are 18 nucleotides in length, wherein the central gap segment is comprised of eight 2'-deoxynucleotides and is flanked on both sides (in the 5' and 3' directions) by wings comprising five nucleotides each. The 2-13-5 MOE gapmers are 20 nucleotides in length, wherein the central gap segment is comprised of thirteen 2'-deoxy-

nucleotides and is flanked on the 5' and the 3' directions with wings comprising two and five nucleotides respectively. The 6-8-6 MOE gapmers are 18 nucleotides in length, wherein the central gap segment is comprised of eight 2'-deoxynucleotides and is flanked on both sides (in the 5' and 3' directions) by wings comprising six nucleotides each. For each of the motifs (5-10-5, 5-8-5, 2-13-5, and 6-8-6), each nucleotide in the 5' wing segment and each nucleotide in the 3' wing segment has a 2'-MOE modification. The uniform oligonucleotides have deoxy and MOE units distributed throughout the length of the oligonucleotide. The symbols for the various unit chemistries in the uniform oligonucleotide sequences are as follows: 'd'=2'-deoxyribose; 'e'=2'-O-methoxyethyl ribose. The internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytidine residues throughout each gapmer are 5-methylcytidines. "Target start site" indicates the 5'-most nucleotide to which the gapmer is targeted. "Target stop site" indicates the 3'-most nucleotide to which the gapmer is targeted. Each gapmer listed in Table 6 is targeted SEQ ID NO: 1 (GENBANK Accession No. NM_002827.2). All the antisense oligonucleotides listed in Table 7 target SEQ ID NO: 2 (GENBANK Accession NT_011362.9 truncated from nucleotides 14178000 to 14256000).

As shown in Tables 6 and 7, several of the gapmers exhibited at least 50% inhibition, including ISIS numbers: 113715, 142082, 373125, 399038, 404159, 404161, 404172, 404173, 404176, 409826, 409827, 409999, 410000, 410001, 410002, 410003, 410004, 438371, 438372, 438373, 438374, 438375, 438377, 438379, 438380, 438381, 438382, 438383, 438384, 438439, 438442, 438443, 438444, 438445, 438450, 438451, 438452, 438453, 438454, 438455, 438456, 438458, 438459, 438460, 438461, 438462, 438464, 438465, 438468, 438469, 438472, 438473, and 438474.

Several of the gapmers exhibited at least 60% inhibition, including ISIS numbers: 113715, 142082, 373125, 399038, 404161, 404172, 404173, 404176, 409826, 409827, 409999, 410000, 410001, 410002, 410003, 438373, 438374, 438380, 438381, 438382, 438442, 438444, 438445, 438450, 438451, 438452, 438453, 438459, 438460, 438461, 438462, 438468, 438469, 438472, and 438474.

Several of the gapmers exhibited at least 70% inhibition, including ISIS numbers: 142082, 373125, 399038, 404161, 404172, 404173, 404176, 409826, 409827, 409999, 410000, 410001, 410002, 410003, 438373, 438374, 438444, 438451, 438452, 438453, 438460, 438461, 438462, 438468, 438469, 438472, and 438474.

Several of the gapmers exhibited at least 80% inhibition, including ISIS numbers: 142082, 404161, 404173, 404176, 409826, 410000, 410001, 410002, 410003, 438451, 438452, 438460, 438461, and 438474.

Several of the gapmers exhibited at least 85% inhibition, including ISIS numbers: 142082, 404161, 404173, 404176, 409826, 410001, 410002, and 410003.

Several of the gapmers exhibited at least 90% inhibition, including ISIS numbers: 142082, 404161, and 409826.

TABLE 6

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 1						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
989	1008	373125	GGCACCTTCGATCACAGCCA	5-10-5 MOE	72	9
1035	1054	113715	GCTCCTTCCACTGATCCTGC	5-10-5 MOE	68	10
2366	2385	404176	TGATCAGGTCATGCACAGGC	5-10-5 MOE	89	14
3283	3302	409845	TATTCATGGCCATTGTAAA	5-10-5 MOE	32	19
3284	3303	404174	TTATTCATGGCCATTGTAA	5-10-5 MOE	47	20
3284	3303	410030	TTATTCATGGCCATTGTAA	2-13-5 MOE	47	20
3284	3303	438377	T _e T _e A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	52	20
3284	3303	438439	T _e T _e A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	53	20
3284	3303	438448	T _e T _e A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	34	20
3284	3303	438457	T _e T _e A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	35	20
3284	3303	438466	TTATTCATGGCCATTGTAA	6-8-6 MOE	25	20
3285	3304	409825	TTTATTCATGGCCATTGTA	5-10-5 MOE	47	21
3285	3304	409998	TTTATTCATGGCCATTGTA	2-13-5 MOE	49	21
3285	3302	438368	TATTCATGGCCATTGTA	5-8-5 MOE	32	39
3285	3304	438378	T _e T _e T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e	Deoxy and MOE units	46	21
3285	3304	438440	T _e T _e T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e	Deoxy and MOE units	30	21
3285	3304	438449	T _e T _e T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e	Deoxy and MOE units	43	21
3285	3304	438458	T _e T _e T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e	Deoxy and MOE units	53	21
3285	3304	438467	TTTATTCATGGCCATTGTA	6-8-6 MOE	33	21
3286	3305	399038	GTTTATTCATGGCCATTGT	5-10-5 MOE	74	22
3286	3305	404159	GTTTATTCATGGCCATTGT	2-13-5 MOE	54	22
3286	3303	438369	TTATTCATGGCCATTGT	5-8-5 MOE	33	40
3286	3305	438379	G _e T _e T _d T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	51	22
3286	3305	438441	G _e T _e T _d T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	40	22
3286	3305	438450	G _e T _e T _d T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	64	22
3286	3305	438459	G _e T _e T _d T _d A _d T _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	68	22
3286	3305	438468	GTTTATTCATGGCCATTGT	6-8-6 MOE	76	22
3287	3306	409826	GGTTTATTCATGGCCATTG	5-10-5 MOE	93	23
3287	3306	409999	GGTTTATTCATGGCCATTG	2-13-5 MOE	75	23
3287	3304	438370	TTTATTCATGGCCATTG	5-8-5 MOE	33	41

TABLE 6-continued

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 1						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
3287	3306	438380	G _e G _e T _d T _d T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _d T _e G _e	Deoxy and MOE units	63	23
3287	3306	438442	G _e G _e T _d T _d T _d T _d A _e T _d T _d C _d C _e A _e T _d G _d G _d C _d C _d A _d T _d T _e G _e	Deoxy and MOE units	67	23
3287	3306	438451	G _e G _e T _d T _d T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _e T _e G _e	Deoxy and MOE units	83	23
3287	3306	438460	G _e G _e T _d T _d T _d T _d A _e T _d T _e C _e C _d A _d T _d G _d G _d C _d C _d A _d T _e T _e G _e	Deoxy and MOE units	82	23
3287	3306	438469	GGTTTATTCCATGGCCATTG	6-8-6 MOE	71	23
3288	3307	404172	TGGTTTATTCCATGGCCATT	5-10-5 MOE	76	24
3288	3307	410000	TGGTTTATTCCATGGCCATT	2-13-5 MOE	83	24
3288	3305	438371	GTTTATTCCATGGCCATT	5-8-5 MOE	54	42
3288	3307	438381	T _e G _e G _e T _d T _d T _d A _e T _e T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d AT _e T _e	Deoxy and MOE units	69	24
3288	3307	438443	T _e G _e G _e T _d T _d T _d A _e T _d T _d C _e C _d A _d T _d G _d G _d C _d C _d A _d T _e T _e	Deoxy and MOE units	50	24
3288	3307	438452	T _e G _e G _e T _d T _d T _d A _e T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _d T _e T _e	Deoxy and MOE units	82	24
3288	3307	438461	T _e G _e G _e T _d T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	81	24
3288	3307	438470	TGGTTTATTCCATGGCCATT	6-8-6 MOE	46	24
3289	3308	409827	ATGGTTTATTCCATGGCCAT	5-10-5 MOE	74	25
3289	3308	410001	ATGGTTTATTCCATGGCCAT	2-13-5 MOE	85	25
3289	3306	438372	GGTTTATTCCATGGCCAT	5-8-5 MOE	52	43
3289	3308	438382	A _e T _e G _e G _e T _d T _d T _e T _e A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	65	25
3289	3308	438444	A _e T _e G _e G _e T _d T _d T _d A _e T _d T _d C _e C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	72	25
3289	3308	438453	A _e T _e G _e G _e T _d T _d T _e T _e A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	72	25
3289	3308	438462	A _e T _e G _e G _e T _d T _d T _d A _e T _e T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	70	25
3289	3308	438471	ATGGTTTATTCCATGGCCAT	6-8-6 MOE	45	25
3290	3309	404173	AATGGTTTATTCCATGGCCA	5-10-5 MOE	85	26
3290	3309	410002	AATGGTTTATTCCATGGCCA	2-13-5 MOE	85	26
3290	3307	438373	TGGTTTATTCCATGGCCA	5-8-5 MOE	70	44
3290	3309	438383	A _e A _e T _e G _e G _e T _d T _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _e A _e	Deoxy and MOE units	54	26
3290	3309	438445	A _e A _e T _e G _e G _e T _d T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _e A _e	Deoxy and MOE units	66	26
3290	3309	438454	A _e A _e T _e G _e G _e T _d T _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _e C _e A _e	Deoxy and MOE units	52	26
3290	3309	438463	A _e A _e T _e G _e G _e T _d T _d T _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _e C _e A _e	Deoxy and MOE units	39	26

TABLE 6-continued

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 1						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
3290	3309	438472	AATGGTTTATTCCATGGCCA	6-8-6 MOE	73	26
3291	3310	142082	AAATGGTTTATTCCATGGCC	5-10-5 MOE	90	27
3291	3310	410003	AAATGGTTTATTCCATGGCC	2-13-5 MOE	86	27
3291	3308	438374	ATGGTTTATTCCATGGCC	5-8-5 MOE	79	45
3291	3310	438384	A _e A _e A _e T _d G _d G _d T _e T _d T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	53	27
3291	3310	438446	A _e A _e A _e T _d G _d G _d T _d T _d A _e T _e T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	38	27
3291	3310	438455	A _e A _e A _e T _d G _d G _d T _e T _d T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	58	27
3291	3310	438464	A _e A _e A _e T _d G _d G _d T _e T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	58	27
3291	3310	438473	AAATGGTTTATTCCATGGCC	6-8-6 MOE	57	27
3292	3311	409828	AAAATGGTTTATTCCATGGC	5-10-5 MOE	43	28
3292	3311	410004	AAAATGGTTTATTCCATGGC	2-13-5 MOE	58	28
3292	3309	438375	AATGGTTTATTCCATGGC	5-8-5 MOE	55	46
3292	3311	438385	A _e A _e A _e T _d G _d G _d T _d T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	36	28
3292	3311	438447	A _e A _e A _e T _d G _d G _d T _d T _e T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	35	28
3292	3311	438456	A _e A _e A _e T _d G _d G _d T _e T _d T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	58	28
3292	3311	438465	A _e A _e A _e T _d G _d GT _e T _e T _d A _e T _d T _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	51	28
3292	3311	438474	AAAATGGTTTATTCCATGGC	6-8-6 MOE	82	28
3293	3312	409829	AAAAATGGTTTATTCCATGG	5-10-5 MOE	42	29
3293	3310	438376	AAATGGTTTATTCCATGG	5-8-5 MOE	36	47

TABLE 7

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 2						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
70726	70745	373125	GGCACCTTCGATCACAGCCA	5-10-5 MOE	72	9
73855	73874	404161	GGTCATTTCCATGGCCAGAG	2-13-5 MOE	93	31
75045	75064	404176	TGATCAGGTCATGCACAGGC	5-10-5 MOE	89	14
75962	75981	409845	TATTCATGGCCATTGTAAA	5-10-5 MOE	32	19
75963	75982	404174	TTATTCATGGCCATTGTAA	5-10-5 MOE	47	20
75963	75982	410030	TTATTCATGGCCATTGTAA	2-13-5 MOE	47	20
75963	75982	438377	T _e T _e A _e T _d T _d C _e C _e A _d T _d G _d G _d C _d A _d T _d T _d G _d T _d A _e	Deoxy and MOE units	52	20

TABLE 7-continued

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 2						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
75963	75982	438439	T _e T _e A _d T _d T _d T _d C _d C _d A _d T _d G _e G _e C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	53	20
75963	75982	438448	T _e T _e A _e T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	34	20
75963	75982	438457	T _e T _e A _e T _d T _d C _d C _d A _e T _e G _d G _d C _d C _d A _d T _d T _d G _d T _d A _e A _e	Deoxy and MOE units	35	20
75963	75982	438466	TTATTCCATGGCCATTGTAA	6-8-6 MOE	25	20
75964	75983	409825	TTATTCCATGGCCATTGTA	5-10-5 MOE	47	21
75964	75983	409998	TTATTCCATGGCCATTGTA	2-13-5 MOE	49	21
75964	75981	438368	TATTCCATGGCCATTGTA	5-8-5 MOE	32	39
75964	75983	438378	T _e T _e T _e A _d T _d T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _d T _d G _d T _e A _e	Deoxy and MOE units	46	21
75964	75983	438440	T _e T _e T _e A _d T _d T _d C _d C _d A _d T _e G _e G _e C _d C _d A _d T _d T _d G _d T _e A _e	Deoxy and MOE units	30	21
75964	75983	438449	T _e T _e T _e A _d T _d T _e T _e C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e A _e	Deoxy and MOE units	43	21
75964	75983	438458	T _e T _e T _e A _d T _d T _d C _d C _e A _e T _e G _d G _d C _d C _d A _d T _d T _d G _e T _e A _e	Deoxy and MOE units	53	21
75964	75983	438467	TTATTCCATGGCCATTGTA	6-8-6 MOE	33	21
75965	75984	399038	GTTTATTCCATGGCCATTGT	5-10-5 MOE	74	22
75965	75984	404159	GTTTATTCCATGGCCATTGT	2-13-5 MOE	54	22
75965	75982	438369	TTATTCCATGGCCATTGT	5-8-5 MOE	33	40
75965	75984	438379	G _e T _e T _d T _d A _d T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	51	22
75965	75984	438441	G _e T _e T _d T _d A _d T _d T _d C _d C _e A _e T _e G _d G _d C _d C _d A _d T _d T _d G _e T _e	Deoxy and MOE units	40	22
75965	75984	438450	G _e T _e T _e T _d A _d T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _d T _e G _e T _e	Deoxy and MOE units	64	22
75965	75984	438459	G _e T _e T _e T _d A _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _e G _e T _e	Deoxy and MOE units	68	22
75965	75984	438468	GTTTATTCCATGGCCATTGT	6-8-6 MOE	76	22
75966	75985	409826	GGTTTATTCCATGGCCATTG	5-10-5 MOE	93	23
75966	75985	409999	GGTTTATTCCATGGCCATTG	2-13-5 MOE	75	23
75966	75983	438370	TTTATTCCATGGCCATTG	5-8-5 MOE	33	41
75966	75985	438380	G _e G _e T _d T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _d T _e G _e	Deoxy and MOE units	63	23
75966	75985	438442	G _e G _e T _d T _d T _d A _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _d T _e G _e	Deoxy and MOE units	67	23
75966	75985	438451	G _e G _e T _e T _d T _d A _e T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _d T _e T _e G _e	Deoxy and MOE units	83	23
75966	75985	438460	G _e G _e T _e T _d T _d A _d T _d T _e C _e C _e A _d T _d G _d G _d C _d C _d A _d T _e T _e G _e	Deoxy and MOE units	82	23
75966	75985	438469	GGTTTATTCCATGGCCATTG	6-8-6 MOE	71	23
75967	75986	404172	TGGTTTATTCCATGGCCATT	5-10-5 MOE	76	24

TABLE 7-continued

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 2						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
75967	75986	410000	TGGTTTATTCATGGCCATT	2-13-5 MOE	83	24
75967	75984	438371	GTTTATTCATGGCCATT	5-8-5 MOE	54	42
75967	75986	438381	T _e G _e G _d T _d T _d T _e A _e T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	69	24
75967	75986	438443	T _e G _e G _d T _d T _d A _d T _d T _d C _e C _e A _d T _d G _d G _d C _d C _d A _d T _e T _e	Deoxy and MOE units	50	24
75967	75986	438452	T _e G _e G _d T _d T _d A _e T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	82	24
75967	75986	438461	T _e G _e G _d T _d T _d A _d T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	81	24
75967	75986	438470	TGGTTTATTCATGGCCATT	6-8-6 MOE	46	24
75968	75987	409827	ATGGTTTATTCATGGCCAT	5-10-5 MOE	74	25
75968	75987	410001	ATGGTTTATTCATGGCCAT	2-13-5 MOE	85	25
75968	75985	438372	GGTTTATTCATGGCCAT	5-8-5 MOE	52	43
75968	75987	438382	A _e T _e G _e G _d T _d T _e T _e A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	65	25
75968	75987	438444	A _e T _e G _e G _d T _d T _d A _d T _d T _e C _e C _e A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	72	25
75968	75987	438453	A _e T _e G _e G _d T _d T _e T _e A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	72	25
75968	75987	438462	A _e T _e G _e G _d T _d T _d A _e T _e T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e T _e	Deoxy and MOE units	70	25
75968	75987	438471	ATGGTTTATTCATGGCCAT	6-8-6 MOE	45	25
75969	75988	404173	AATGGTTTATTCATGGCCA	5-10-5 MOE	85	26
75969	75988	410002	AATGGTTTATTCATGGCCA	2-13-5 MOE	85	26
75969	75986	438373	TGGTTTATTCATGGCCA	5-8-5 MOE	70	44
75969	75988	438383	A _e A _e T _e G _d G _d T _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _d C _d A _e	Deoxy and MOE units	54	26
75969	75988	438445	A _e A _e T _e G _d G _d T _d T _d A _d T _e T _e C _d C _d A _d T _d G _d G _d C _d C _d A _e	Deoxy and MOE units	66	26
75969	75988	438454	A _e A _e T _e G _d G _d T _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _e C _e A _e	Deoxy and MOE units	52	26
75969	75988	438463	A _e A _e T _e G _d G _d T _d T _e T _e T _d A _e T _e T _d C _d C _d A _d T _d G _d G _d C _e C _e A _e	Deoxy and MOE units	39	26
75969	75988	438472	AATGGTTTATTCATGGCCA	6-8-6 MOE	73	26
75970	75989	142082	AAATGGTTTATTCATGGCC	5-10-5 MOE	90	27
75970	75989	410003	AAATGGTTTATTCATGGCC	2-13-5 MOE	86	27
75970	75987	438374	ATGGTTTATTCATGGCC	5-8-5 MOE	79	45
75970	75989	438384	A _e A _e A _d T _d G _d G _e T _e T _d T _d A _d T _d T _d C _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	53	27
75970	75989	438446	A _e A _e A _d T _d G _d G _d T _d T _d A _e T _e T _d C _d C _d A _d T _d G _d G _d C _e C _e	Deoxy and MOE units	38	27
75970	75989	438455	A _e A _e A _e T _d G _d G _e T _e T _d T _d A _d T _d T _d C _d C _d A _d T _d G _d G _e C _e C _e	Deoxy and MOE units	58	27

TABLE 7-continued

Inhibition of human PTP1B mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID NO: 2						
Start Site	Stop Site	ISIS No	Sequence	Motif	% inhibition	SEQ ID NO
75970	75989	438464	A _e A _e A _e T _d G _d G _d T _d T _e T _e A _d T _d T _d C _d C _d A _d T _d G _d G _e C _e C _e	Deoxy and MOE units	58	27
75970	75989	438473	AAATGGTTTATTCCATGGCC	6-8-6 MOE	57	27
75971	75990	409828	AAAATGGTTTATTCCATGGC	5-10-5 MOE	43	28
75971	75990	410004	AAAATGGTTTATTCCATGGC	2-13-5 MOE	58	28
75971	75988	438375	AATGGTTTATTCCATGGC	5-8-5 MOE	55	46
75971	75990	438385	A _e A _e A _e A _d T _d G _e G _e T _d T _d A _d T _d T _d C _d C _d A _d T _d G _d G _e C _e	Deoxy and MOE units	36	28
75971	75990	438447	A _e A _e A _e A _d T _d G _d G _d T _d T _d A _e T _d T _d C _d C _d A _d T _d G _d G _e C _e	Deoxy and MOE units	35	28
75971	75990	438456	A _e A _e A _e A _d T _d G _e G _e T _d T _d A _d T _d T _d C _d C _d A _d T _d G _e G _e C _e	Deoxy and MOE units	58	28
75971	75990	438465	A _e A _e A _e A _d T _d G _d GT _e T _e T _d A _d T _d T _d C _d C _d A _d T _d G _e G _e C _e	Deoxy and MOE units	51	28
75971	75990	438474	AAAATGGTTTATTCCATGGC	6-8-6 MOE	82	28
75972	75991	409829	AAAAATGGTTTATTCCATGG	5-10-5 MOE	42	29
75972	75989	438376	AAATGGTTTATTCCATGG	5-8-5 MOE	36	47

Example 6

Example 7

Dose-Dependent Antisense Inhibition of Human PTP1B mRNA in HuVEC Cells

Dose-Dependent Antisense Inhibition of Human mRNA PTP1B in HepG2 Cells

Several antisense oligonucleotides, which displayed significant antisense inhibition of PTP1B mRNA in the study described in Example 5 were further tested in HuVEC cells at various doses. Cells were plated at a density of 2,000 cells per well and transfected by electroporation with 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1000 nM, 2000 nM and 4000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS3000. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 8 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

The antisense oligonucleotides, tested in the study described in Example 6, were further tested in HepG2 cells at various doses. Cells were plated at a density of 20,000 cells per well and transfected by electroporation with 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1000 nM, 2000 nM and 4000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS3000. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 9 as percent inhibition of PTP1B mRNA, relative to untreated control cells. The mRNA levels were also analyzed using rhesus monkey primer probe set RTS198, and

TABLE 8

Dose-dependent antisense inhibition of human PTP1B in HuVEC cells									
ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	2000.0 nM	4000.0 nM	IC ₅₀ (µM)
142082	15	30	40	42	71	84	90	94	0.2
404173	15	19	33	54	69	81	86	93	0.2
404176	9	26	34	34	67	80	88	94	0.3
409826	17	16	28	44	60	73	85	95	0.3
410002	0	0	24	52	54	77	90	96	0.4
410003	9	7	19	46	60	80	91	95	0.4
438374	20	22	40	44	59	70	79	85	0.3
438460	14	21	23	42	62	78	85	95	0.3
438474	27	0	13	34	42	68	74	86	0.6

the results are presented in Table 10. The start and stop sites of each oligonucleotide on rhesus monkey SEQ ID NO: 3 are presented in Table 11.

the study described in Example 7 were included in the assay for comparison. Cells were plated at a density of 20,000 cells per well and transfected by electroporation with 78.125 nM,

TABLE 9

Analysis of dose-dependent antisense inhibition of human PTP1B in HepG2 cells using RTS3000									
ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	2000.0 nM	4000.0 nM	IC ₅₀ (μM)
142082	0	0	7	0	26	38	60	82	1.4
404173	2	0	1	19	0	29	47	80	1.9
404176	0	0	5	13	2	33	62	79	1.7
409826	0	0	0	2	15	29	46	76	1.9
410002	13	6	0	11	8	28	44	75	2.0
410003	0	0	9	11	22	33	30	83	1.9
438374	0	0	17	11	23	38	33	61	2.9
438460	4	0	10	11	9	26	52	79	1.8
438474	0	0	2	11	6	20	52	54	2.8

TABLE 10

Analysis of dose-dependent antisense inhibition of human PTP1B in HepG2 cells using RTS198									
ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	2000.0 nM	4000.0 nM	IC ₅₀ (μM)
142082	14	19	2	0	80	41	63	80	1.5
404173	0	0	2	0	16	26	60	83	1.6
404176	0	0	0	5	0	31	59	80	1.9
409826	0	0	0	16	23	10	49	72	2.3
410002	0	0	0	0	0	0	40	100	>4.0
410003	0	1	12	0	10	41	51	82	1.6
438374	0	0	0	9	43	22	49	55	2.8
438460	0	0	0	9	30	42	47	81	1.4
438474	2	0	9	38	19	31	49	60	2.5

40

TABLE 11

Target sites of antisense oligonucleotides targeting PTP1B on rhesus monkey gene sequence (SEQ ID NO: 3)			
OligoID	Start Site	Stop Site	SEQ ID NO
142082	4495	4514	27
404173	4494	4513	26
404176	3571	3590	14
409826	4491	4510	23
410002	4494	4513	26
410003	4495	4514	27
438374	4495	4512	45
438460	4491	4510	23
438474	4496	4515	28

45

50

55

Example 8

Dose-Dependent Antisense Inhibition of Human PTP1B mRNA in HepG2 Cells

Short antisense oligonucleotides to the target site of ISIS 142082 were designed. The target sites, motifs and sequence details of these shortmers are presented in Table 12. These antisense oligonucleotides were tested in HepG2 cells at various doses. Some of the antisense oligonucleotides from

60

65

156.25 nM, 312.5 nM, 625 nM, 1,250 nM, 2,500 nM, 5,000 nM and 10,000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS3000. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 13 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

TABLE 12

Target sites of antisense oligonucleotides targeting SEQ ID NO: 1						
ISIS No	Start Site	Stop Site	Sequence	Motif	SEQ ID	NO
142082	3291	3310	AAATGGTTTATTCCATGGCC	5-10-5		27
446431	3292	3309	AATGGTTTATTCCATGGC	4-10-4		46
446432	3293	3308	ATGGTTTATTCCATGG	3-10-3		48

TABLE 13

Dose-dependent antisense inhibition of human PTP1B in HepG2 cells									
ISIS No	78.125 nM	156.25 nM	312.5 nM	625.0 nM	1250.0 nM	2500.0 nM	5000.0 nM	10000.0 nM	IC ₅₀ (μ M)
113715	6	12	17	17	16	45	61	86	3.3
142082	14	34	23	47	60	81	86	90	0.8
404173	8	22	29	45	60	73	83	88	0.8
409826	19	18	41	56	75	84	89	91	0.5
410003	0	0	19	39	55	81	91	92	1.0
446431	10	24	26	38	57	74	85	92	1.0
446432	0	8	10	10	10	26	40	67	6.0

Example 9

15

Dose-Dependent Antisense Inhibition of PTP1B mRNA in LLC-MK2 Cells

The antisense oligonucleotides from the study described in Example 8 are also cross-reactive with rhesus monkey PTP1B gene sequence (SEQ ID NO: 3) and were further tested in rhesus monkey LLC-MK2 cells at various doses. Cells were plated at a density of 25,000 cells per well and transfected using electroporation with 78.125 nM, 156.25 nM, 312.5 nM, 625 nM, 1250 nM, 2500 nM, 5,000 nM, and 10,000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS198. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 14 as percent inhibition of PTP1B mRNA, relative to untreated control cells. The start and stop sites of each oligonucleotide on rhesus monkey SEQ ID NO: 3 are presented in Table 15.

TABLE 14

Dose-dependent antisense inhibition of PTP1B mRNA in LLC-MK2 cells									
ISIS No	78.125 nM	156.25 nM	312.5 nM	625.0 nM	1250.0 nM	2500.0 nM	5000.0 nM	10000.0 nM	IC ₅₀ (μ M)
113715	0	0	4	13	27	53	57	70	3.3
142082	2	12	31	41	69	74	80	92	0.9
404173	2	0	22	29	36	61	78	84	1.6
409826	12	0	19	38	66	66	82	92	1.2
410003	0	0	0	26	32	65	81	91	1.8
446431	0	0	9	32	45	70	79	58	1.4
446432	0	0	7	16	10	20	26	43	37.0

50

TABLE 15

Target sites of antisense oligonucleotides targeting SEQ ID NO: 3				
ISIS No	Start Site	Stop Site	Sequence	SEQ ID NO
113715	1035	1054	GCTCCTTCCACTGATCCTGC	10
142082	4495	4514	AAATGGTTTATTCATGGCC	27
404173	4494	4513	AATGGTTTATTCATGGCCA	26
409826	4491	4510	GGTTTATTCATGGCCATG	23
410003	4495	4514	AAATGGTTTATTCATGGCC	27
446431	4496	4513	AATGGTTTATTCATGGC	46
446432	4497	4512	ATGGTTTATTCATGG	48

55

60

65

Example 10

Dose-Dependent Antisense Inhibition of Human PTP1B mRNA in HuVEC Cells

The antisense oligonucleotides, tested in the study described in Examples 8 and 9, were further tested in HuVEC cells at various doses. Cells were plated at a density of 20,000 cells per well and transfected by electroporation with 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1000 nM, 2000 nM and 4000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS3000. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 16 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

TABLE 16

Dose-dependent antisense inhibition of human PTP1B in HuVEC cells									
ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	2000.0 nM	4000.0 nM	IC ₅₀ (μ M)
113715	10	0	22	24	65	86	92	98	0.2
142082	52	78	89	93	95	96	98	98	<0.3
404173	35	66	80	89	95	98	97	97	0.05
409826	57	72	82	64	97	98	98	98	<0.3
410003	43	47	75	84	48	95	96	91	0.05
446431	33	63	75	87	96	97	98	98	0.05
446432	0	11	30	45	66	79	85	76	0.3

Example 11

Dose-Dependent Antisense Inhibition of PTP1B mRNA in Cynomolgus Primary Hepatocytes

The antisense oligonucleotides from the study described in Examples 8-10 were further tested in cynomolgus primary hepatocytes at various doses. Cells were plated at a density of 35,000 cells per well and transfected using electroporation with 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 1,000 nM, 2,000 nM, and 4,000 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR using primer probe set RTS198. PTP1B mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 17 as percent inhibition of PTP1B mRNA, relative to untreated control cells.

TABLE 17

Dose-dependent antisense inhibition of PTP1B mRNA in cynomolgus primary hepatocytes									
ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	2000.0 nM	4000.0 nM	IC ₅₀ (μ M)
113715	4	26	25	43	46	73	82	95	0.4
142082	25	37	50	67	74	87	86	88	0.1
404173	18	20	43	54	67	82	85	89	0.2
409826	34	47	51	65	76	87	88	90	0.1
410003	8	20	44	53	68	79	80	83	0.2
446431	9	14	35	54	57	79	79	88	0.3
446432	4	0	1	3	0	11	6	37	>4.0

Example 12

Tolerability of Antisense Oligonucleotides Targeting Human PTP1B in a Mouse Model

ISIS oligonucleotides that demonstrated dose-dependent inhibition in the studies described in Examples 8-11 were evaluated for tolerability in a mouse model by monitoring changes in the levels of various metabolic markers in CD1 mice. Two more ISIS oligonucleotides, ISIS 446433 (4-10-4 MOE; 5'-GTTTATTCATGGCCATT-3' (SEQ ID NO: 42); target start site at SEQ ID NO: 1 is 3288) and ISIS 446434 (3-10-3; 5'-TTTATTCATGGCCAT-3' (SEQ ID NO: 49); target start site at SEQ ID NO: 1 is 3289) were designed as shortmers to ISIS 409826 (target start site at SEQ ID NO: 1 is 3287) and were also evaluated in this study.

Treatment

CD1 mice (available from Jackson Labs, Bar Harbor, Me.) were maintained on a 12-hour light/dark cycle and fed ad libitum normal lab chow (Harlan Laboratories, India-

napolis, Ind.). Animals were acclimated for at least 7 days in the research facility before initiation of the experiment. Antisense oligonucleotides were prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were dissolved in 0.9% PBS for injection.

Groups of five CD1 mice each were injected subcutaneously twice a week with 100 mg/kg of ISIS 142082, ISIS 373125, ISIS 404173, ISIS 409826, ISIS 410002, ISIS 410003, ISIS 438452, ISIS 438460, ISIS 446431, ISIS 446432, ISIS 446433, or ISIS 446434 for 4 weeks. One group of five CD1 mice was injected subcutaneously twice a week with PBS for 4 weeks. This PBS group served as the control group. Blood samples were collected via tail snipping. Two days after the last dose, body weights were taken, mice were euthanized and organs and plasma were harvested for further analysis.

Body and Organ Weights

The body weights of the mice were measured weekly. The body weights are presented in Table 18. Liver, spleen and kidney weights were measured at the end of the study, and are presented in Table 19. The results demonstrate that none of the ISIS oligonucleotides had any adverse effect on the overall health of the mice.

TABLE 18

Weekly body weights of CD1 mice during antisense oligonucleotide treatment (g)				
	Week 1	Week 2	Week 3	Week 4
PBS	29	31	32	34
ISIS 142082	31	34	34	36
ISIS 373125	29	31	32	35
ISIS 404173	31	33	34	36
ISIS 409826	31	34	34	37
ISIS 410002	32	35	35	36
ISIS 410003	31	34	34	37
ISIS 438452	32	35	36	39

83

TABLE 18-continued

Weekly body weights of CD1 mice during antisense oligonucleotide treatment (g)				
	Week 1	Week 2	Week 3	Week 4
ISIS 438460	31	34	34	37
ISIS 446431	30	33	33	36
ISIS 446432	27	30	30	33
ISIS 446433	30	33	33	37
ISIS 446434	30	33	34	37

TABLE 19

Organ weights of CD1 mice after antisense oligonucleotide treatment (g)				
	Liver	Fat	Spleen	Kidney
PBS	1.7	0.45	0.11	0.53
ISIS 142082	2.3	0.33	0.18	0.52
ISIS 373125	1.9	0.38	0.16	0.53
ISIS 404173	2.3	0.41	0.23	0.59
ISIS 409826	2.2	0.37	0.17	0.54
ISIS 410002	1.9	0.22	0.30	0.76
ISIS 410003	2.1	0.44	0.22	0.60
ISIS 438452	2.2	0.42	0.18	0.55
ISIS 438460	2.2	0.34	0.17	0.52
ISIS 446431	2.1	0.34	0.19	0.53
ISIS 446432	1.7	0.31	0.13	0.46
ISIS 446433	2.2	0.35	0.17	0.53
ISIS 446434	2.2	0.36	0.18	0.56

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured bi-weekly. The results are presented in Tables 20 and 21, and indicate that most of the ISIS oligonucleotides were considered tolerable in the mice, as demonstrated by their liver transaminase profile.

TABLE 20

Effect of antisense oligonucleotide treatment on ALT (IU/L) of CD1 mice			
	Week 0	Week 2	Week 4
PBS	27	26	20
ISIS 142082	38	35	105
ISIS 373125	30	27	51
ISIS 404173	30	31	124
ISIS 409826	26	34	236
ISIS 410002	27	203	219
ISIS 410003	31	29	99
ISIS 438452	32	40	217
ISIS 438460	30	40	216
ISIS 446431	29	38	114
ISIS 446432	26	27	35
ISIS 446433	25	76	115
ISIS 446434	23	44	146

TABLE 21

Effect of antisense oligonucleotide treatment on AST (IU/L) of CD1 mice			
	Week 0	Week 2	Week 4
PBS	54	62	50
ISIS 142082	75	59	103
ISIS 373125	55	57	97
ISIS 404173	52	61	117

84

TABLE 21-continued

Effect of antisense oligonucleotide treatment on AST (IU/L) of CD1 mice				
	Week 0	Week 2	Week 4	
5	ISIS 409826	49	59	192
	ISIS 410002	51	151	417
	ISIS 410003	64	47	122
	ISIS 438452	59	56	157
	ISIS 438460	65	56	217
10	ISIS 446431	56	66	140
	ISIS 446432	50	51	74
	ISIS 446433	54	87	121
	ISIS 446434	42	64	132

15 Plasma Glucose Levels

To evaluate the effect of ISIS oligonucleotides on glucose metabolism, plasma levels of glucose were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Table 22, expressed in mg/dL. None of the ISIS oligonucleotides had any adverse effects on the glucose metabolism of the mice.

TABLE 22

Effect of antisense oligonucleotide treatment on plasma glucose levels in CD1 mice				
	Week 0	Week 2	Week 4	
25	PBS	175	188	182
	ISIS 142082	195	178	161
	ISIS 373125	187	201	177
	ISIS 404173	185	213	168
	ISIS 409826	183	187	187
	ISIS 410002	183	164	137
	ISIS 410003	198	218	168
	ISIS 438452	168	197	175
	ISIS 438460	212	203	169
	ISIS 446431	192	188	148
	ISIS 446432	194	193	175
	ISIS 446433	216	198	151
	ISIS 446434	199	189	159

40 Plasma Lipid and Triglyceride Levels

To evaluate the effect of ISIS oligonucleotides on cholesterol and triglyceride metabolism, plasma levels of each were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Tables 23 and 24, expressed in mg/dL. Most of the ISIS oligonucleotides did not have any adverse effects on the lipid metabolism of the mice.

TABLE 23

Effect of antisense oligonucleotide treatment on plasma cholesterol levels in CD1 mice				
	Week 0	Week 2	Week 4	
55	PBS	162	145	153
	ISIS 142082	156	136	126
	ISIS 373125	137	106	104
	ISIS 404173	162	124	154
	ISIS 409826	153	142	146
	ISIS 410002	136	63	47
	ISIS 410003	160	131	96
	ISIS 438452	143	128	121
	ISIS 438460	146	140	129
	ISIS 446431	139	124	116
	ISIS 446432	146	135	137
	ISIS 446433	152	144	145
65	ISIS 446434	147	147	144

85

TABLE 24

Effect of antisense oligonucleotide treatment on plasma triglyceride levels in CD1 mice			
	Week 0	Week 2	Week 4
PBS	153	153	162
ISIS 142082	170	153	114
ISIS 373125	142	116	112
ISIS 404173	195	140	107
ISIS 409826	182	120	80
ISIS 410002	137	99	51
ISIS 410003	152	138	102
ISIS 438452	123	134	93
ISIS 438460	165	146	85
ISIS 446431	131	160	123
ISIS 446432	168	194	136
ISIS 446433	186	117	133
ISIS 446434	145	101	84

Cytokine Levels

To evaluate the effect of ISIS oligonucleotides on factors involved in inflammation, blood was collected after the end of the treatment period for measurement of cytokine levels. The samples were sent to Aushon Biosystems (Woburn, Mass.) for analysis. Levels of murine IL-6, JE, MIP-1 α , and TNF- α were measured using murine antibodies. The results are presented in Table 25. Most of the ISIS oligonucleotides did not have any adverse effects on the cytokine levels of the mice.

TABLE 25

Effect of antisense oligonucleotide treatment on plasma cytokine levels in CD1 mice				
	mIL-6	mJE	mMIP-1 α	mTNF- α
PBS	250	20	1	4
ISIS 142082	225	145	4	23
ISIS 373125	77	91	3	17
ISIS 404173	88	155	1	24
ISIS 409826	33	112	3	15
ISIS 410002	113	225	28	84
ISIS 410003	111	138	4	24
ISIS 438452	62	148	1	15
ISIS 438460	64	184	2	9
ISIS 446431	52	170	1	15
ISIS 446432	57	75	1	3
ISIS 446433	64	138	3	61
ISIS 446434	59	127	0	21

Example 13

Tolerability of Antisense Oligonucleotides Targeting Human PTP1B in a Rat Model

The ISIS oligonucleotides from the study described in Example 12 were further evaluated for tolerability in a rat model by monitoring changes in the levels of various metabolic markers in Sprague Dawley rats.

Treatment

Sprague Dawley rats were maintained on a 12-hour light/dark cycle and fed ad libitum normal lab chow (Harlan Laboratories, Indianapolis, Ind.). Animals were acclimated for at least 7 days in the research facility before initiation of the experiment. Antisense oligonucleotides were prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were dissolved in 0.9% PBS for injection.

Groups of four rats each were injected subcutaneously twice a week with ISIS 142082, ISIS 373125, ISIS 404173,

86

ISIS 409826, ISIS 410002, ISIS 410003, ISIS 438452, ISIS 438460, ISIS 446431, ISIS 446432, ISIS 446433, or ISIS 446434 at a dose of 50 mg/kg twice a week for 4 weeks,

followed by a dose of 30 mg/kg twice a week for 8 weeks. One group of four rats was injected subcutaneously twice a week with PBS for 12 weeks. This PBS group served as the control group. Blood samples were collected via tail snipping. Two days after the last dose, body weights were taken, rats were euthanized and organs and plasma were harvested for further analysis.

Body and Organ Weights

The body weights of the rats were measured weekly. The body weights are presented in Table 26. Liver, spleen and kidney weights were measured at the end of the study, and are presented in Table 27. 'n/a' indicates no data being available for that particular group at that particular time point due to all the rats in the group being euthanized before the time point.

TABLE 26

Bi-weekly body weights of Sprague Dawley rats during antisense oligonucleotide treatment (g)							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	288	369	405	442	463	500	495
ISIS 142082	295	348	318	345	337	347	345
ISIS 373125	304	385	399	419	427	421	448
ISIS 404173	294	346	352	377	384	391	401
ISIS 409826	292	346	350	355	356	373	356
ISIS 410002	297	333	323	324	306	335	n/a
ISIS 410003	299	341	328	320	307	305	301
ISIS 438452	301	327	335	333	327	347	332
ISIS 438460	304	345	346	347	356	377	n/a
ISIS 446431	307	376	340	357	353	357	349
ISIS 446432	287	340	344	363	372	399	404
ISIS 446433	298	331	318	354	n/a	n/a	n/a
ISIS 446434	303	366	356	n/a	n/a	n/a	n/a

TABLE 27

Organ weights of Sprague Dawley rats during antisense oligonucleotide treatment (g)				
	Liver	Fat	Spleen	Kidney
PBS	15.9	2.1	0.8	3.6
ISIS 142082	21.8	0.7	4.5	5.2
ISIS 373125	17.9	1.1	1.9	3.4
ISIS 404173	17.7	1.1	2.3	4.3
ISIS 409826	19.8	0.5	3.6	4.4
ISIS 410003	18.7	0.5	3.8	3.5
ISIS 438452	17.3	0.6	3.1	3.8
ISIS 446431	22.1	0.4	6.1	5.3
ISIS 446432	18.1	1.2	3.3	3.8

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured bi-weekly. Plasma levels of bilirubin (mg/dL) were also measured using the same clinical chemistry analyzer. The results are presented in Tables 28, 29 and 30. 'n/a' indicates no data being available for that particular group at that particular time point due to all the rats in the group being euthanized before the time point.

TABLE 28

Effect of antisense oligonucleotide treatment on ALT (IU/L) of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	58	68	54	48	48	46	46
ISIS 142082	54	75	40	44	49	62	57
ISIS 373125	57	61	60	48	48	45	38
ISIS 404173	49	52	53	41	51	53	42
ISIS 409826	51	59	56	50	42	37	40
ISIS 410002	46	65	75	73	103	126	n/a
ISIS 410003	49	78	62	49	61	59	66
ISIS 438452	46	57	58	53	51	52	50
ISIS 438460	49	88	162	96	114	91	n/a
ISIS 446431	51	57	45	45	40	55	49
ISIS 446432	52	59	48	43	44	49	46
ISIS 446433	53	120	65	86	n/a	n/a	n/a
ISIS 446434	53	76	161	n/a	n/a	n/a	n/a

TABLE 29

Effect of antisense oligonucleotide treatment on AST (IU/L) of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	84	92	86	79	91	74	81
ISIS 142082	87	89	86	126	136	154	149
ISIS 373125	79	72	93	124	111	95	81
ISIS 404173	75	69	88	75	89	96	83
ISIS 409826	75	74	96	112	108	90	106
ISIS 410002	67	87	155	173	229	245	n/a
ISIS 410003	71	95	106	136	161	160	186
ISIS 438452	70	84	104	157	164	174	167
ISIS 438460	79	122	214	287	216	172	n/a
ISIS 446431	73	79	93	137	129	158	153
ISIS 446432	80	76	86	99	96	105	102
ISIS 446433	77	151	128	234	n/a	n/a	n/a
ISIS 446434	81	137	359	n/a	n/a	n/a	n/a

TABLE 30

Effect of antisense oligonucleotide treatment on Bilirubin (mg/dL) of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	0.11	0.15	0.14	0.16	0.25	0.16	0.13
ISIS 142082	0.12	0.11	0.18	0.12	0.12	0.15	0.15
ISIS 373125	0.13	0.13	0.15	0.36	0.14	0.15	0.13
ISIS 404173	0.11	0.13	0.14	0.13	0.13	0.14	0.10
ISIS 409826	0.12	0.12	0.15	0.12	0.11	0.10	0.10
ISIS 410002	0.11	0.13	0.18	0.13	0.19	0.54	n/a
ISIS 410003	0.12	0.12	0.14	0.16	0.14	0.17	0.14
ISIS 438452	0.12	0.13	0.15	0.13	0.14	0.13	0.13
ISIS 438460	0.11	0.14	0.22	0.28	0.15	0.17	n/a
ISIS 446431	0.14	0.17	0.19	0.13	0.10	0.16	0.16
ISIS 446432	0.12	0.14	0.13	0.12	0.11	0.14	0.13
ISIS 446433	0.12	0.12	0.18	0.20	n/a	n/a	n/a
ISIS 446434	0.12	0.17	0.20	n/a	n/a	n/a	n/a

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function, plasma levels of blood urea nitrogen (BUN) and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Tables 31 and 32, expressed in mg/dL. The total urine protein to creatinine ratio was also calculated and the results are presented in Table 33.

TABLE 31

Effect of antisense oligonucleotide treatment on BUN (mg/dL) of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	17	20	20	18	26	18	16
ISIS 142082	21	23	31	23	31	24	29
ISIS 373125	21	21	24	19	31	21	21
ISIS 404173	18	19	21	19	25	21	20
ISIS 409826	20	21	24	23	28	22	26
ISIS 410002	19	22	25	23	29	32	n/a
ISIS 410003	18	20	23	23	30	29	26
ISIS 438452	19	22	27	25	29	22	24
ISIS 438460	20	23	25	26	31	24	n/a
ISIS 446431	19	21	24	23	29	24	23
ISIS 446432	20	21	24	20	29	23	19
ISIS 446433	18	21	25	53	n/a	n/a	n/a
ISIS 446434	18	23	120	n/a	n/a	n/a	n/a

TABLE 32

Effect of antisense oligonucleotide treatment on creatinine (mg/dL) of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	0.2	0.3	0.4	0.3	0.5	0.4	0.3
ISIS 142082	0.3	0.3	0.5	0.4	0.5	0.5	0.4
ISIS 373125	0.3	0.5	0.6	0.4	0.6	0.6	0.4
ISIS 404173	0.3	0.3	0.5	0.4	0.5	0.6	0.4
ISIS 409826	0.3	0.4	0.6	0.4	0.5	0.5	0.4
ISIS 410002	0.3	0.3	0.6	0.4	0.5	0.5	n/a
ISIS 410003	0.3	0.3	0.6	0.4	0.6	0.6	0.4
ISIS 438452	0.3	0.3	0.6	0.4	0.5	0.5	0.4
ISIS 438460	0.3	0.4	0.5	0.3	0.5	0.5	n/a
ISIS 446431	0.3	0.3	0.5	0.4	0.5	0.5	0.4
ISIS 446432	0.3	0.3	0.6	0.4	0.5	0.5	0.4
ISIS 446433	0.3	0.3	0.5	0.4	n/a	n/a	n/a
ISIS 446434	0.3	0.4	0.8	n/a	n/a	n/a	n/a

TABLE 33

Effect of antisense oligonucleotide treatment on total urine protein to urine creatinine ratio of Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	1.5	1.4	1.2	1.6	1.3	1.2	1.2
ISIS 142082	1.2	4.3	4.0	7.7	6.6	7.5	7.4
ISIS 373125	1.3	3.9	3.8	6.7	6.2	8.8	9.7
ISIS 404173	1.1	4.8	5.5	6.4	7.4	10.2	11.9
ISIS 409826	1.2	3.7	3.8	5.9	9.8	28.8	37.6
ISIS 410002	1.2	3.9	4.1	6.0	9.7	26.3	n/a
ISIS 410003	1.3	4.5	5.3	5.9	7.6	10.8	18.0
ISIS 438452	1.4	3.3	3.1	5.1	8.0	9.2	10.5
ISIS 438460	1.3	4.0	4.5	7.3	16.0	53.9	n/a
ISIS 446431	1.2	4.5	5.0	5.3	7.2	8.0	8.8
ISIS 446432	1.3	4.2	4.4	6.2	9.1	7.6	9.2
ISIS 446433	1.1	3.4	5.7	81.5	n/a	n/a	n/a
ISIS 446434	1.1	3.7	25.8	n/a	n/a	n/a	n/a

Plasma Glucose Levels

To evaluate the effect of ISIS oligonucleotides on glucose metabolism, plasma levels of glucose were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Table 34, expressed in mg/dL.

TABLE 34

Effect of antisense oligonucleotide treatment on plasma glucose levels in Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	150	140	155	152	163	138	144
ISIS 142082	153	137	155	145	142	130	135
ISIS 373125	153	135	136	143	133	106	135
ISIS 404173	162	138	149	152	145	144	154
ISIS 409826	155	141	150	145	143	132	135
ISIS 410002	152	139	148	151	130	124	n/a
ISIS 410003	152	138	146	140	132	126	143
ISIS 438452	166	134	162	153	135	143	147
ISIS 438460	166	140	151	156	150	130	n/a
ISIS 446431	154	143	155	147	153	139	145
ISIS 446432	159	141	155	152	152	138	153
ISIS 446433	158	138	141	118	n/a	n/a	n/a
ISIS 446434	166	149	124	n/a	n/a	n/a	n/a

Plasma Lipid and Triglyceride Levels

To evaluate the effect of ISIS oligonucleotides on total cholesterol and triglyceride levels, plasma levels of each were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Tables 35 and 36, expressed in mg/dL.

TABLE 35

Effect of antisense oligonucleotide treatment on plasma cholesterol levels (mg/dL) in Sprague Dawley rats							
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
PBS	55	57	64	51	73	64	53
ISIS 142082	62	41	54	62	70	64	62
ISIS 373125	73	59	66	51	66	61	39
ISIS 404173	57	41	68	62	87	85	75
ISIS 409826	57	42	79	65	86	122	110
ISIS 410002	69	57	75	65	73	96	n/a
ISIS 410003	72	44	70	67	89	76	73
ISIS 438452	63	33	53	51	71	70	61
ISIS 438460	64	40	98	81	94	146	n/a
ISIS 446431	64	41	56	54	63	68	59
ISIS 446432	62	44	70	50	80	80	65
ISIS 446433	59	63	95	139	n/a	n/a	n/a
ISIS 446434	63	48	91	n/a	n/a	n/a	n/a

TABLE 36

Effect of antisense oligonucleotide treatment on plasma triglyceride levels (mg/dL) in Sprague Dawley rats						
	Week 0	Week 2	Week 4	Week 6	Week 8	Week 12
PBS	66	73	82	80	98	106
ISIS 142082	92	30	71	44	25	28
ISIS 373125	66	28	20	24	24	28
ISIS 404173	48	28	28	35	31	49
ISIS 409826	68	29	28	25	31	68
ISIS 410002	71	23	23	27	71	n/a
ISIS 410003	78	22	22	37	30	64
ISIS 438452	89	33	39	34	50	35
ISIS 438460	98	20	34	35	33	n/a
ISIS 446431	72	29	38	36	35	48
ISIS 446432	n/a	41	37	31	37	53
ISIS 446433	68	21	29	129	n/a	n/a
ISIS 446434	69	27	103	n/a	n/a	n/a

Cytokine Levels

To evaluate the effect of ISIS oligonucleotides on factors involved in inflammation, blood was collected after the end of the treatment period for measurement of cytokine levels.

The samples were sent to Aushon Biosystems (Woburn, Mass.) for analysis. Levels of rat IL-6, MCP-1, MIP-1 α , and TNF- α were measured with their respective antibodies. The results are presented in Table 37.

TABLE 37

Effect of antisense oligonucleotide treatment on plasma cytokine levels in Sprague Dawley rats				
	rIL-6	rMCP-1	rMIP-1 α	rTNF- α
PBS	315	403	6	77
ISIS 142082	74	3082	38	697
ISIS 373125	<25	2215	7	15
ISIS 404173	125	2244	60	499
ISIS 409826	<25	6041	52	100
ISIS 410003	245	3315	40	444
ISIS 438452	105	4513	26	519
ISIS 446431	924	3104	54	402
ISIS 446432	29	2007	46	610

Example 14

Measurement of Viscosity of ISIS Antisense Oligonucleotides Targeting Human PTP1B

The viscosity of the antisense oligonucleotides selected from studies described in Examples 12 and 13 was measured with the aim of screening out antisense oligonucleotides which have a viscosity more than 40 cP at a concentration of 165-185 mg/mL. Oligonucleotides having a viscosity greater than 40 cP would be too viscous to be administered to any subject.

ISIS oligonucleotides (32-35 mg) were weighed into a glass vial, 120 μ L of water was added and the antisense oligonucleotide was dissolved into solution by heating the vial at 50 $^{\circ}$ C. Part of (75 μ L) the pre-heated sample was pipetted to a micro-viscometer (Cambridge). The temperature of the micro-viscometer was set to 25 $^{\circ}$ C. and the viscosity of the sample was measured. Another part (20 μ L) of the pre-heated sample was pipetted into 10 mL of water for UV reading at 260 nM at 85 $^{\circ}$ C. (Cary UV instrument). The results are presented in Table 38 and indicate that all the antisense oligonucleotides solutions are optimal in their viscosity under the criterion stated above.

TABLE 38

Viscosity and concentration of ISIS antisense oligonucleotides targeting human PTP1B		
ISIS No.	Viscosity (cP)	Concentration (mg/mL)
142082	3.8	188
404173	3.8	163
410003	4.5	176
446431	3.2	180
446432	2.4	175

Example 15

Six Month Tolerability Study of Antisense Oligonucleotides Targeting Human PTP1B in a Mouse Model

ISIS oligonucleotides selected from the studies described in Examples 12-14 were evaluated for long-term tolerability

in a mouse model by monitoring changes in the levels of various metabolic markers in CD1 mice.

Treatment

Male CD1 mice were maintained on a 12-hour light/dark cycle and fed ad libitum normal lab chow (Harlan Laboratories, Indianapolis, Ind.). Animals were acclimated for at least 7 days in the research facility before initiation of the experiment. Antisense oligonucleotides were prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were dissolved in 0.9% PBS for injection.

Groups of ten CD1 mice each were injected subcutaneously twice a week with 25 mg/kg of ISIS 142082, ISIS 404173, or ISIS 446431 for 24 weeks. One group of ten CD1 mice was injected subcutaneously twice a week with PBS for 24 weeks. This PBS group served as the control group. Blood samples were collected on days 140 via mandibular bleeds. On day 168, blood was collected via terminal cardiac puncture under CO₂ anesthesia, the mice were euthanized and organs were harvested for further analysis.

Plasma Glucose Levels

To evaluate the effect of ISIS oligonucleotides on glucose metabolism, plasma levels of glucose were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Table 39, expressed in mg/dL.

TABLE 39

Effect of antisense oligonucleotide treatment on plasma glucose levels on day 168	
	Glucose
PBS	214
ISIS 142082	177
ISIS 404173	204
ISIS 446431	191

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) on day 168 were measured. Plasma levels of bilirubin (mg/dL) were also measured using the same clinical chemistry analyzer. Alkaline phosphatase, which is synthesized in increased amounts by damaged liver cells, is also a marker of liver disease (Narayanan, S. Ann. Clin. Lab. Sci. 21: 12-8, 1991) and was similarly measured. Albumin, which is typically decreased in liver disease (Oettl, K. et al., Biochim Biophys. Acta. 1782: 469-73, 2008), was also similarly measured. The results are presented in Table 40.

TABLE 40

Effect of antisense oligonucleotide treatment on liver metabolic markers on day 168					
	ALT (IU/L)	AST (IU/L)	Bilirubin (mg/dL)	Alkaline phosphatase (IU/L)	Albumin (g/dL)
PBS	50	82	0.2	44	2.5
ISIS 142082	148	197	0.1	56	2.3
ISIS 404173	68	137	0.1	57	2.5
ISIS 446431	115	173	0.1	42	2.4

Cardiac Function

To evaluate the effect of ISIS oligonucleotides on heart function, plasma levels of creatine phosphokinase (CPK) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.) on day 168. An increased level of this marker indicates heart muscle injury (Barohn, R. J. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa.: Saunders Elsevier; 2007: chapter 447). The results are presented in Table 41.

TABLE 41

Effect of antisense oligonucleotide treatment on cardiac marker CPK on day 168	
	CPK (IU/L)
PBS	98
ISIS 142082	120
ISIS 404173	107
ISIS 446431	159

Pancreatic Function

To evaluate the effect of ISIS oligonucleotides on pancreatic function, plasma levels of amylase were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.) on day 168. An increased level of this marker indicates acute pancreatitis (Sternby, B. et al., Mayo Clin. Proc. 71: 1138-44, 1996). The results are presented in Table 42.

TABLE 42

Effect of antisense oligonucleotide treatment on pancreatic marker amylase on day 168	
	Amylase (IU/L)
PBS	1101
ISIS 142082	1374
ISIS 404173	1280
ISIS 446431	1232

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function, plasma levels of blood urea nitrogen (BUN) and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Results are presented in Table 43, expressed in mg/dL.

TABLE 43

Effect of antisense oligonucleotide treatment on kidney metabolic markers on day 168		
	BUN	Creatinine
PBS	20	0.3
ISIS 142082	24	0.2
ISIS 404173	21	0.2
ISIS 446431	19	0.3

Example 16

Measurement of Half-Life of Antisense Oligonucleotide in CD1 Mouse Liver

CD1 mice were treated with the ISIS antisense oligonucleotides selected from studies described in Example 14,

and the oligonucleotide half-life as well as the elapsed time for oligonucleotide degradation and elimination from the liver was evaluated.

Treatment

Groups of ten CD1 mice each were injected subcutaneously twice per week for 2 weeks with 50 mg/kg of ISIS 142082, ISIS 446431, ISIS 404173, or ISIS 409826. Five mice from each group were sacrificed 3 days and 56 days following the final dose. Livers were harvested for analysis. Measurement of Oligonucleotide Concentration

The concentration of the full-length oligonucleotide was measured. The method used is a modification of previously published methods (Leeds et al., 1996; Geary et al., 1999) which consist of a phenol-chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS 355868, a 27-mer 2'-O-methoxyethyl modified phosphorothioate oligonucleotide, GCGTTTGCTCTCTTCTTGCGTTTTT, designated herein as SEQ ID NO: 50) was added prior to extraction. Tissue sample concentrations were calculated using calibration curves, with a lower limit of quantitation (LLOQ) of approximately 1.14 µg/g. Half-lives were then calculated using WinNonlin software (PHARSIGHT).

The results are presented in Table 44. Antisense oligonucleotides with half-lives within 11-34 days were chosen for further studies.

TABLE 44

Full-length oligonucleotide concentration (µg/g) and half-life (days) of oligonucleotide in CD1 mouse liver		
Days	Full length conc. (mg/g)	Half-life (days)
142082	265	19.8
	42	
446431	293	19.6
	45	
404173	281	14.8
	24	
409826	304	18.4
	41	

Example 17

Effect of ISIS Antisense Oligonucleotides Targeting Human PTP1B in Cynomolgus Monkeys

Cynomolgus monkeys were treated with ISIS antisense oligonucleotides from studies described in Examples 15 and 16. Antisense oligonucleotide efficacy and tolerability, as well as their pharmacokinetic profile in the liver and kidney, were evaluated.

Treatment

Prior to the study, the monkeys were kept in quarantine for a 30-day time period, during which standard panels of serum chemistry and hematology, examination of fecal samples for ova and parasites, and a tuberculosis test, were conducted to screen out abnormal or ailing monkeys. Six groups of randomly assigned three male and two female cynomolgus monkeys each were injected subcutaneously thrice per week for the first week, and subsequently, once a week for the next 12 weeks with either 8 mg/kg or 40 mg/kg of ISIS 142082, ISIS 446431, or ISIS 404173. One group of three male and two female cynomolgus monkeys was injected subcutaneously thrice per week for the first week,

and subsequently, once a week for the next 12 weeks with 40 mg/kg of ISIS 409826. A control group of three male and two female cynomolgus monkeys was injected subcutaneously thrice per week for the first week, and subsequently, once a week for the next 12 weeks with PBS. Terminal sacrifices of all groups were conducted 48 hours after the last dose, on day 93.

During the study period, the monkeys were observed daily for signs of illness or distress. Any animal showing adverse effects to the treatment was removed and referred to the veterinarian and Study Director.

Inhibition Studies

RNA Analysis

RNA was extracted from liver and the abdominal adipose tissues for real-time PCR analysis of PTP1B using primer probe set 1 (forward sequence GACCAGCTGCGCTTCTCTA, designated herein as SEQ ID NO: 51; reverse sequence CAGAGGAGTCCCCCATGATG, designated herein as SEQ ID NO: 52; probe sequence TTGGCTGTGATCGAAGGTGCCAAA, designated herein as SEQ ID NO: 53) or primer probe set 2 (forward sequence GGGCCTTTGCCTAACACA, designated herein as SEQ ID NO: 54; reverse sequence CGACACCCCTGCTTTTCTG, designated herein as SEQ ID NO: 55; probe sequence CGGTCACTTTGGGAGATGGTGTGG, designated herein as SEQ ID NO: 56), each targeting different regions of the PTP1B mRNA. Results are presented as percent reduction of PTP1B mRNA, relative to PBS control, normalized with RIBOGREEN®. As shown in Table 45, treatment with ISIS antisense oligonucleotides resulted in significant reduction of PTP1B mRNA in comparison to the PBS control. Treatment with ISIS 404173 caused reduction of PTP1B mRNA levels similar to that with treatment with ISIS 142082.

TABLE 45

Inhibition of PTP1B mRNA in the cynomolgus monkey liver and fat tissue relative to the PBS control					
ISIS No.	Dose (mg/kg)	% inhibition in liver (probe set 1)	% inhibition in liver (probe set 2)	% inhibition in fat (probe set 1)	% inhibition in fat (probe set 2)
		409826	40	38	45
142082	8	12	14	13	16
	40	46	48	34	28
446831	8	0	8	6	1
	40	8	18	14	12
404173	8	4	13	8	4
	40	26	22	38	31

Protein Analysis

Tissue was extracted from liver For measuring PTP1B protein levels by western blot analysis. Specifically, PTP1B protein samples from monkeys treated with ISIS 404173 were compared with those treated with ISIS 142082. The results are presented in Tables 46, 47 and 48 expressed as percentage reduction compared to control levels. The levels of PTP1B levels were normalized against total protein levels, as well as against a constitutively expressed protein, IR-β. Treatment with ISIS 404173 caused greater reduction of PTP1B liver protein to that with treatment with ISIS 142082 at the lower dose of 8 mg/kg (Table 47).

TABLE 46

PTP1B protein level reduction after treatment with ISIS 404173 in the cynomolgus monkey liver		
Dose (mg/kg)	% inhibition (normalized to total protein)	% inhibition (normalized to IR-β)
8	49	42
40	67	66

TABLE 47

PTP1B protein level reduction after treatment with ISIS 404173 or ISIS 142082 at 8 mg/kg in the cynomolgus monkey liver		
ISIS No	% inhibition (normalized to total protein)	% inhibition (normalized to IR-β)
142082	20	4
404173	33	27

TABLE 48

PTP1B protein level reduction after treatment with ISIS 404173 or ISIS 142082 at 40 mg/kg in the cynomolgus monkey liver		
ISIS No	% inhibition (normalized to total protein)	% inhibition (normalized to IR-β)
142082	65	63
404173	60	56

Tolerability Studies

Body and Organ Weight Measurements

To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body and organ weights were measured after terminal sacrifice. Body weights were measured and compared to that of the PBS control animals. Organ weights were measured and treatment group weights were compared to the corresponding PBS control weights. The data is presented in Table 49. Treatment with ISIS 142082 did cause increases in liver and kidney weights at the higher dose.

TABLE 49

Final body and organ weight weights in the cynomolgus monkey relative to the control						
Dose (mg/kg)	Body weight (kg)	Kidney (g)	Liver (g)	Spleen (g)	Gastocnemius muscle (g)	
PBS	—	2.2	9.6	10.5	2.3	10.6
409826	40	2.3	14.0	18.5	6.0	8.8
142082	8	2.3	10.6	13.0	3.7	9.5
	40	2.2	20.9	17.7	7.0	9.0
446431	8	2.3	11.6	12.7	4.8	10.2
	40	2.3	15.9	16.1	9.6	7.7
404173	8	2.3	11.6	12.8	4.8	11.1
	40	2.2	14.8	15.5	3.7	8.7

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function, blood samples were collected from all the study groups 7 days before the start of treatment, as well as on days 30, 58, and 93 of the treatment period. The blood

samples were collected in tubes without any anticoagulant for serum separation. The tubes were kept at room temperature for 90 min and then centrifuged (3000 rpm for 10 min at room temperature) to obtain serum.

Levels of transaminases were measured using a Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured and the results are presented in Tables 50 and 51, expressed in IU/L. Alkaline phosphatase, which is synthesized in increased amounts by damaged liver cells and is also a marker of liver disease and was similarly measured, and the data is presented in Table 52. The levels of AST, ALT and alkaline phosphatase in all the treatment groups were similar to that of the PBS control group.

C-reactive protein (CRP), which is synthesized in the liver and which serves as a marker of inflammation, was also similarly measured, and the data is presented in Table 53. Treatment with ISIS 142082 and ISIS 409826 at the higher dose resulted in high levels of CRP, suggesting liver inflammation.

Bilirubin is also a liver metabolic marker and was similarly measured and is presented in Table 54, expressed in mg/dL. Bilirubin levels of all the treatment groups were found to be similar to that of the PBS control group. Gamma-glutamyltransferase (GGT) is an enzyme produced in the liver and is a useful laboratory marker for early liver damage or cholestatic disease (Betro, M. G. et al., Am. J. Clin. Pathol. 60: 672-8, 1973). GGT levels were measured and the results are presented in Table 55, and demonstrate no difference between the PBS control and the treatment groups.

TABLE 50

Effect of antisense oligonucleotide treatment on ALT (IU/L) in cynomolgus monkey serum					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	37	44	42	35
409826	40	39	51	86	74
142082	8	37	39	45	36
	40	49	62	59	69
446431	8	52	54	67	86
	40	38	58	87	99
404173	8	34	50	41	45
	40	44	50	63	73

TABLE 51

Effect of antisense oligonucleotide treatment on AST (IU/L) in cynomolgus monkey serum					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	40	49	55	44
409826	40	48	53	73	59
142082	8	44	45	49	42
	40	54	70	72	69
446431	8	57	43	48	50
	40	41	60	63	81
404173	8	44	53	57	59
	40	46	65	71	74

97

TABLE 52

Effect of antisense oligonucleotide treatment on alkaline phosphatase (IU/L) in cynomolgus monkey serum					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	784	834	1021	838
409826	40	728	883	1178	981
142082	8	718	739	788	688
	40	666	656	711	774
446431	8	742	745	885	908
	40	778	759	768	735
404173	8	888	957	1135	1155
	40	931	958	1135	1263

TABLE 53

Effect of antisense oligonucleotide treatment on CRP (mg/L) in cynomolgus monkey plasma					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	1.0	1.8	1.4	1.2
409826	40	1.0	4.3	4.8	4.8
142082	8	0.8	1.2	0.9	1.0
	40	0.8	2.6	3.4	12.1
446431	8	1.4	1.4	0.9	1.1
	40	0.8	2.4	2.2	6.7
404173	8	1.4	1.9	1.5	1.8
	40	3.1	1.6	1.2	1.6

TABLE 54

Effect of antisense oligonucleotide treatment on bilirubin (mg/dL) in cynomolgus monkey plasma					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	0.19	0.20	0.20	0.17
409826	40	0.17	0.13	0.13	0.10
142082	8	0.17	0.18	0.16	0.14
	40	0.16	0.13	0.13	0.08
446431	8	0.21	0.17	0.18	0.15
	40	0.19	0.18	0.15	0.12
404173	8	0.23	0.19	0.20	0.16
	40	0.22	0.15	0.14	0.13

TABLE 55

Effect of antisense oligonucleotide treatment on GGT (IU/L) in cynomolgus monkey plasma					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	65	74	79	71
409826	40	84	86	94	87
142082	8	63	67	68	62
	40	67	72	71	61
446431	8	60	62	62	63
	40	61	58	62	60
404173	8	57	66	66	68
	40	56	63	69	79

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function, blood samples were collected from all the study groups. The blood samples were collected in tubes without any anticoagulant for serum separation. The tubes were kept at room temperature for 90 min and then centrifuged (3000

98

rpm for 10 min at room temperature) to obtain serum. Levels of BUN and creatinine were measured 7 days before the start of treatment, as well as on days 30, 58, and 93 of the treatment period using a Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan). Results are presented in Tables 56 and 57, expressed in mg/dL. Treatment with ISIS oligonucleotides had no adverse effect on either BUN or creatinine levels.

TABLE 56

Effect of antisense oligonucleotide treatment on serum BUN levels (mg/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	28	28	25	28
409826	40	32	30	28	32
142082	8	26	25	24	26
	40	28	28	25	25
446431	8	28	27	25	26
	40	28	27	25	28
404173	8	28	30	24	27
	40	28	24	25	23

TABLE 57

Effect of antisense oligonucleotide treatment on serum creatinine levels (mg/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	0.83	0.88	0.94	0.78
409826	40	0.77	0.84	0.92	0.82
142082	8	0.74	0.78	0.79	0.71
	40	0.72	0.80	0.86	0.73
446431	8	0.79	0.75	0.83	0.71
	40	0.76	0.83	0.88	0.77
404173	8	0.81	0.91	0.87	0.82
	40	0.76	0.84	0.92	0.76

Cholesterol and Triglyceride Levels

To evaluate the effect of ISIS oligonucleotides on lipid metabolism, blood samples were collected from all the study groups. The blood samples were collected in tubes without any anticoagulant for serum separation. The tubes were kept at room temperature for 90 min and then centrifuged (3000 rpm for 10 min at room temperature) to obtain serum. Concentrations of cholesterol and triglycerides were measured 7 days before the start of treatment, as well as on days 30, 58, and 93 of the treatment period using a Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan). Results are presented in Tables 58 and 59, expressed in mg/dL. Treatment with ISIS oligonucleotides had no adverse effect on either cholesterol or triglyceride levels.

TABLE 58

Effect of antisense oligonucleotide treatment on serum cholesterol levels (mg/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	135	163	162	143
409826	40	153	150	140	116
142082	8	116	151	159	141
	40	110	140	138	128

TABLE 58-continued

Effect of antisense oligonucleotide treatment on serum cholesterol levels (mg/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
446431	8	125	144	141	133
	40	93	99	95	81
404173	8	123	147	149	136
	40	135	135	125	124

TABLE 59

Effect of antisense oligonucleotide treatment on serum triglyceride levels (mg/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	47	55	45	54
409826	40	30	29	33	42
142082	8	23	31	37	32
	40	28	28	35	42
446431	8	24	46	34	93
	40	31	44	47	56
404173	8	28	38	25	28
	40	30	38	45	34

Hematology

To evaluate any inflammatory effect of ISIS oligonucleotides in cynomolgus monkeys, blood samples were approximately 0.5 mL of blood was collected from each of the available study animals in tubes containing the potassium salt of EDTA. Samples were analyzed for red blood cell (RBC) count, white blood cells (WBC) count, platelet count and hemoglobin content, using an ADVIA120 hematology analyzer (Bayer, USA). The data is presented in Tables 60-63. Treatment with ISIS oligonucleotides did not significantly alter the blood cell count or hemoglobin levels, compared to the control.

TABLE 60

Effect of antisense oligonucleotide treatment on WBC ($\times 10^3/\mu\text{L}$) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	11.6	12.6	11.1	8.9
409826	40	12.4	12.7	15.3	10.8
142082	8	11.3	15.2	12.8	9.7
	40	11.9	13.2	12.5	8.5
446431	8	9.7	13.4	12.7	9.3
	40	10.7	11.5	11.9	10.2
404173	8	14.9	18.9	14.9	11.8
	40	11.1	14.2	12.9	10.8

TABLE 61

Effect of antisense oligonucleotide treatment on ABC ($\times 10^6/\mu\text{L}$) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	5.5	5.6	5.8	5.1
409826	40	5.6	5.8	6.1	5.6
142082	8	5.4	5.4	5.6	5.2
	40	5.7	5.6	5.8	5.5

TABLE 61-continued

Effect of antisense oligonucleotide treatment on ABC ($\times 10^6/\mu\text{L}$) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
446431	8	5.5	5.3	5.5	5.4
	40	5.5	5.4	5.8	5.3
404173	8	5.9	5.9	6.1	5.7
	40	5.1	5.4	5.5	5.5

TABLE 62

Effect of antisense oligonucleotide treatment on platelets ($\times 10^3/\mu\text{L}$) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	592	555	571	516
409826	40	536	493	400	338
142082	8	439	477	349	284
	40	461	454	401	263
446431	8	438	397	359	282
	40	516	337	369	323
404173	8	489	491	420	355
	40	520	470	389	316

TABLE 63

Effect of antisense oligonucleotide treatment on hemoglobin levels (g/dL) in cynomolgus monkeys					
	Dose (mg/kg)	Day -7	Day 30	Day 58	Day 93
PBS	—	12.5	12.8	13.1	11.9
409826	40	12.6	12.8	13.3	12.5
142082	8	12.3	12.5	13.0	12.2
	40	12.1	12.0	12.1	11.5
446431	8	12.3	12.1	12.4	12.6
	40	12.7	12.6	13.3	12.4
404173	8	12.7	13.0	13.3	12.7
	40	11.6	12.3	12.4	12.6

Analysis of Factors of Inflammation

To evaluate the effect of ISIS oligonucleotides for complement C3 analysis as an inflammation factor, blood was collected from all available animals in tubes without anticoagulant for serum separation. The tubes were kept at room temperature for 90 min and then centrifuged (3000 rpm for 10 min at room temperature) to obtain serum. Complement C3 was measured using an automatic analyzer (Toshiba 200 FR NEO chemistry analyzer, Toshiba co., Japan). The data is presented in Table 64, expressed in mg/dL. Treatment with ISIS 409826 resulted in low complement C3 levels, indicating a diseased state.

TABLE 64

Effect of antisense oligonucleotide treatment on serum C3 levels (mg/dL) in cynomolgus monkeys						
	Dose (mg/kg)	Day -7	Day -1	Day 30	Day 58	Day 93
PBS	—	136	138	148	149	129
409826	40	129	131	101	101	90
142082	8	126	135	126	127	111
	40	133	134	106	121	111
446431	8	130	144	128	132	125
	40	129	130	111	117	114

101

TABLE 64-continued

Effect of antisense oligonucleotide treatment on serum C3 levels (mg/dL) in cynomolgus monkeys						
	Dose (mg/kg)	Day -7	Day -1	Day 30	Day 58	Day 93
404173	8	127	136	137	136	127
	40	125	134	101	103	102

Analysis of Insulin Levels

To evaluate the effect of ISIS oligonucleotides on the thyroid gland, blood was collected on days 42, 84 and 91 from animals fasted overnight in tubes treated with EDTA. The tubes were kept on ice and plasma was obtained after centrifugation (3000 rpm for 10 min at 4° C.) within 30 min of blood collection. Insulin levels were measured using an automatic analyzer (Toshiba 200 FR NEO chemistry analyzer, Toshiba co., Japan). The data is presented in Table 65, expressed in ng/mL.

TABLE 65

Effect of antisense oligonucleotide treatment on plasma insulin levels (ng/mL) in cynomolgus monkeys				
	Dose (mg/kg)	Day 42	Day 84	Day 91
PBS	—	29	26	26
409826	40	14	22	15
142082	8	8	4	8
	40	8	10	10
404173	8	9	10	7
	40	6	3	2

Pharmacokinetic Studies

Measurement of Oligonucleotide Concentration

The concentration of the full-length oligonucleotide as well as the total oligonucleotide concentration (including the degraded form) was measured. The method used is a modification of previously published methods (Leeds et al., 1996; Geary et al., 1999) which consist of a phenol-chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS 355868, a 27-mer 2'- β -methoxyethyl modified phosphorothioate oligonucleotide, GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 50) was added prior to extraction. Tissue sample concentrations were calculated using calibra-

102

tion curves, with a lower limit of quantitation (LLOQ) of approximately 1.14 μ g/g. The results are presented in Tables 66 and 67, expressed as μ g/g tissue. The ratio of the concentrations in the kidney versus the liver was calculated. Treatment with ISIS oligonucleotides did not result in any abnormality in the ratio. The results indicate that ISIS 404173 is a better renal accumulator than ISIS 142082 at the higher dose.

TABLE 66

Total oligonucleotide concentration (μ g/g) in the liver of cynomolgus monkey				
ISIS No.	Dose (mg/kg)	Kidney	Liver	Kidney/Liver ratio
409826	40	4424	954	4.64
	8	1688	1044	1.62
142082	40	6385	1774	3.60
	8	1323	641	2.06
446431	40	6662	1159	5.75
	8	971	712	1.36
404173	40	7180	1464	4.90

TABLE 67

Full-length oligonucleotide concentration (μ g/g) in the liver of cynomolgus monkey				
ISIS No.	Dose (mg/kg)	Kidney	Liver	Kidney/Liver ratio
409826	40	3472	728	4.77
	8	1232	653	1.89
142082	40	4103	1244	3.30
	8	1204	416	2.89
446431	40	5645	846	6.67
	8	650	424	1.53
404173	40	5039	1094	4.61

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 56

<210> SEQ ID NO 1

<211> LENGTH: 3318

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

gtgatgcgta gttccggctg ccggttgaca tgaagaagca gcagcggcta gggcggcggg      60
agctgcaggg gtccgggatt gcagcgggcc tcggggctaa gagcgcgacg cggcctagag      120
cggcagacgg cgcagtgggc cgagaaggag gcgcagcagc cgccttggcc cgtcatggag      180
atggaaaagg agttcagaca gatcgacaag tccgggagct gggcggccat ttaccaggat      240
atccgacatg aagccagtga cttcccatgt agagtggcca agcttcttaa gaacaaaaac      300

```

-continued

cgaaataggt acagagacgt cagtccttt gaccatagtc ggattaaact acatcaagaa	360
gataatgact atatcaacgc tagtttgata aaaatggaag aagcccaaag gagttacatt	420
cttaccagg gccctttgcc taacacatgc ggtcactttt gggagatggt gtgggagcag	480
aaaagcaggg gtgtcgtcat gctcaacaga gtgatggaga aaggttcggt aaaatgcgca	540
caatactggc cacaaaaaga agaaaagag atgatctttg aagacacaaa tttgaaatta	600
acattgatct ctgaagatat caagtcatat tatacagtc gacagctaga attggaaaac	660
cttacaacc aagaaactcg agagatctta catttccact ataccacatg gcctgacttt	720
ggagtccctg aatcaccagc ctcatcttg aactttcttt tcaaagtcg agagtcaggg	780
tcaactagcc cggagcagcg gccctgttg gtgcactgca gtgcaggcat cggcaggctc	840
ggaaccttct gtctggctga tacctgctc ttgctgatgg acaagaggaa agaccttct	900
tccgttgata tcaagaaagt gctgtagaa atgaggaagt ttcggatggg gctgatccag	960
acagccgacc agctgcgctt ctctacctg gctgtgatcg aaggtgcaa attcatcatg	1020
gggactctt ccgtgcagga tcagtggaag gagctttccc acgaggacct ggagcccca	1080
cccgagcata tccccacc tccccggcca cccaacgaa tccctggagcc acacaatggg	1140
aatgcaggg agttcttccc aaatcaccag tgggtgaagg aagagacca ggaggataaa	1200
gactgcccc tcaaggaaga aaaaggaag cctttaatg ccgcacccta cggcatcgaa	1260
agcatgagtc aagacactga agttagaagt cgggtcgtgg ggggaagtct tcgaggtgcc	1320
caggtgcct cccagccaa aggggagccg tcactgccc agaaggacga ggaccatgca	1380
ctgagttact ggaagccctt cctggtcaac atgtgogtgg ctacggtcct cacggccggc	1440
gcttacctct gctacagggt cctgttcaac agcaacacat agcctgacct tcctccactc	1500
cacctcaacc cactgtccgc ctctgcccgc agagcccacg cccgactagc aggcattgcc	1560
cggtaggtaa gggccgccg accgcgtaga gagccgggc ccggacggac gttggttctg	1620
cactaaaacc catcttccc ggatgtgtgt ctcaccctc atccttttac tttttgccc	1680
ttccactttg agtaccaaat ccacaagcca ttttttgagg agagtgaag agagtaccat	1740
gctggcggcg cagaggaag gggcctacac ccgtcttggg gctcgcccca cccagggctc	1800
cctctggag catcccaggc gggcggcacg ccaacagccc ccccttgaa tctgcaggga	1860
gcaactctcc actccatatt tatttaaca atttttccc caaaggcatc catagtgac	1920
tagcatttc ttgaaccaat aatgtattaa aatttttga tgtcagcctt gcatcaaggg	1980
ctttatcaaa aagtacaata ataatactc aggtagtact gggaatggaa ggctttgcca	2040
tgggctgct gcgtcagacc agtactggga aggaggacg ttgtaagcag ttgttattta	2100
gtgatattgt gggtaacgtg agaagataga acaatgctat aatatataat gaacacgtgg	2160
gtatttaata agaaacatga tgtgagatta ctttgtccc cttattctcc tcctgttat	2220
ctgctagatc tagttctcaa tcactgctcc cccgtgtgta ttagaatgca tgtaaggctc	2280
tcttgtgtcc tgatgaaaa tatgtgctg aatgagaaa ctttgcctc tgcttactaa	2340
tgtgccccat gtccaagtcc aaectgctg tgcatgacct gatcattaca tggtgtggt	2400
tcctaagcct gttgctgaag tcattgtgc tcagcaatag ggtgcagttt tccaggaata	2460
ggcatttgcc taattcctgg catgacactc tagtgacttc ctggtgagge ccagcctgtc	2520
ctggtacagc aggtctctgc tgtaaactcag acattccaag ggatgggaa gccatattca	2580
cacctcagc tctggacatg atttaggaa gcagggacac ccccccccc ccacctttgg	2640
gatcagcctc cgccattoca agtcaaacct cttcttgagc agaccgtgat ttggaagaga	2700

-continued

```

ggcacctgct ggaaccaca cttcttgaag cagcctgggt gaeggtcctt taggcagcct 2760
gccgcccgtct ctgtcccggg tcaccttgcg gagagaggcg cgtctgcccc accctcaaac 2820
cctgtggggc ctgatgggtc tcacgactct tccctgcaag ggaactgaag acctccacat 2880
taagtggcct tttaacatga aaaacacggc agctgtagct cccgagctac tctcttgcca 2940
gcattttcac attttgcctt tctcgtggta gaagccagta cagagaaatt ctgtggtggg 3000
aacattcgag gtgtcaccct gcagagctat ggtgagggtt ggataaggct taggtgccag 3060
gctgtaagca ttctgagctg ggcttgttgt ttttaagtcc tgtatatgta tgtagtagtt 3120
tgggtgtgta tatatagtag catttcaaaa tggacgtact ggtttaacct cctatccttg 3180
gagagcagct ggctctccac cttgtttacac attatgtagt agaggtagcg agctgctctg 3240
ctatatgctt taagccaata tttactcctc aggtcattat tttttacaat ggccatggaa 3300
taaaccattt ttacaaaa 3318

```

<210> SEQ ID NO 2

<211> LENGTH: 78001

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

cagattcccg gtctcatccc tagaccaaag atatctgaat catttggcga tgggtccagg 60
aacctgcatt attcaacaca cttcccagggt gaccgtaaat gtcaaaagac aaaattacaa 120
caaaactaaa catcttaatt ggcttcattc atgattctag aatcgggcaa gacttcattc 180
ctcaaaaatag cacaagtgtc ccaatgagct gagcagagga gggtgggttt atagacagaa 240
aagggtgtaa aaaagcagaa acaaaagaaca aaaagcagat tggtcatttc aaagtactt 300
tccttgtaag gcaggaacag ggaaacagaa caagagagaa ataactgatt ggtcgcacgc 360
ggttacttca gggtactttt tgttgtaagg attaaagcaa agggaaactt attatgttga 420
ttaaacgggt ctgcttggga aatcaggggt tgtatctctc ttctgatttt gtgaaagggt 480
atcagtctga tgatgtagaa ctttagcatg agtgactcca ttttgatttt tagtctagtc 540
tggtgagacc ctaatgccag aacttttttt gtttggttgt ttctgctctg ttgccagggc 600
tggagtgcag tggagctatc ttggctcact gcaacctctg cctccagggt tcaagcgatt 660
ctcctgcctc agcctcccaa gtactgggga ttacaggcat gcgccaccac gcccgctaa 720
tttttttttt tttttttttt ttttagcagaa accgagtttc accatgttgg tcaggctggg 780
ctcggactct tgacctcagg tgatccacct gcgtcggctc cccaaagtgc tgggattaca 840
gggtgtgagcc accacacca gccctttttt ttcaagacag ggtctctctc tgccacccaa 900
gggtggagtgc agtggcgcca aaacagctca ctgcagcttc cacctcctgg gctcagggtga 960
tcttcctgcc tcagcctccc cagcagctgg gccccaccac accggctaat tttttaactt 1020
ttagtagtga cgagggttga ttctgttacc caggctggtc tggaactcct ggctcaaga 1080
catccgctg cctctgcctc ccaaagtgtc gggattacag atgtaagcca ccgcgctgg 1140
gctcctatga tttttattta acataatgca ccatggaatt tgtgctctgc ttagttcagt 1200
ctgagcagga gttccttgat acttcgggaa acaactgaaa tcattccatc cccatccatt 1260
cattcctgca gcacccaagt gaaattctg cgtttcagac agggacacta cccttagaga 1320
gcagtggtct tccccagcag cgtagtgaag catgatactc ctgagtttca tgaaaaaagg 1380
gcagacatct ggccagagct gggaggcagg aaatagagca cggtgccctc ctcccatact 1440

```

-continued

ccagcttgga ttactgagge tggggcccag gccctgcagg aaaggaggtg catgactact	1500
ttaaggccac tcactctgtg actcaacggg cgggtcggg gctggaactc aatgccctcc	1560
cgggcctgga gagcccacgc gccgtggcg gggctcccgg ggtegcctag gcaacaggcg	1620
cgcgcccgc cagagcccag agccccaaag cggaggaggg aacgcgcgct attagatata	1680
tcgcggtgct ggggccactt cccctagcac gcccccggc tcctcccgc ggaagtgctt	1740
gtcgaattc tcgacgctg attggtcct ctgcttcagg ggcggagccc ctggcaggcg	1800
tgatgcgtag ttccggctgc cggttgacat gaagaagcag cagcggctag ggcggcggtg	1860
gctgcagggg tcggggattg cagcgggct cggggctaag agcgcgacgc ggccatagagc	1920
ggcagacggc gcagtgggcc gagaaggagg cgcagcagcc gccctggccc gtcattggaga	1980
tggaaaagga gttcagcag atcgacaagt ccgggagctg ggcggccatt taccagggtc	2040
gggagcgcgc cggagcgtgg cgggcccttc gcttaggccg cttgaacatc ccctcagacc	2100
tccagggccc agactccctc tgggtcttgc cctctgcctc gctcctactg cttgaggatt	2160
cgatgggaca gcgacgcact gcgtccccc accctttgtc cccggggcgg gcgtgtttct	2220
cgccgcagcg tcggagcccc cttcgatccc ccacctccct tctgttctcc agctcgggtg	2280
atctctcaag cggggggacc gccggtctgt gctctcaacg cgaatccctc gcaccccgac	2340
cccggccct gcctgtccac tctttgtccc ctgggggat ttagcaccac cactatttcc	2400
ttttctggag tggaccacct cagactctct tcctttgtct ccctggggga aaaggttact	2460
ccccccgtcc ctcttcaca tttcctttcc cctagtctca gtgtgcgctg agtcccagag	2520
atgacagtcc cctttccctt ttctgttcat tcatttattg gataggagtt ggcaagctta	2580
ttctgtgcta ggcaccgctt aggcattgga ggtggtggtt gctaatcagg acaggcaaga	2640
tcctagcctt agtggggcct agagtcgaat agggcaatca aacacaaaag caaataattt	2700
cagatagtga caggtgctgt gaagagaacg acttcctaac ggggtacagg gtgactgcat	2760
agaaggccgg ctgtcttaga gaaggggatc aggggaaggc tgtcaagga ggagacattt	2820
gctttgtgag ctgaaccaag aggagcagaa agccgtgaga atatggggct aaagaacctt	2880
ctagccagga ggcctgcggt acccactcca ttggggccat gatattattc tttcaggcag	2940
ggactcagga aggttaacgt tttaacctc tctaaaatag catctttcct caatgagcag	3000
cttagtcttt ggtcgtggca gagatgacct tgtcttagga gtcactcct tgtgtgttaa	3060
aaagttagga aaggagggtt tctcatatat ctataaaaca agtagttaa aacacaaaga	3120
gctcttcctt tcacaagcag ctgaataaga tacatactcc caattaaatg tcattgaggg	3180
ggttgttaag attaaactaa accacacttg cacagtatct taaataagcg atatacagaa	3240
tagagagatt ttgttacttg tgtaaagga gacagcagat gattctgttt tcagcttata	3300
ggctcaaaag gcaaatgtg agatccatca gctgtagtat taaaatctat tttgagctcc	3360
gcttagaaaag gaaaaaagg ttaagcagtt ctttggtatg cttgactaac aaaagccttt	3420
ttttttggca gccttgattt tcattgtgat ttacatcaag cttatttgac aggattcttt	3480
ttatttgac tgtagtgtgt atattagtt ctgctagact aatatttcta accactgtaa	3540
tctatatact aataagtatg attgatcagt atataaaatt tgtagccat atctggtctc	3600
tgaattagct gaatgaattc cataagggac tttgagactg tgtagacaaa ttttctgcat	3660
cagtttaatg cagtagagtc taaaatgtct ttaaatgaaa attgttggtc tgaagtgtg	3720
gagttgatta tgatacacc catcacagtg gaagcattgt ggagagaagt cttttccact	3780
gaaattgact gagttgacaa caagaaatac gtattgtaac ttagttctta gttgaatttt	3840

-continued

atctcttaca attttaagcc agagtgggtt gacctgtcac ccaagcatgg ttaaaattgt	3900
atcagcatg caactagcat ggagtgtgtc agtcttcaat tcatttcctt cattgttctt	3960
aagtttttct gccacaatta aaccccacaa gttagtcaag gtgttgagat tttcactgct	4020
tcttaaatgga ttgccacatt cctgaggta gtttcttttg gtcttagaga attgtcaggg	4080
ccagcttttc tcacctccac tgtatggata tttttctttt ctaagatcct gaaatcagaa	4140
gcttttctcc taagtgtaaa agtagctctt tgtcatacaa ctgtagcgtt ttctgaacaa	4200
gagttcagat gaccttgagt ctaaagtggc taactttcca aggtgtgtat cgctttacca	4260
aaaccattat ttttcaagga ttcaaagaat gtgtttacaa ttgatagaaa atggaagttt	4320
aaaaaaatta atactttata gcatgttgaa atgagggcag ccttatacaa agtcatactt	4380
tgagcttgcc tagcctattg tgcacagaga ataatgtaat ttttgcttac aacttggtaa	4440
gcaggtcagt tattctaact tattttctga ttagaacaaa aagatgtaaa aacttgaaaa	4500
ctattgggaa aagaacaaag agtgaagagg acttttgagt gctgaggaat gtggcagctt	4560
ggaaaaacaaa ctttttaggc agagattctt tgctaggtea gtttgataaa gtgagcataa	4620
ccgtattttt aatctttaat gctaatgaat agcatagatg ctaataagca tctaggtcta	4680
taaaaagtea gctttgatag tgtatataga tggctttaa cattgttttc tagcatttaa	4740
acactttcaa atcatccggt tgcctgattg ggcctagctg tctaagagga gagaatgagc	4800
ccagatgagg aaaagagatt gattttactg agctagaatg agaggagaga gggttgagtg	4860
aatgaaaaga atagctcatg tgcctcccctc catctgtagt ttaagagggg ttgggtccgg	4920
tgttttgctt gttttctcgt ctgtaaatc tttgattctc tgacaccact cactatattt	4980
cattgtgaat gatttgattg tttcagataa aggggactgc aataatacct tgtgacatga	5040
aggcaagatt tattcatggt agaggcaggc tttgtaaaat gggccactct tccaattgac	5100
atttgttttt atagctgttt tcattatgaa atacaatcta atgcoctgact aggttaaaac	5160
catgttgtaa caatagttca ctaaaattcc ttactgatat acagottatg ttgttatatt	5220
ccaaaaagat gaattataaa atttgccaat aatgtttatt taaatactat tttcttcaga	5280
ggaaaaaaaa ctattttatg caaaggagaa agatctatac actatgactc acttcactta	5340
aaaaaaaaaa gactaacgga aatgacatgg agagactggg aagttctagt catcttgagt	5400
gaccatttag atctaaatgt tcttgtttag ccctggtttg agtgaactaa atttaggtgt	5460
ctgatcagta ctttggaat ggtgtaaatg cctttgtaat tgtctggact gatattagat	5520
taactgggag cacaagtaga aatagtgaag gaaagaactt tttgctattg ttatttgaca	5580
tcactggcat atttatagga atactttggt gtttttgaa gtaagtaaac caaccagtg	5640
ttctaaaaag tcagctgggg gataatggta atgccgctgt ttcttagctg caagttatct	5700
gccgttactt ctctccatt ttgcatttta tcttgaatag ctctcaaaa cctattaaaa	5760
tacctggtat tgaataatgt aattgaatgt gtaactgaatt tcacagtgga aatgaataag	5820
aaatttcctg tggaggtttt ttgacttagc tactgaaata acggcctttt gttgtgtgat	5880
tctttccctt ttctctttgt taaagaaaac tgtcttgtga tctttagat tacagaatcc	5940
ttttggcaat ttctgttctc agcactgctt tttctttctt tctttctttt aatagaaat	6000
ggggttttgc tgtgttgccc aggttggctc tgaactcctg gcttcaagcg atcctcccac	6060
cttggcctcc tgaagtggg attgcaggcg tgagcaggta cttttctga ggctgctg	6120
agcctatata tattttgcac aatttggcat tctcctctac agtgtttatg ctgatttgtt	6180

-continued

tctggtaaca	actaatactg	gcaaatcggc	tgggcattgt	actttatgct	gcccattatc	6240
aggaaaattg	gaattctagc	tgggtcattg	ttcccagatg	atgtagtttg	gcaccagcca	6300
ttccatgttc	acattttgag	tatccaggag	ggctggggac	tttggagtag	ttggtgattc	6360
cctctgccac	atttcaactg	ttggctacta	tggcatcctt	tccaccacac	tagtagtcta	6420
ggttctcaga	tgttgcttat	gagcctgcaa	tggtttctag	tttcacactg	cagaaatgag	6480
tgaagccggg	taccggtaa	tatggtocca	tcateactag	agtaattcat	tgttctaaaa	6540
ccagatctga	gtctctcact	cctctgcaac	tacttctgat	tctttcataa	cacttgtaaa	6600
gtccaaactc	ctcttttagc	tggcagccag	cttccagtc	ttccctccta	tgtggettcc	6660
attctagcca	gacaagaaag	ggcagcgttc	tccaaactca	tcctgcctct	tcattcctct	6720
ataccattgc	tgagcacttt	ggtgaggatg	cctctcccgt	tcaatctagc	ttgcatcttc	6780
cagctcgaat	gtgtgcttcc	ttgcaccaga	gttttgctcc	gtcacctgtg	tgttttcata	6840
caagctggca	catatctctt	ctaagccct	gctgtcattg	tagctgcgtc	tttacaaca	6900
ttttttttt	aaatttttat	aaagtcaagg	tctcactata	ttgcccaggc	tggctctaaa	6960
ctcctgggct	caagtgatcc	tcctgccttg	gcctcccaga	gtgctgggat	tataggtatg	7020
agacactgtg	cccagctgta	gctgctactt	tatatcccag	gtctatctcc	aatggagccc	7080
aagcttctcg	aggccactcg	ttgtatcttt	ctcattcctc	ttgaagtcc	ctgctcctgg	7140
cacagagtag	gtacctaaaca	agagttggga	ttgaattgat	ggtcagtact	ttgctagcct	7200
gatggtataa	agatgtacaa	aacatgttcc	tggctcccac	tctagggggg	caatgatgga	7260
aacaaataga	ttagcccaca	ttagtaccaa	tagtagaggt	cactctggga	gaaggccccc	7320
accacatttt	gagtcattgg	ctaagtgggt	aatttagtat	tgctctgtgc	agtggctttg	7380
gaagaaaggc	tggcattctt	agccagtaga	agctgatacc	actgatttgt	ttcacagaag	7440
ctttaaatat	aacaataaat	ttgtgcttgg	cctacgggtg	actttacagg	caacttgag	7500
gtaatatggt	tgtctctcta	agaattggtg	aattcctctt	ccctcatccc	tcctgactgg	7560
ttctcacaag	cctagcgggc	ctttgcatgt	ggttggttca	taaaataact	tttgattttg	7620
ggatataaaa	tatagttctc	cataaaataa	cgactgttac	caagtctttg	attttttttt	7680
tcaaactata	aatggtaatg	acattctttg	gcctttgatc	agaccacct	taggggcaag	7740
agagtagttt	catgttttgc	ttttctagct	gtcccctgtg	tctgggtata	gttgcagtct	7800
cagctgtcat	actaacagtg	ctgagtgagt	cccttacttt	ctttgggttt	tggtttctcc	7860
cttgtaaaaa	tgatcctgga	ctaactgatc	attaagtcca	ggccaagtaa	taaaaatcct	7920
taatgtactc	acaaatacaa	tttaattgtc	ctgaataatc	cttgtaaaaa	ctgcagcagt	7980
tactcagttt	tgaagggtgt	ggttgggtac	tattaggctc	aaaagtttat	aggagctttg	8040
tgagtatagt	taacaactca	aaagaatggg	gtgttttttc	ccgaggggca	tgaatggtt	8100
ttgataaata	gagttcattt	gacttggtaa	tgtggaaaat	gagtagccct	gacacgtacg	8160
ctatgctttt	gcagtttttc	tctcaagtag	caattgggtg	gcttttctctg	taaaagatag	8220
aggaaactgat	tcttgagaat	ttacgaaagc	ttcaacccta	actaggtatg	caaagaatag	8280
ttgcccttta	tgttgtaatt	ttaggaagaa	acctacatct	ggtctaagtt	tcatttgaat	8340
aatatgatag	tttacacatc	tgccatattt	gagaagaaag	tacctaaagc	tccagcattt	8400
tagaaataat	gctttacttt	gtgtagaaat	ggtcttttag	gtttaatage	tgetgcctc	8460
tcctttttca	aagcagcttg	acataatcat	gagtatcttg	ctgacagctt	gtaaattttg	8520
attgtatgaa	aactgaaaat	aagaccattt	cacatggaag	attcctcct	gcctgaaac	8580

-continued

agccaaagaa	aactgtagcc	atcaaatcta	ttgatctctg	ggctttggta	caagtcacac	8640
tactacaaat	aaaataatac	caagtactta	taaagtattt	tcagtccttt	taaagtttat	8700
ttttttaata	tttttttga	gatggggtct	tgctgtgtcg	tccaggctgg	agtgacgtgg	8760
cacaatcttg	gctcactgca	acctccacct	cctgggctca	agtgatcctc	ccacctcagg	8820
ctcccaagta	gctgagacta	caggcatgtg	ccatcacgcc	cagctaattt	ttgtattttt	8880
ttggagtaga	gatgggattt	tgctgtgttg	cccaggctgg	tcttgaactc	ctgggcttaa	8940
gccatctgtc	tgccctcaggc	tcccaaagtg	ttgggattac	aggtgtgagc	cactgtgccc	9000
ggcccagccc	tttttttaag	agaaaaacgt	atgacatcgt	tcgatttact	gagtgtttat	9060
ggttttacta	aggcagtaag	gttttatgga	taccctatgg	taattagata	gaattagtgc	9120
tctgaagtca	gctctgtaat	atggactcag	agtaaacatg	gcaaagggac	acttaaggtc	9180
tgcatthttc	ctgggaaata	aacgtattct	ttactactct	gaatctagtg	ctgggaaatt	9240
ctaaatcctt	cttgaggatt	aaccacttga	agtaaagttt	tgggtcccaa	gtaggcttgt	9300
gtccctgtct	ccttctcttt	acttttcaga	tgthttcttc	tagagactga	ggatatthtt	9360
acttttacag	atgaagaagg	aagcctcggc	tgtgtttgtg	gcttttgtgg	gtgagcaaca	9420
tcacttgcaa	agataagatg	agcatagcaa	aactaggctt	tcaaaataat	ttttaaaaat	9480
ttcttagtga	ttagaaaagg	aaaactcttc	ccttgtctct	gttaagaaac	gtttttcgac	9540
ttttttcctt	tcttaatgga	tcttttattg	gcacttctct	tccttttgca	gaatcttact	9600
taaaagtca	tacgttaccat	tacagcaaac	agcttagcta	atthttatcc	agatgggccc	9660
cggttacagg	attgtacact	attgcgaatt	tcttacagga	aagtgaacat	caagtaatta	9720
ttccaaatag	agttctctta	agaacgtgag	ttacttaaaa	atgtctaagg	atgaagtca	9780
ttctgaatat	aacttcactc	aagagaacaa	ataagcaaac	tgcatthtagc	ataacatggt	9840
aaattagctt	taactctctc	tgatgtttga	acatttgtcg	ctgttaacta	ctgtttcact	9900
tttcaaata	tcagggtcta	gtttgcttct	gtaaggataa	agggaaaata	cgcttctact	9960
gagtcataaa	tatttttgtg	gctaactttt	gcacagagaa	aagaggcctc	taagaaggta	10020
cccagtgaa	ttttttttcg	gggcagggag	agaatatgtc	atthtttggg	ttgttgtgtg	10080
tgthgtcatt	gtthtgcttt	gttgthttta	ctctgaactg	aactgtatct	tgacagcact	10140
tttgaattaa	gagcattact	cttattgttc	tctactactc	ggacgcccac	tcctctgttc	10200
catagtgtta	aggatcatgc	tccgaggtgg	ggtgaggcag	aatggggcca	agatcagaaa	10260
gttacattaa	gctacatcag	gtttatacaa	gcataaaacc	aaatthttgg	agcagtcctc	10320
agaatacaac	ctggthtagc	cacacctaaa	ggttgctctt	gaatattcct	tgagaatcca	10380
catccctaga	atgctggggt	tcaatgggcc	ctthtatgtac	ctatcatggt	gtcattthctg	10440
agcattthcta	aatattcctt	catgtcttac	tgacagthtt	tcttgaataa	atcttaggaa	10500
tattagtgcc	attatcagta	ttthgtttgg	tctgttcaca	ccacaaataa	ctaccaggt	10560
ctgctacttg	ccctatttcc	tctacctgct	aatgaaaatg	ctthttgaaag	tttgagtaac	10620
agtattggag	tgtgcacagt	ggtattggta	ggttctgtac	tcacctctaa	ccactgttht	10680
tcacctthtg	tgagcttgaa	gtthctccaa	aaaatthtatc	acaaaactta	tcagacatag	10740
ttaatacact	cagagagaga	atcactgaaa	aagtagatgt	agthtaacaa	accagtgcc	10800
ttthttttac	ccatgaatac	atattthgtca	actaaacctc	atthttgcaac	ttgttccact	10860
actcgaatgg	taacaaactt	ttggthttccc	aatagatttg	gaagatgttg	ctthttgaaag	10920

-continued

```

taggaaatag atggctttag aagatggaag aatattttgt ttgaagtggg agcgtgggtat 10980
gtccttagct gtctgtgaaa tgcagctgaa gatgggtgtg ggccttcac tgcatttccc 11040
atcttcagtt tgaggaggtg gttacccttc taaccactta agaactgcat ggtacatgct 11100
gttttattta cagggcaaaa ctgtgctccc gtagtttccc tgggtgcttc cttcacgtta 11160
acacagtgtc atcgtttggc agtgtttatg tgccagggtc catgttagaa ggaggaaagg 11220
tatagcgaag ttaaagggtg cagttggcct cccacctta gttttgtaag tgcctttaa 11280
gtttgatttt ttaggttga tcataaggaa gtgataagta tggtaggtta tttgtggtt 11340
gagctaattt tagtctcttt ttacagcttg ctttgtatcc tttgccatta aaacatgctt 11400
tctagaaaga caacttttga atgtaggaca cagtctatat tctatacttg gctacatttc 11460
aaaaaatatt ttctcagtac tttggaagt ggacagttgg aagcatagtg acagtattta 11520
aaaatccttg atccggccg ggcagtggtg ctcacgcctg taatcccagc actttgggag 11580
gccgaggtg gtggatcact tgaggtcgg agttcaggac cagcctgacc aacatggtga 11640
aacctgtct ctactaaaaa taaaaaata gccgagcgtg gtggtacatg cctgtaatcc 11700
cagctactca ggaggctgag gcaggagaat cgcttgaatc tgggaggcgg aggttgcat 11760
gagccgagat cataccattg cactacagcc tgggggacaa gagtgaaact ctgtctcaa 11820
aaaaaaaaaa aaattaagtg atttctttgc tttgtgacac ttctactttt ccagcaagta 11880
aattatattc ttcatacag gtatgaaatt cttgttccaa gctagtggtt aaaaaggcac 11940
agttgatatt agaggattg taaaagatta tgaccacgcc tgcaatgtac tgaagcaagg 12000
ctttgctggg ctgtgatag gaaaccttc ccagcctgtg cccttgcttg atagaacatt 12060
ttgctcctaa gggtaggtgc ctgtatctgt ctccagctact ggtagtttc acacagaaca 12120
gttgtgttcc agagctttag tctcaagctg cctgtctccc ctgaagcagc caccctgagc 12180
atgtgcactc acaggagggg acatgtgagg tcatggaaga agacgactca ggaagaagaa 12240
gacttggtt tgggttctga ctctgccttt gactgttgtg ggattttgag gagttgcata 12300
caggatctgt aaaatgtagt cattagacta gactagacag ccatatagca ttacctagat 12360
gtaactttct acaagacat ggtcacagga gaagaccaga gggtaggggtg atctttctgg 12420
aaaaattggg gcttcatgcc ttactcatgc tagatattgt agcattatat ggctgtgcct 12480
gatcccccta atctaaaagt gggacagAAC tttaaaattt catattaact caaattaaaa 12540
cttgaaaaaa acccattatt tccttaaaaa taataaaatg ccctgtgggg gcataagtca 12600
cattatattt taaaattcct gaatgccaca tggatgaatg tagttccttt tgaattctt 12660
ctttgtctta aagaggaatg ttggattttg taattggact aaaaaatctt ccatttgaga 12720
gagaaacagt ctgctgcatg ttctaccctt gttcaggata aaaccacta atagctaaca 12780
tttattgaat tctgtgtgtg gcctcaggca ctgtgcaaag tcctttacat gcaatgctgt 12840
ttattatata ctgtcaattg gtctataaca gcaggaaatg tttcaggagg acaatgaggt 12900
cccagacct cagtcttctc ctgtgtcctg gattcagctt cacaatagca ctatggcagt 12960
gtggccactg cttcagcttc cacatacatg gctgtgaaga gagacagggg attgtgctaa 13020
gcctccccga tttattagga cataggagga gagagtttgt agtttttgac ctttgctag 13080
ttttctaacc tctttcctag atgtcacaaa ttggccaccc acagtcatat tttgcttgc 13140
tcacgcaatg ctttttaaaa aagagaagag ttaatttgt gccattgttt ataaatgaat 13200
caggagaaat gacatgcaac tctggattct ggctctctt gaaaaatctg aaaatcacac 13260
cgtctgagct tacactggca gtggctctgt ggactgaggg acacaactcc tttggatgt 13320

```

-continued

```

acatgtgtgc gttgcagagt ttaccacagt cccacagtgg gtcacactgt ccttgctcgg 13380
gtacactacc tagcacttga gtttgcacc cctaccccaa gctgagtttt ctctgcaagc 13440
ttgatgttaa tgttatgtga tgcttggcct tgtaggtatt tggatatatta tcgtagata 13500
aaattgaagc aaagggctaa aggggtggtg gctgagggga gtgcccttga cagtaaagtc 13560
taggataaaa tcattggcca ggtactcctt ccttcccgc ccttctctt ttctctttat 13620
cctcagcctc cttctgtat tttgaggaag ttagaagcca ccaccathtt tcccacctc 13680
aggcaactga gtgtggctgt atttctgtcc catgttcagt tatttccagg aactatthtt 13740
gatgaccaac ttgaagtac attgggtggg cctaattggg gctgataaaa gaatgaggtg 13800
accaaatacg cttgactga gacggctacg aagtaaggtt ttaaatgact tgctttgtga 13860
cttggtcagg agtgatacca tttgtcatgt gtccaacttc atgactaaat ggttgcctca 13920
ccttatctc atagctataa taaaataaaa taaatacata cattgcaggg aggaatgat 13980
cttgtaaag gtctctccct tttagcaaca aaagtacata ttatggttga gaacatgctt 14040
ttctttgat cctcttgaa cacctattac tctatagagg tatgttgtgt atggcaaatt 14100
agaacaagca atagataagg atgattctt accattataa cccagtcaag gtctttgtcc 14160
taagttttgt acctttctcc agagggaaag gtatttgtat ttatttattt atttttgagg 14220
cagagttttg ctcttgttgc ccaggctggg gtgcaatggc acgatctcag ctcaactgaa 14280
catccgcctc ccgagttcaa gtgattctcc tgcctcagcc tcccagtag ctgggattac 14340
agggtccctc cacgatgcc ggctaatttt ttttttttt tttgtatttt tagtagagat 14400
ggggtttcat catgttggcc aggctggtct tgaactcctg acctcaggtg atccatccac 14460
ctcggcctcc caaagtgttg ggattacagg catcagccac tgcctccggc caggtatttg 14520
tatttttagt ctctatgcct taccgtctca gatcaggagg atttgggtgat ttatcgaatg 14580
tgggggaag ggaagaagag gaaacgggag gaatgtcca gattagggaa atagctagat 14640
ggaagatgca gcccctcatc aaggtgggga cacaggaaaa ggaacgtgtg caaagaagat 14700
ggtgatctgg ttgtgacat gttgtagag gacgtccagg gaagcatctg gtaggtggtg 14760
gggtgtttaa atatagaaca ttcggagaat gctccgaagc ttcagagaac ccttcccaaa 14820
aggacaaaac cagctcagtg ttttagcact ccgggatcat atggcatgac agcatggctg 14880
ctttatactt ttttgtgat gtgaaattaa aaccaaccac tcaggaccaa tttctctgaa 14940
gctttttgtc aatctttcat ttgcttttct cgtctagatt gtaagctcct tgcagccagt 15000
gtctgttgat tcagtcattc aaaaaataat acatgaacag ctactaggtta ccaggctctg 15060
tgctgggcag ttgggatatg tggtagggaa gacaaaactg gtccctgccc ttaggaagt 15120
cagtagtcca gcagacaaag tggctgaata aagataatct cagttcacag tgataagagc 15180
tcttacagcc ctaggctcca ggtgctgtgg ggatgctcag gaaaaggtat ctaattggga 15240
ttgggagcag gcaaaacaaa taaaggatag tgtataaagg taatatctag ttgaagtct 15300
gaagggaag gaggagttag cctgtatatt ctctgagtct ctcctaate tgggattgac 15360
ttctgtctcg tctctgttca tattaagtgt cacctaggct tgaagggtg agatcatatt 15420
tcacttctt cctctttggt cttaacctt ctctgtacc ccctcacaca atgcatatgc 15480
attattctct tattgtatat attttctct tcttctttt catgttctct ctgccattac 15540
ttttaaactc gactgccata tggcctctaa acgcttccag aagggtagcc tagtggaggt 15600
tattccatca tggccttgag ctcatgagc cagatagtg aggcattctg gtaggtgtct 15660

```

-continued

tctccaggag ggtgatattt gtttcattgt aaattttgta gccctagaac accaacaaca 15720
gtgcacagta attagtaggc aggcagtaca ggattcattg aagtgaagtg ataactttta 15780
tccaagtatg tatgcagata atctttgatt tgtacaaaaa aaattatatt ttaatatgta 15840
aagatttttt aaaagaatct tcaagtttta gccttcccac taggaatata ttgaaaacat 15900
gtgcctagtt cactgacttg cagctgccac tatgagaata aaggctcat ttagttggtg 15960
tgaatttttaa gggatatttt caatgatgtt ggctgggtta tcccattatg tggctttttt 16020
tttttttttt tttttttttt gaggtggagt ctgctctgt caccagggt ggagtgcagt 16080
ggcgcaatct cgactcactg caacctccgc ctcccgggtt caagcgattc tgctgtctca 16140
gcctcctaag tagctgggat tacaggcgcc tgccactacg cccagctaat ttttggattt 16200
tttggtagag aagggtttca ccatgttggc caggctggtc tcgaaactct gacctcatga 16260
tccactcact tcagcctccc aaagtgtctg gattacaggc gtgagccacc atgcccagcc 16320
tatgtgctct tattagcaat tctcagtaca cagatagctt tgagtgatc tttcaagtca 16380
agtaccttat taaaaactc aagtgtactg ataattatct tactttttaa tggctaagtg 16440
ataagactga atttttaggt actgtaacac ttcagattac agattctgat atttttatgg 16500
ttatttatat ttatttattt ttgagatgga gttttgctct tgetgcctag gctggagtgc 16560
aatggcacga tctcggctca ctgcaacctc cgcctcccag gttcaagcga ttctcctgcc 16620
tcagcctcct gagtagctgg gattacagtc acccgccact acagccggct aatttttggt 16680
atttttaata gagacaatgt ttcaccatgt tggccagggt ggtctcgcac ttctgacctc 16740
tggcgatccg cccgcctcgg cctcccaaag tgctgggatt acagcgctga gccaccgcac 16800
ctggcctggt tacttaaaatt taaatacaaa aattatgttg attaattctg aatgatttcc 16860
tgattgctcc cegtttaoca ttcacacatt tattaaatc ttcgcttgc atatagaagc 16920
agtctctctg ccatatatgc catatagata acagaactag ctgtctgcaa accactgaaa 16980
ttgtgaaaac atctcccctt ttttctgtt tctaattcta gctatgagga ttatatacag 17040
aagtagtctt ggatttgatt tttttttttt tttgatgatt gttttttgat agttgttgac 17100
tacaatcat ttaaacgtct gaaaggggaa aggttttctt taaaatgga tgacaaagga 17160
gaataaaaag gtattttgac tatttttttg aatgatgagt ttttttttc tctttctgt 17220
tttcttttg agtcatttat gtgtcactga gtggatacca tggaaactgt ggcagaagta 17280
gatatatggg gtaaaagaac catagtcat aagctccttg acagaatcac tgaagtgtag 17340
ccgttatatg gccactgtcg cagggggagg cagcagtttt gaagaagggg atgagtaata 17400
atgagtgata aaaaggcatc ctggatagaa gaccaaactc tgcagaagac cccagtttga 17460
ttatgctttt gttttctgat ttgcggagga gagtgaaaat gcctgagggg tgcgggggag 17520
cacatagggt gtatgtgtgt gtgtgtgccc gtgcagattc tctctttcac tgtatgtatt 17580
tgtatgcatg tatgtatctt aggacttaag ctttctagtc aataaattgc catagtgggg 17640
aattgcttaa ttgcttgcct tctgttgtg tatttaattt aattttattt ttaatgattt 17700
ttttggggg gtacagggtc ttaactatgt tgtccaggct ggtcttgaac tcctaaactc 17760
aagtgatcct cccgcctcgg gctcccaaaa tgctgggatt acaggtgtga gccaccatgc 17820
ccagcttagt tgtattttta atgggcctgt ttgcagcatt ccctactccc cttagtttac 17880
ctggctcaca acctgtcttt ccatatcaag gcttctgtca cccctggccc atgtcagtgc 17940
atttgggcag cccaccagc atcatcacct catgtcccag ggaacttctt gttcctctct 18000
tccagctatt tccttccctg gcagttgaga tagtctctac ctttgacctc ctgttaagct 18060

-continued

```

cagaccttct gctctctagt tacagcctct gtgctgccag attccctcgc tcagttgctt 18120
tctctagttt gggttttctc ctttattcag atttccagct gtttctctcc tccccccacc 18180
gcagcctcct cacttccctc cttatgcctc tgagactgtg gtcagtcact ttagatgctg 18240
cctctccact gaacttgtgt ccatcttctt acctaccacc tctagccctg gagcaggctc 18300
ttccccctgc tttgtcttcc tgggcccagg ctccctaagcg ctgctggaaa aaaaatcccc 18360
cagtattgag cccctagaaa tccagtcctt aatcccaaat ctgtctcccc cagcatctgg 18420
ccatcagatc taaagcttac ctgccatcct ttccacctca tttctctcac aggggaaaag 18480
gagcctttgc tcctagagtc tgcgctcctg accccttccc atctcacctg ttcaaggcat 18540
cttgcaataa ggggttgggt actctcgagg aatggatccc aggcctccc tattatcatc 18600
ttatgtatgc cagttcaacg ttctcagctt cctccagccg agacggcccc tccagccact 18660
gctttatact ctcttctctt ggttgaatt tttgaagtaa ataggtcact ctgccatcg 18720
ttcatcttcc agtcactctg tgtgtttatc ttccagggaa gtgaggctct atgctaccaa 18780
gccactgaaa taattttttt ttttttccag actgagtctt gctctgtcac ccaggetgga 18840
gtgcagtgcc gcagtcttgg ctcaactgaa cctctgcctc ccggcttcag gcgattctcc 18900
tgccccagcc tcctgagtag ctgggattac aggtgcctgt catcacgctt ggctaatttt 18960
ttgtattttt ggtagagatg gggcttcacc atgttggcca ggcttgttgg catgttgacc 19020
atgttggcca ggctagcctc aagtgatcca cccgtcagcc tcccaaagtg ctgagattac 19080
aggtgtgagc caccgcacct ggctgaaat aattcttgac aagatctgct tccttgttac 19140
taatacagtg gatattttgc atcctaattt taatgcagtt cagtgtggtg gacctgtatt 19200
tgcataattg atattccctt cctgtttta ataactctat tttttcctt tcttttata 19260
ctcctgcttc tctagctagt cctagacctt actcatcggt gtcttctctg tttgttctc 19320
aacttgagga gttcctacag ggtttacca atctgctgct ttcatttagc ccttttgctc 19380
tttttgagcc atctcattca ctaccocagg atgtagcctc ggcccttgaa ttcagtgtgc 19440
acacatacac tgtgcactat gggacagcct tcagaggcac tttgttctcg aaattgtggt 19500
ggcttttgcc tctcatggag ccttgcatat gctgtttcct ctgctggaa taccctacct 19560
tttacttaac tgattctcgt tcttcttcc agtcacattt tgtacattc tctggaag 19620
ctttctctga tttcccctt ccacaggctc aagttaactg ccttgtctag gtctcccat 19680
ggcctctga aggcctcctt tcatagcacc atgtctgagt atactgtaat aacacgcatt 19740
gctctgtaat agcctgttta cttacctatt gccaaagtaat ctatcaagtc ttataaagg 19800
eggggctgct tttgttctag tcatttgtat ctcttagtac ccaatatagt gtttggcata 19860
tagaaaaata ccaacaaggc cagtgcagct ggctcatacc tgtaatccga gcactttggt 19920
aggctgaggt gggcgatca cttgaggtca ggagttgag accagcctgg ccaacatggt 19980
gaaaccctgt ctctactaaa aatacaaaaa ttagccaggc gtggtggcgg gtgcctgtag 20040
tcccagctac ttgggaggct gaggcaggag aatcacttga actggggagg tggaggttgc 20100
agtgagctga gatcactcca ctgcactcca gcctgggtga cagagtgaga ctccatctta 20160
aaaaaaaaaa agactccatc ttaaaaaaaaa aaaaaaagaa aaaagaaaga aaatacccaa 20220
taagtagttc ctgaatgaat agatgagaat gctgtttaga aggttcatga attgaaacc 20280
gtgattgcta gggaggcttt gagttgatgg tattgtgttg aaccatgtgt taccaggat 20340
caatttagat tttacacttt gttttctctg ttccctttta tagtaatttt ctgtatgtg 20400

```

-continued

tgttttcccc	ccatgagatt	gtataccatt	tctcagcgag	aactgtgtgt	aatgcttgg	20460
ggctccctca	tgggtgcctt	catggaattg	gacttcgttt	cagtggatct	gatcccagtt	20520
atgttaatgc	tcgatggagc	taagtcttat	ctcgaagcag	tccatgtctt	catcagctgg	20580
ccctgcctcc	atgccctgca	cagaccatgc	cactctggag	aggtagtttc	cctgtggctt	20640
attagtctta	tgttccagtg	tgctggccaa	gtatgagaga	catcagtggt	atgagagagt	20700
ctctctcatt	caaactctgt	aggttttgta	gctgggactg	accagtgtct	acaggaata	20760
gaggcattta	ttaaaagcca	gagatttttc	aagttgcagg	aagcaaagct	cttgttagct	20820
atgattttgt	gggtgggttg	gtagtccaat	ataaaagtaa	aaactggatg	acaatgggag	20880
gagcatgctt	gggtctccaa	agttagatca	tttttcttaa	gtaatttgtc	tttaaacctt	20940
tactggtttg	gaatttcctg	agattttgat	cttgccagaa	agtttatagc	aaaagttctg	21000
agcagatgac	acttttgcgt	ctgaaaccaa	atcattgttt	ttgtttttaa	cttttttctt	21060
aatatattat	ccttagttca	gccctgaaga	ttattctggt	atgtgtggat	ctcaactttc	21120
cccccatctc	ctggatcttt	gtgaaatgaa	tggtattaat	tgaatagaga	aggaagatat	21180
aaacataaac	ttagtcaaaa	acttgttctt	gactaggcaa	gttgggcttt	atagctttga	21240
gctgatgaca	tgtctattct	tgtgaaaaag	ggatttttag	tggtggtttg	gcttcttgtt	21300
atatttgatt	tattattatt	atcattatca	ttatttttga	gacagagtct	tgctctgtcg	21360
cccaggctgg	agtgacgtgg	ctcaatctcg	gctcagtgca	acctccgctt	cccaggttca	21420
agcgattctc	gtgcctcagc	ctctggagta	gctgggatta	caggcgggtg	ccactacacc	21480
tggctaatat	ttgtattttt	agtagagaca	ggtttcacca	tggtggctag	gctggtcttg	21540
aactcctgac	ctcaggtgat	ccacctgcct	tggcctccca	aagtgtctgg	attacaggcc	21600
ttagccactg	tgctggctg	attttttttt	tttttttttt	tttaggtttg	ttttaactgg	21660
aactttacgt	gaatgtaatt	gaatttagaa	taaaagcact	taatttcaca	gtgtgcagtg	21720
aactttctgt	tacttatttt	aacagtaaaa	ccccttgca	taaatgactt	ggagcaaaga	21780
ttgctttttt	aaaaaatggt	ttaatttgg	tttcttttct	tgagatggag	tcttgcctg	21840
tcaccaggct	ggagtatggt	ggcgcgatct	tggtcactg	cagcctcccc	gcctcctagg	21900
ttcaagcgaa	tctcctgcct	cagcctcctg	agtagctggg	actacaggca	catgccacca	21960
tgcccageta	atttttgtat	tttttagtaga	gacagggttt	caccatgttg	gtcaggatgg	22020
tcttgatctc	ttgaccocgt	gatccaccct	cctcggcctc	ccaaagtgtt	gggattacaa	22080
ctgctgggat	tacaagtgtt	gggattacaa	gcgtgagcca	ccacgcctgg	ccaatttttt	22140
tttttttttt	ctttttgaga	cagagtttca	ctctgtcacc	caggctggag	tgcagtgta	22200
cagtcaaaac	tactgagcag	ccttaacctc	ctgggctcga	atgatcctcc	tgctcagcc	22260
tcccagtaaa	ctgagactac	aggcatgtac	cactgtgccc	agctaattgt	ttttttattt	22320
tttatttttt	gtagggacag	ggctctgcta	ttttgcccag	gctagtctac	aactcttggg	22380
ctcaagcagt	cctcctgcct	tgacctccca	aaatgttggg	attacaggga	caagccactg	22440
cacctggcca	aggattgttt	tttaagttaa	ctgagaccca	gccttattag	tgggtcccaga	22500
gcagacctgg	gacctgaagg	gaaccctttt	cttctgggtc	agcgtctttc	ctctgatggg	22560
ctactttctt	ggagcctttg	attgcctgtc	atcagagtaa	ctgagtttga	acagagtagg	22620
tagttctctt	ccagaccacc	acactcacca	gctttcattc	tgtttctctc	gttttagactg	22680
tggttctgaa	tcctcagttc	tatttactga	gtgtttttaa	acataaaaat	gccttttaat	22740
gagattgaag	gccagagggt	ggacagttga	ggacaaaagta	gaaataaaaac	cttcaaggcg	22800

-continued

gggttgttgg tgggagtcct tttttgtttg tttgtttttt gagactgagt ctctctctgt 22860
 caccagcct ggagtgcagt ggcacaatct cagctcactg caacctccgc ctcccagatt 22920
 caagctattc tcctgcctca gcctccttag tagctgggat ttcaggctcc cgccaccatg 22980
 cccagctaatt ttttattttt ttggtagaaa cggggtttca ccatgttggc caggctggtc 23040
 tcaaactcct gacctcaggt gatctgtctg cctcagcctc ccaaagtgtc gggattacag 23100
 gcgtgagcca ctgtgcctgg cagggagctc tatagaagct gtcgtggaca atgtgggaag 23160
 tagtgagcct ttgtattcca gtatgtggg ctccactgtg cttgctctgg cccccggctg 23220
 ctctctgtgt gttattgagt ccccatccac ggccatactc ttcgtcctgc ttctctcctt 23280
 accatcctct ccccgctagt ggtaccacgg ctaccactag caattactga catgtgggat 23340
 cttagggcta ctteccata aggctgcagg gcatgtggg ttggctacgc gcatggtaac 23400
 catggtagcc ctgtggttct ccacatgtgc gccttgtgac ctgggattgg ctgcagacta 23460
 gtaataaact gcgtctctctg gtatggaatc tgtctgtagt tgtactttct acctctgtat 23520
 ttaaggggag atctgtaac taccaatgcc agttgaagag gatggatgat agagatgta 23580
 acaaacagct gaaaaactaa ctacaatgc ctgcaaaaata gaacagcagg tttttgtggc 23640
 aaaactttgt gtcctagagt ttgtttttta aatctctca tataatctgt tttaaatcga 23700
 gagcttttgg gtaaaagcca tggctagtct tacatgtcat ggagtaccta gcttgtgagg 23760
 ttcacagttt attatttaca gagtgcctcc ttaaatcttc tttgggtcgg ttcagcgaat 23820
 gttgctcaga tggacttttt tggctgacat agagtcaaaa tggtaatcaa gcatgaaagt 23880
 acagacagtc cttaacgcac aaatgtgtca tgcctgaaaa gttggaaagt tggttctctg 23940
 gagctctgat tgtattgtcc tgtagaatcc gtgttgtgaa tgggtggttaa atcccaatg 24000
 agtccgtaga acctatataa tctgcaatat acctgcagta ttccaattaa tatgtaattc 24060
 ccccatagaa ctatgttaat gatttgtatg tatggtattt aatattatac ataataatga 24120
 ttgtatgaat aaaaaacatt ctgggctcca tgtggatgat ggggtgtgtg tgtgtgtctg 24180
 tctatgtgtg ggtgggtgtg tgttcataga tcccttttcc tgcaatcctg gcaactggaat 24240
 tggttttatc atttccaatt aagtttcatt cccatgaatt ttggagtaca gactgggtcc 24300
 aggtatgcag ggcatagatt agagccctga gaaataggat taggctggaa ttgctgggtt 24360
 ggagatcagt agcttccagg aacacttttt gggcctggct gtcttcatta tcccctttt 24420
 ttttctcctg gggctgcag gtattgcct gttttgttcc tctaataatca cttttttttt 24480
 ttttctgctt ttgaccaggg tttttgctc tggctacaaa ctgaatatcc tctcagactc 24540
 tcctgatttt gaaataaata tatagttttt ttgagggtgt ctagcgaatt tctaaatcta 24600
 aatgttggc cagagttatt acatactaat tttgctatga gaggttgtag aatcccagat 24660
 gactaatctt gtaaacata cacgcatttc catctaattc tccattgtat atcatgttgc 24720
 agaaaaaac agcctctaga gtttacattg cctcctttga ctatatttct tatttaagat 24780
 tagttttcag ataagacctt tccatggcag tacataactg tacagagggc ttccaactg 24840
 tcttgggagc tctcatctct gggagacatc acattaccca ctgccccctg cccccgccc 24900
 ccagcctgga tgcactcagc ctgtacccca tttctgtcct cagccaaaca ctgctgaaat 24960
 gcaagagctt tcaattgcta gccagtgaag atgcagacta agggatttcc atgtagaagc 25020
 ccgctctttt cagctggctc gtcagagact ggaggccct tgcctgttca catgaggctt 25080
 tttgtccctg acttgggtggc tgcgttttca cttctcagca gaaagggaca cccttgcctc 25140

-continued

```

ccccagaaa ggaagatttg atgtaccact tccgaaaggt tcagtcgggc atcactgtaa 25200
ccaagaagat aggtcagggt aggcctggagg tggaacaggg ctgctcgcta gaactccaga 25260
ttgttcaca agtgccttct ggcagagaat gatggaagct tccgtgattt tttttctcc 25320
ttaatagtta tgagcacaga agaggagcag attgtctggc tatagaagct gtcttatttt 25380
ttatTTTTgt ttttgagatg gagtctttct ctctgceca ggctaaagtg caatggcgcg 25440
atctcgctc actgcaacct cgcctccc agtcaagcg attctctgc ctcagctcc 25500
tgagtagctg ggaattacag gcatgcgcca ccatgccaga ctgatttttg tattagagac 25560
agggtttcc catgttggtc agtctggttt cgaactcctg acctcaagat ctgccacct 25620
cagctccca aagtgttggg attacagggt ttagccactg caccggcg aagctgtcat 25680
attaatagc actttctgct ttagcaaat ttaatccaaa tgagacttta gattttcttg 25740
ctctgactta ccagcagttc cttgaaacac atttaattat tttgcccaga aaactactca 25800
agcacttacg ccattttttt accgtgaaaa tatgctgcat tattttaaaa tatattagaa 25860
gtcagtaacc ataagatttt atatgttttc taatgtattc tgtaagcttt ctgctgcttt 25920
tgtttgaag gtgtattttg taacgtagag gactgcttta tctgcttcta agcttgattt 25980
ttgtttttac tgtaattttt tttcttttg ctgtattgag aaatacattg agtaattata 26040
aagtcagtg catgtttata agttaatatt tgtatctatt ccttagttac tctaactcaa 26100
aacctaaagt aatctcaac tctaattttc tctgacatcc agttgactgc caagctctcc 26160
aactaatcc ttatctttt ttttttaaag agatgcagtc ttgctttgct acccaggctg 26220
gagtcagtg gtgcaatcat agcttactgt aacctcaaat tctgggctc aatgatcct 26280
cccagctcag cctctggagt agctgggct acaggctctt gctaccatgc ccagctaact 26340
ttttattttt attttttata gagacagagt ctcactgctg ctccagctgg ccttgaactc 26400
ctgcctcag gcggaactcc tgcctcagg cggctctcct gcattggcct cccaaagtgc 26460
tggaattaca ggcccaattt tattcttggg atgtatgtct gaaactcttt ccttcaactc 26520
cttcccaagc cttagtccag gccctctca tctgtggtct tcaaagtgc cttcagctgg 26580
ttcaggtcct tcctttctgc tgtatctttc atgggaggac atgttatgta tcactgtcct 26640
acttgaaaac ttccattccc cattgatgag ggtgttacct ccagattcct aacacagggtg 26700
ctgaaggcat gcctggataa aggcactccc ttgatctcct ggccaggctc ccgtacacct 26760
gcagcgcag ctccacatcc tgtctttact gatgctgtgt cttctgctg cggagccacc 26820
caccattcta ttcacagccc ctgcctcagc ggagcacgtg cctccctctt cctacactga 26880
gctgtccttt ctattgaate cctcttttt tgtagtatgg gaaatatttt attatgaata 26940
ctctttctc tgttgcctcc gtgaccacgt taactttgcc ctaattcgcc ttaggactcc 27000
atctgcttag gggaaagtta ggatttgggt acagaaagca agctgctaga aagaacagtg 27060
tttagcttct gacaggcaaa ataggatttt gcaacatgct tttccttttt aatgcttaga 27120
cattttatat gaattaatat ttttatttgg ttgcttatac attactttct ttttagctag 27180
aatgtgaacc ctataggaac atggggattg cctttcacat ctttgtatcc tcagtaacta 27240
atgttcagtc accctgtggt cttgtgtcgt atatacattt agccttctt aattaaacca 27300
tatgtactgg tccccctccc cccccccaa atagagagaa agaaattcct tgaatactac 27360
attgccagta tcaaacacac ccttgatata ctctggggaa agggagggtat cagttgaaaa 27420
gagaaaagag gttaaaatct aggcattaaa atgtgtaagg cttagatgct ggcaatttaa 27480
ggtatgtttt cctgaggtta attttgattg tgtgcaattt ttacctata tctaactgta 27540

```

-continued

ggatttagtc accacataag atgggatacc tccataaatc cttcagaaat gtttgtgaaa 27600
 ttaaataaag ccttattgaa gactcagctc ttgagagtca tctacctacc taacagttat 27660
 tcttgaacag aagagtctta cttttccocta taaggcagtg tgatagccat ctgtatattc 27720
 atataaatta tgttggcgct tacttcattt aaaaatgtat tccgtgaatg cagttgccag 27780
 gcggtgtgct gatcagaaac gtgtaccaat ggccctctttt ataattataa gaggaagacc 27840
 aacctgaaac agtcacacaa atgattaatt ttaattgtgg aggagtgcctg ggaaagaaaa 27900
 ataaaagatg caatgcaagt gtttacaaag gagctttgag cttgtttgaa gtggtccttg 27960
 ggcaacttaag caaggcttaa agaattgatgt gattagaagt ggcttagcaa ttctaaagaa 28020
 cacaggggag gcgtgtggcc agaacttgg tccctagagc acatgcctc ctgacatacc 28080
 atttccttaa gttaatgttt taccactata cataggccct cccctttgtt taccagatt 28140
 ttttaattt taaggatgtt ttaataact tagaatcctg taatttgtt aacagtctg 28200
 tattcccttt acttatattc cttgagattt tataaaatat tttttacatg tcccaagtct 28260
 tgattataac tttttacctc ttgttaagaa atacttactt ttctattttt atgctatatt 28320
 tcatgtttac tgtagaaaac aaaaaagta aaattttct ttattcctat cactgcagct 28380
 tataagcact ctaaacattt tgatctatat ttgccaatc atatatatta gttaaaattg 28440
 ttgttgacat aattgtagat tctgtgcag ttgaaagaaa taatacagag ctgagcgcg 28500
 tggctcacgc ctgtaatccc agcactttgg gaggcgagg caggcagatc atgaggtcag 28560
 gagtttgaga ccagactggc caacatggcg aaacctgtc tctactaaaa atacaaaaat 28620
 tagctgggtg tgggtggcgg cacctgtaat cccagctagt tgggaggctg aggcaggaga 28680
 atcgtttgaa ctccggaggc agaggttgca gtgagccgag atggtacat tccactccag 28740
 cctgggcaac aagagcaaga ctgcatctca aaaataataa taataataat aaataaactt 28800
 taaaaataaa acagagagat cccatgtgcg ctttgctag ttccccatc cactgcccac 28860
 aacattttgc agaactgcag tacagtatca caaccacaat actgacattg atacagtctg 28920
 ctcatcttat tcattattcc ccagtgttac tctgatccac gtgtgtatgc attgtgtttt 28980
 caatactctt ttattataaa gctgttttta atgtgattca attctagggt gttttgttct 29040
 gccctcaaaa agcattccct ctccaatca tatctccgtc atacctgtg atgttttctt 29100
 taaacctgtt ttaagaaagc agctacctgt aagagaaatg agattgaaa cagaattgcc 29160
 aatctgcttg tactttataa gctgttgat tgtttagata cggtttagcc agtttatagt 29220
 taccctgggt gctgaaaggt atgctggatg atacctaac aacagagaac cattgaaatgc 29280
 cgttcaaaat ggactgaagc atcagcaatg tctgaaaaag gcctgacagt aatgtacatg 29340
 tcaaatggcc cgtaatttaa gcagagtaga gtaagtagaa gaataaacat ggggaaagt 29400
 ccagcaacag aggaggcttt gagcttttgc tcttcatctt gagtggatgt tgttctcagg 29460
 tggtaatagg ccactcagct ttctccactg gctgcctctc tggggaacaa ataaccgaaa 29520
 agatactcag caccctgggt ggtacatagg tggtcagttg atttatactt cctggttttc 29580
 agtgttgctt gaattttcta aatggaaca cagtaocttt ataatacaga aacaatccc 29640
 agttttgatt tgagggtgtt gtaaaaagt aaaaaaaaaa aaacagaaat gtgaaaagga 29700
 agttgtgtta gagtatttgg agttgagaaa gcatgaaaag gacagaagag aagctggttg 29760
 tcagggtgca tggggtagct acaagcacac tgaccagaaa gtcagctgga aaaaaatgt 29820
 agaaacagga gataaacgg ccaagggct atacaagcaa acagcaagga cctgagaaga 29880

-continued

```

aaaactagtt aggtgtgact gtcagagtga tgtgtacagt gtgatccttt ctgtgtaaaa 29940
acaagcagta agaattegct gtttacgttt gcgtgtgttt ggagaagagt ggggaagagt 30000
aggcactgcc agactgtgaa cactggttag gttattgtta tatctttgta ttatatacac 30060
tggacatggt atttgataa tatgagaaga aatttataa atcattaaat cttttggcat 30120
ttaggaacat ttgtgttttc taatagttgc ttctatacta ttatctttat tatatgccct 30180
tcatectctc agtgtttggc tgtgtttgtg attccctttt gtgagcagtg ttgaagttag 30240
ctaataatca tttcttctcc cttctttcac cctcctccag agtctgattt gaagtattcc 30300
tagctgctac ctataaaagc aataagcaag attgttttac ttttcacaaa ctgctcctgt 30360
tctgtgctcc tgccctggac atagctgtag tatagagtgt tgtctccctt acatccttct 30420
atcttagaac tactagtaaa tattaatgct cactctaagt tcttctcaat tctttttttt 30480
tttttttttt ttttttttga gaaagagttt cgctcttgtt gcccagctg gagtgcaacg 30540
gcacgatttc ggctcaccgc aaacctccacc ttctgggttt aagcgaactc cctgcctcag 30600
cctcctgagt agctgggatt acagtcacgt gccaccaccc ctggcaaat ttgtattttt 30660
agtagagaca aggtttcttc catgttggtc aggctgggtc caaactcccg acctcaggtg 30720
atccacctgc ctcagccttc caaagtgtg ggattccagg cgtgagccac cgcgcccagc 30780
ctcttctctc aattcttctc gaagctcttt ctgcaactaga ttctcagga agggcttgtg 30840
ggaacaatct tctgtgaatc aacagtacat attcataata gtttgcagc agcctattat 30900
tttaaggcca tttggtctgt atataaaaat gtttggatca cattttcttt ctttaaggta 30960
aatatggtat tctgttgtct tctggtataa agcattgctg taaatgtttg acagtctaata 31020
tatcttttgc ttataagtga cttagggttt tttgtctatg tgcccaaagg attttttccc 31080
tctttctctc tttttttttt tttttttttt tttttaaaca gacaggatct caccctgttg 31140
cccaggcttt agtgcagtga ggcagtcaga gcttactgaa gttttgaact cctgggcttg 31200
aggaacaaaag gattttttta accttttaat tcaaagtctc atcatttatg caacctatgc 31260
ttggtgttgg ctgttttggg ttgttctccc tcaaaaatcc atgtgctctt tcaatatgta 31320
gttttaaatc tttttttttt aatttcagga aaatctttaa ttagagtttt ccgtttttcg 31380
tctgtgacat tgcttgggtt tccttcttca ggaactcagc ctgttatgtg tatgtttgat 31440
cttctttgcc tgtcgtctgt ttctttcact tcctctcact tttttaaact tcatttatta 31500
aaaaaaaaatt tttttttoga gacagagttt cgctcttgtt gcccagctg gagtgcaatg 31560
gcgtgatctc ggctcactgc aaacctccgc tcccagggtc aagtgattct cctgcctcag 31620
tctcccaagt agctgggatt acaggcatgc gccaccacgc ccagctaatt ttttgtattt 31680
ttagtagaga cagggtttct ccatgttggc caggctggtc ttgaactcct gacctcgtga 31740
tctgcccgcc tcagcctccc aaagtgtctg gattacaggc gtgagccact gtgcccagcc 31800
ttattaaaaa ttttaaaaac atacatttaa acttaacaga aaaattatga gagagaaggg 31860
gggtgtgcca ggctttttta aacaaccagc tcttacatga actcatagag tgataactca 31920
ttaccatgag gacggcatca agccgttcat gaaggatctg gcccogtgac ccagacacct 31980
cctactaggt ccatttttaa cattggggat cacatttcaa cgtgagattt ggagggggca 32040
aaactacaaa ccattgtcact cagggttgg aggagcaagt accacctata ctttgactc 32100
aggtagaaaag gcaaaatata caggaaataa gctgctaccg tccagggttc agcagaggtg 32160
cccacagcc tgccaagtac tcaagagtcc agcctctagg gagctaataca tcatggtgag 32220
ctcttcgagg cacagggagc tgggaagaca gtgcttgcca cccctgctg aatagtgttt 32280

```

-continued

gcacagagag ttctgttggtg tcttgattgg gtccctcctgc cactgggaat gctgtggatt 32340
atactaggtc tctatctggc ttgtttcagg gctccatgtg aaaaccttct tgatataccta 32400
gccatccacc tgctcagtc ctagtttgca aggaggctgt ggggagccta gattctgtgt 32460
cagatagaat gtactacatt ccgtctcagg aatgtaccac atcagaaaa acgtgagacct 32520
gcaggagaag tagaggtgaa gaggcacatt cttccgagaa atgtttctct caacacccag 32580
cattccctgg atatcagcag gaaattactc actgctagaa aatgcccatt gagccttctg 32640
ttaaggaggt caaggagag aacagagaaa gttctcaaag ttgacttggg cactgggtact 32700
ttcttatgog gttcttattt tgtttgocat cgtcatcctc atgctatgtc tattttctca 32760
atccaaatcc actgctttca ccttggttct ttctgaccgg tttggcacac tcattcagta 32820
aatccttatg gagagcccaa tgtctgcata attgtgctgt gctgatgacc aagctagacc 32880
tacgagtgtc ggctcctttg agatgtacgg gacagctctt ctgtcatctc ttctgggaag 32940
cctctccagg cttgggtgaac agtggcaaga tgtttaacag ttgtacatgt gtcccatggt 33000
cctttctaag agcctgggca aaccagaccc ggtcgcaggt catcgtagta tggcgtgagc 33060
ttcctctctc ctttctgacc ttttgtgta tggcaagaac ctgcagagtg acacaagcag 33120
caggcttctg aggttctctc agcctcagaa tggccgtccc ttctccccc tggccctcat 33180
tgctgaggtt tcctttgaag caacagtgc ggaacagact aggggaagca gcttggacat 33240
agctgtatga tttattacca cccattgagg ccaaccaaaag tcggcaagga gaggtagcag 33300
gtcagtggtg cctggaagct tcctctttcc tttgcaccag atgtgactgc tctgcaatta 33360
ctcctaaatt tgctactctc gtttttacta gccaaccttg atgtttttcc cttcttctg 33420
tagaatagac ttcccctctg atcagtactt tctactcaac actatttgtg gccacagtgg 33480
gaactcattg aggacaggga ccatgacatt actacctgac ccatcaaacac ttggcataac 33540
ttgaaatgca aggacaaaaa ttggctgcaa gtacaatgtg gtcttcactc tgaaggtgat 33600
ccttaaaact tggctttggc atcatattgc cttaatatac ctaggggatt gggtaaaacc 33660
agttacttta aaagagtttt acaattctgg ccttctagct atcttgtctt cttaaacaag 33720
agcacaagat gaatgtatct tagtgaatt ttatatggtt tgctttgagt aatcttgca 33780
agattgattt ttagcacagt aggaaagaca cattctaata gtgatttttt tccccgagtt 33840
tatgtactgc tgttgcatga aaactctgact agatttaatg ttccctaaagt tctttgttca 33900
tcctgatttt tgcaggctct agggaaagct ttgttttctt cttaacctaa cttagatggt 33960
gtcatttcat gagctttgga ggaagagtgt atagccaatt gtgtaatgtc tttaaaggat 34020
attatctctg caatagttgt ttataaggcc taagtatttc atgtaataat agtggccccc 34080
gatctgtttc tagcaatagg tatatggatt ttggttccca tatagttgta gttgtggctt 34140
tgagatattg agcaagccct ttaagaaag gatttggcat ccctcagcct tcaaaagctt 34200
ctcaaaattg atcatatggt attagcaaag gtttactgcc tgcttccatt gtatagacaa 34260
tttatttttt atgtattocg ttctaagaag gcagatgacc aaaagatctt gcactctgtg 34320
cccaaggctt gtgactagag aggaaagaga taagaatact tttttaaaat cccattttac 34380
taaatatggt gaggaagtgg taagatatat taatttgttg agatttttct gttatgccta 34440
ttatatgaaa taggtactct gaacatggct tcttaattaa atatattga taaaatacaa 34500
cttgcttccc ctggagttta gaagtcagat aactgccatg gagagctatg ctttctttgt 34560
tttaaagatc tgcttatgaa catgataaac aggaacaatt taatgttttc aatattttct 34620

-continued

tgtatTTTtac	tgcaagTTta	tacacaacat	aaatatgggg	gaagggggaa	atgTTTtatac	34680
cagagccatc	ctgcccattc	tttccTTaca	gaaggacaaa	ggagcagtat	ttatTTtaac	34740
tacaaaaata	ctattgtagg	tttTaaaaat	tccgtatatt	ttgatatcct	gtgTtccctc	34800
tgacctTTaa	tttgctaaat	agttgcaaag	aatgaaggta	acctgcatca	tcttctTaaa	34860
aaccaactct	atctaattat	aatagTTTgt	ctatctctga	aaaatagtga	tgtgTtcatt	34920
ctgaaatcag	aactaccgga	tcagctgca	ttttgttact	atttgaattt	cgggagaggg	34980
aggaggatgc	agcctTTtoga	gctgctgaaa	tacacaaaaca	caaagaagac	accaagcata	35040
gtagaactgt	gTtaagctga	ccaagccaga	agaagcacct	attctcagca	tagtatgaga	35100
cgtaaaggca	atataatggg	catagTTgaa	gatggtagaa	ggaaaataga	ctctgatggt	35160
ttaatgTtaa	atgctTTTTt	taaaaaagt	gtattccaat	atcgaagaag	aagactTTct	35220
actTTtagaa	gcaataaagg	aaattgcaga	ggaaagggtc	aataggtTgg	aatacataaa	35280
aattaaaaac	tttTaaactt	ttttTTTTtg	agacagagtc	tactctgTc	accagggctg	35340
gagtGcaatg	gtGcaatctc	ggctcGctac	aacctccgct	tctgagTtc	aagcaattct	35400
cctgCctcag	cctcccaggt	agctgggatt	acaggcatgg	gccaccactc	ctggctaaata	35460
tttgtatTTt	tagtagagac	agggtTtcac	catgtTgtcc	aggctgatct	caaactcctg	35520
acctcgtgat	ccgctgCct	cggcctccca	aagtGctggg	attacaggca	tgagccaccg	35580
cgcctggact	aaattgTttc	agtattaatt	ttttTaaaa	caagatctta	ctgttgccca	35640
ggctgaagta	cagtggccca	atcatggcta	actgcagcct	tgactTctgg	gcctcaaggg	35700
atcctcccac	ctcagcgtcc	cagtagctg	ggaccacaga	catgtaccac	cacaccagc	35760
tacttgtTTt	atTTttatTt	ttgtagagat	gaggtTtcac	catgttgccc	aggctggtct	35820
cgaactcctg	ggcccaagca	atcctcctcc	cttggcctcc	caaagtGctg	gtattacagg	35880
tgtaagccat	tgcgcctGc	ctgattTTTT	aaatgtGcaa	acagataagt	tggaaaagtG	35940
atttccaata	aagataaaga	gttgatggTt	ttaaaatacg	taaagagctt	atatgaatga	36000
gaaaaaacct	aacattccaa	aagattagaa	ggcaaaggac	agaagaagaac	aaatcactat	36060
gtctgggaag	ggacatgaag	gagcaggttc	ccactgggcc	agcggggctc	aaaccactg	36120
gggacgtccg	agagactgca	agggccatgc	cttcacattg	ccgtacctga	gaagcaagga	36180
gctggggTat	TtatctctTt	cacactTtg	gaggctgagg	tgggGggatc	acctgaggTc	36240
aggagTtoga	gactagcctg	gccaacacag	tgaaccccg	tctctactaa	aactagaaat	36300
aattagctgg	gtgtggTggc	acacacctgt	aatcccagct	acttGgaagg	ctgaggcatg	36360
agaattgctt	gagcccagga	ggtagaggct	gcagtgagca	taaattgcac	cactgcactc	36420
cagcctgggt	gaaactctgt	ctcaaaaagt	aataataatc	atgataaata	aaataacatt	36480
agattgTtag	cagaagtgc	cacaggTttc	tcccacctct	ctgcaagTtg	ctgagTgtga	36540
ttcccatcaa	gaggtacaat	gtctTTTTat	TTTTatTTta	TTTatTTtat	TtatattgCt	36600
TatgtTgtct	aggctgTtTc	caaactcctg	agctcaagTg	atcctTctac	gtcagcccc	36660
caaagtTgtg	ggattacagg	catcagccac	tgcacctggc	ccagataact	tttcttgagt	36720
aggaatttcc	agtcaccctg	aacattgcat	gccttcgtag	tggggaagac	aataggaaac	36780
cacaggctgt	aggctaaaaat	gggtTgtgtt	tcttGtaacg	tcatgacaag	gcataaccCa	36840
tcttggcata	gTaaatagta	agcactcact	gaactgatga	TTTTaaatct	TtgctgtTTa	36900
ttcagcaata	tcctaaatta	gcgctatgtt	agtggagTtg	catctccctc	atggattagt	36960
ctgaaaaaga	tgagaaatct	gtatgtagac	caagTtatcc	TTaaactgct	cataatgtat	37020

-continued

gatgcaecgtg gttttacgtg tacagcctgg taccattggt cttaggcaca tttcagtgcc 37080
agaactctta ataccagga agaagcaaaa agaaagatgg aggtgcagct agaggttgtg 37140
gcctttgaac gattcattct gccttaataa gagtggctcg gctgagctcg gtggctcaca 37200
cctgtaatcc cagcactttg ggaggccaag gcaggcagat cgcttgagcc caggagtcca 37260
agaccagccc aggcagcata gcgagacccc cctcctcccc gtctctacaa aaaaatagaa 37320
acaatgagcc aggcagctgg gaacgtatg cgtggtgccct gtagtctcag ctaccagtt 37380
ggctgaggtg ggaggatcac ctgagcccta gaagtcgagg cttcagtgag cccttattgt 37440
gccactgcac tccactctag gtgacagagc gagacaggtc ctgtctcgaa aagaaagaag 37500
aagaattaaa aaaagtgatt agatcccttg tgtttgggac acttggtggc agcagggatg 37560
gtagcgttta tgagggttc atgtaacatc gcctagctca gacatctggt tgactgtctt 37620
ccccctgaa gcgcaggctc tgtgagggca ggtcttttgt cttctctggt aatcttcata 37680
tgcttagtgc ttgccacata gttgatgctc agtcgatatt tggatgaatt gaagggatta 37740
atgcattgaa tctgaacott gctttcttaa tgcatatggg gagttctttg gaaagccaca 37800
cagaggagct tggttgcctg cttcctctct tcccagatt gtctttttat tgttgtggct 37860
tcaactgaagc actctcactt caaataattt tgggcattgg tcgtatttta ttctttgttc 37920
cttcttcate cttaccctc agatggtatg tagaaaagta cactacatct agaaagtact 37980
ttataaactc atttgggtga taataataca tatgcctttt ccttggctct ggtagcagaa 38040
tcttggtcca ctcttggaat acaaacgaaa ttcttaacca aagccagttt cattttgatg 38100
ttctattttc ctcccattca cactccaaat tgtgcaccaa agtatcatcc tagttttgtg 38160
aggatggttc tccatacttc agggtaggag tatcatgtgg attcctatga tacctttctc 38220
cctgggacca tggaggcag cagctggtga ttgatagtct gattcccggg gaggaaagct 38280
gtgagccttc cacttgacaga tgtctgocaa ctacatgtgt ccttagtcaa ctgtaccact 38340
gtcctccggc aacacagcaga agcccagggc ctgaagttct taagctgtca ttatggaaag 38400
cagaaggtaa acaaacagaga agtgaagta gatttaattt tttagactgt tctcttacag 38460
gaatggtttt gtggttctca gcattttaa aaaaatagtg gttccaatat gttttattga 38520
catcaattac tgtaagtctg attcattttc tgccatttga tttctaccca aggtgaaatt 38580
catgacattt aacagaaagc ataagtgatt ttttaaaagc agacactatt agggacggta 38640
aaaataagat ttaaagtcgg gacacttgaa aaagcaattt ttataccttt ggtaacgatt 38700
ctattctgat tctttgtata aataatataa acaaaggctc tagaagctta ctataatgaa 38760
gttggtgtgc tgtttctaaa ttctggttta aggcccaaat tcattttatc tgcattaact 38820
tttttttttt tgagagctct gctctgtcac ccaggctaga gtgcaatggg atgatctcgg 38880
ctcactgcaa cctctgcctc ccgggttcaa gcgattctcc tgcctcagcc tcccagtag 38940
ctgggattat aggtgtgcgc caccacgccc ggctaatttt tgtattttta gtagagacgg 39000
ggtttcaacta tgctggctcag gctggtctca aactctgac cttgtgatcc gectgcctcg 39060
gcctcccaaa gtgctgggat tacaggcgtg agccactgca cccggcctg ttaaaatttt 39120
tcagtgttag accactatgt caatatgttg ctttactga caacagtatt ttcttaaga 39180
taggataccc catttctaga tgaatctcat tctagctgga aaataatttt tcagttctga 39240
aactacatca ggcctcaggg aatcaaaact agctatttag cacacacata taaagtggt 39300
ttgctttata aacgatttag ggtcaccatc aatgacaatg gtcccttttt attgtatttt 39360

-continued

taagagtttc	ttatcttaaa	tgctgcata	actgtagagt	tttaaaaaa	ttaagtaaat	39420
gaccatgta	atgctctatt	aagcttccaa	acaatattgt	aatttacttt	gaagattttt	39480
ttttattctc	aacatectgc	agcttgaccg	tttgctccg	tgtctcagtg	ctgcttattt	39540
tgaggtgtgg	actggagtcc	atctgtcccc	cttgctctg	aactgctccg	ttttgtgttt	39600
cgtaattctt	catgctgcat	cctgggogca	tttctctgta	gtagctttca	atttgcctcat	39660
gctttgactg	ggcttagtct	agcgtttatc	ctatctctta	aggtttttta	aaaaattttc	39720
atgattatlc	atltatttcc	aggattttct	atltcttcag	tcacatctcc	ttgttctggt	39780
tttacttctt	cctgtttttta	ttcataacat	ctttttttata	cacgattcct	tcattgtattt	39840
ctaactctaa	gtatatctaa	ttgcttattt	gattcttttt	tttttttatt	gagacagggg	39900
cttactctgc	caccaggccg	gagtgcagtg	acatagtcac	agctcaactgc	agcctcaact	39960
acttggaetc	aagcgactt	cccacctcag	cctcccaggt	agctaggaat	acaggtgtga	40020
gagccgccc	accagctga	ttgtctctac	tatgttgccc	aggtctgtct	tgaattcctg	40080
ggctcatgtg	atctgccctt	cttgccctcc	tgaagtgtct	agattatagg	tgtgaaccac	40140
tgcacctggc	caagtatggt	tatttattta	ttctaatttg	agagggagtc	tcgctctgtc	40200
gtgccagggc	tgtagtgcag	tggcacaatc	ccagctcaact	gcaacctctg	cctcctgggt	40260
tcattgcgatt	ctcttgcctc	agcctcctga	gtacctgggg	ttacagtgtc	gtgccaccac	40320
acctagctaa	tttttgtggt	tttagtacag	gcgggggttt	acctgtgtgg	ccaggtctgt	40380
cttgaacttg	tgacctgaag	tgateccgcc	gccttggcct	cccagggtgc	tgggattaca	40440
ggcatgagcc	accacgcttg	gcccagat	gtttattttt	aaagtcccca	acaagctata	40500
caataaattg	catatggaat	ggatttttgt	tctagtgtgat	ttgttggtta	tcattttag	40560
aactaactag	ttgtctctg	tgtttgatac	cttgcctcta	ggctattttg	agttggggagc	40620
cttttgtttt	gtttttattc	tcattgctgt	tttgagccta	gctgtgcctt	tatggttttc	40680
tctaaattta	attgaccatt	gttttatatt	tggagcagtg	gggtgacatc	agagtgtgaa	40740
agcagcccca	ccctctccac	cagaaggtct	ccatgccagt	ttcacgaagc	atltttctatg	40800
ccctcattcc	tgccttatac	ccttgatttg	tggggagttt	gtaaagcagt	tgattgtttt	40860
ttttccactg	agttttccaa	gtgcacataa	ttgttctgtt	agtgacttgt	agctccatta	40920
tctattaacc	ttgcccaga	ccactgtaca	agcggaccca	acgttctctc	cagctgtggc	40980
agggacagtt	acttggatc	ctgctgcctt	ttcaatgctg	accagttttg	cccttctctc	41040
ccctcaacc	ctgtctttca	ttcaactatc	accaaaccaa	aagattctgg	tttgcctttt	41100
agtatgtggt	cttattcagt	acatagtcac	tttaaaattt	aaacccaaac	agacttggtta	41160
ctgattagct	taattttaag	ctttttcttt	attattaaac	agtgtagttt	atcttagcat	41220
ttcatattaa	gtatatgatt	tatttccatat	tgccttatatg	aatgtacaca	taaatataat	41280
aaaaatattt	tcctaagggt	ttgttagtaa	attatctcgt	ttcattaact	ttcatatata	41340
gcattgcttt	tgacctggaa	gacattgaac	ctctgatgat	ttgtatattc	ctcggagtat	41400
actttgttac	atagaaattt	tctcattttat	aatgagattt	gtgattaaca	aaatttggtc	41460
aacatgcatt	actttgaaga	tctggtttct	aaaattttat	gctagttacc	ccaccccccc	41520
ttctatata	atctccctat	tcagcgacta	ctgcaagagt	tccaggaaat	gtacactgtg	41580
tgttcaacta	ctgcatttta	aatcattgccc	tttactatata	ttctgcattt	cccttcaate	41640
tagctctgtc	tgtacatttc	tgaagccag	tagcttccct	gaagaaccag	gtaacaaccc	41700
gaacaatcaa	attagataac	cattttgtaga	atggaggttc	cgggagatct	tagaagatgt	41760

-continued

gatgggtgct aagggacttt gtagttocct gaagttccag tgagtaaaag gtacccttgg 41820
aatTTTTtTat tccttcagac ttttaaaaca gagatcactt tcaaaaatta ctctttctgc 41880
tttgaatcca tgttttagta actatTTtTga cactgTTtTgg tcagaaggct gtgtgggtca 41940
actgcaaata aataaaataa atgtgatttc agtaatttcc atTTtTtaac aagtaattga 42000
gaaaatagga ttggatcaga tatttGctta tacacattcc ctttcaggag cacttctgtt 42060
ctataaagaa tgttggTata ttgttaagga cacttcaagc tttgggaacc tttgaagtat 42120
ccattgatTC agttaacaaa attatgttga gtgcctaccc tgggcctggg cctgtgttag 42180
gaggggacac taagatgaga gtccaaagca cttcttctca gactcctggc tgctaattggg 42240
ttgctgcctc tacttcttca cttagcagat agcttTaaaa tgagtaatgc atTTtTaccat 42300
ggagcccgta agagacattc acccagttgt ggaccgagga gaagggtgtt aaaccagat 42360
tgtgatgttt cacttgatga agtgcttaat ataaacatgg aaatatttcc gcaaggataa 42420
actggcTTTT atgcctgtgt gttttcagga gaaatagaaa tctctaataca aatattgcca 42480
gcttttcacc caagtttgac tttttgcta attgagttg ggaggtgtct gaataatgga 42540
taatgagctt tcctgaataa atataaaaat taattaactc caggctctaa ttcattctgt 42600
taccagagtt ttgtaagcat gttaccocct tgtgttcatt gggagatcat ctgttacctt 42660
ctaaatgag tggggaagga tgggaaatga ggaagagcta taaaaactat tcaggtgaag 42720
aaggTTTTctg cccctccttg ccccttTtaa aatctccagc tcagcagatg ctttgtTtaa 42780
acttgatcaa gtgcttgTga atcttctag cctagctaaa tcataacttt ggaaggactt 42840
gctttttctc ctcatgacaa tggtttacca cagaaatgat tcagatcact ttgtgtgcct 42900
gatgcctatg taaaatgata cagtgaatg gaaaccattt acctgtaagc tttgggcaca 42960
cccaagcctg cttcaggagc acatgatcag gcgtgcactc tgggagagcc gtacacattt 43020
gacatctatg atgtgtggcg ttttattcta tcacatttct gaaatctaca ctaagagaaa 43080
ggaggctctt aaaaaaccac tgaggTgtgg actgggggaa ggagagatcc gtaaagaacc 43140
tgtttgttac ctgttgatc tatttcccat tggTaaaatt tctaatttag tgtgatccag 43200
ccctgaaatg ctgaggcaca cactgaatga ctccctgacat ctttagtgtt tttgttcagg 43260
ggactcttct gggaaatctgt ttcattggca gtttattatt cccttttggg ttggctcatc 43320
agtttaccCa gcagtcatct taatcggttt taaaggcttt tatTTtattt tgtttctct 43380
gtggaaattt tacacattca gtgattaga agtagttatt taatctttgg ttagcataat 43440
aaaagatctt ctagggacat tttttgctg cagtggaagg ctagttaaat gtgttcatta 43500
gtcatgaatc tgctttttct atagctgttg gaaacgtagc tcccctgtga tacagttgta 43560
gaatacagaa atctcgtttt gctgttacgg tacggtagtc tacttacttt cttccaaacc 43620
attaatgtta tagttacctt taattgcgta ggtcctatca cccctcaatt ttaagactct 43680
aagcctggca ttttatctta caaaatgaaa tataaagact tgtactcaga gtatgtgtgt 43740
gttttcata taccattcta aagtagagaa agatgagggg ttcgccagaa actgatttct 43800
aataaattat ccagaaactg accccttctc acctcttctg ttaactgtcac tgtggtttca 43860
gccacagcat cctttgtctg attgttacct tagtttctctg actgtatcct tccttacacc 43920
attgatccct gcaatcccat ctgcgcgtag cagccagaag ggatccactt actgctgtga 43980
tcagaaatcc tcagccaggt gcagtggctc atgcctgtaa tctcagcact atgggaggct 44040
gagactggag aattatttga gcccaggagt ttgagaccag cctcaaaactg ggtaataata 44100

-continued

```

tgagacctca tctctacaaa caggaaaaaa aaaatTTTTT tTTTTTTTT aactagccag 44160
gtatagtgtc aatatactcg tctggggatc cagcatgctc tccctgacct gcagcttcat 44220
ctccaccact ttgccctca ctcccaccac aatggctttc ttctcttctc cagacatgcc 44280
gtgctctctc ctacctggaa tattccctc caaacattcc catggctcac tccctcacct 44340
tcatcagatc tctgttcag tgtcactttt actggaaggt cttttgtgac catcctactt 44400
attataaaaa aataatctgc ccaaccttct ccttttattt cctctacttg atttttcaat 44460
ttagtactta tcagctgaca tatatTTTgt ctctctgtct ctctctgtct ctcatagaag 44520
gtaaattcta taaaggaagg aatTTTtatg ttTggttctt tgctgtagct ccaatattca 44580
aaacagtgcc tgacacacag taggcccttt atattTgtg aataaatgtt gacactctga 44640
tatctaattt ttgtctggTg actaatcga aaactataga gtgataataa aagcattacc 44700
ttagtagact ggaagggat gagcgtagg atgaactttc tgcctggcga tcttTgctgaa 44760
tttagggagg agattggggT tcaaggagg ctgaaatggc taggattTgc agagcagggt 44820
actaaggatg agcaggctat gacagaaaga actccagaaa tctgcaaagg gatcacctTg 44880
agtctggctg gatacagtgt acactTtTga gggTgtctct tcatgagctt ggataaagaa 44940
caactgtTgg ggagTggata attcccagca ctcatTcaag cttgcatcgg ccagaacgga 45000
gagagacaga cctctgTaat acgtaggata ttTgTtagaa acattcaacc gaaaaccatc 45060
agatatgcaa aaagTataa taataagTaa acaatgtgat gcatagctag aagaaaaatc 45120
agacattaga agcaagccca gaaatgacag atgataaatt agcagataag gacattaaaa 45180
cagctattat aaataactta gcagattTaa agaaaaacaa cataatgagg ataatggaag 45240
aaaaacaacc gaataccatt tctaaagaag aaaaatacaa tatctgaaat gagaattTtag 45300
ctggatagga ttaatagTtt aggcactgca gaagaaaaaa acagcatcta tatgagaata 45360
taccCaaggg aagtacagag aggaaaaaaa tTgTgattTg gggTgcctc agTgacatat 45420
ggaacaatat taaacaagTc Tgccccaaa atactTgaag gaataaggtt caagTttttt 45480
ccagTttTaa Tgaaaactat aagcctacag attcaagcat ttcaacaaac cttcagcaaa 45540
ataacaaaa ccacagtagg cctggcacac Tgtctcatgc ctgcaatccc agcactTtTg 45600
gagctgagT caggaggatt gctTgagatc TgctTgggca acatagccag accctgtctc 45660
tacaAAAAat aaatgaaat aaattagctg gatTgTgagg tccacacctg taactctagc 45720
tagcctggag gctaagaagg gaggattTgc TgagcccagT agTtcaaggc TggagTgagc 45780
taggactgca tcactgcact ccagcctagg caacagcaag accacatctc tctctctctc 45840
tctctctctc tctcaaaagg cagtgaata acgacttatt Tggggaaaaa ataaaggcag 45900
agaattTgtt gccagcagac tagcataaaa aaaaggaagT cctTgaaaca gaagagaaat 45960
gataaaagat ggaattTtTg atatatacta aagaatgagg attgctaaaa gtgacataca 46020
tagataaata Tgaaatatat tttttttTta aaatttattt aaagcaaaaa taaaaataca 46080
tcatatTtat aacatagaaa taaaaaatgt atgataatag cataaaggat aagtTgacaa 46140
atgctgtTgt cgtatTttTg gTaaaaTgca ctattattTg aaagtagacc atcgtgaatt 46200
cgatgcatat TgTaaaccaa atagaacact aaaaaatgaa aataaagaga tatTgTctaat 46260
gtgccaatTg Tggagataag atagatgcaa aaaaagaaaa acattcaaaa gaaggcagag 46320
acagaggaaa aaaggaccaa agatcaaatg agTcaaatag aaagcagcta aactgcaat 46380
atggcagatt taaatctagc catgtcaata gttatattaa atgtaaatgt tctaaatacc 46440
Tgaattaaag gatgaagatt gTcagattag attgaaaaag catgacccaa ctacatgctg 46500

```

-continued

tctgtaagaa attagaaaa gaacaaatta aatccaaagt aagaagaaag gaaatagagt 46560
agaagttagt gaagtataaa acaaagagca aagaaaatca attaaatgaa aagctggttc 46620
tttgtaaaga tcagtaaaat tgataaattt ctactctaac tggccaagaa aaaagaaaag 46680
acatacaaat taacagtatc aggaagaaaa acagagaatt caaaggagtg taatgcaaac 46740
tttatgctag taaatgcaat aagttagatg gtatggaaaa aaatgtgaac aatacaaagc 46800
agactgtggt tgcctttggt ggcagtagcg ggggtgggagt ggaaggtga attgactgga 46860
accagaagca caagtgaact ttttgggtg atggaaatgt tttgtatctt ggttgcattg 46920
atagttaaat ggttgtagac attgcttaaa actcactgaa cacttaagtg ggtatgtttt 46980
attatttcta aatatacct caaaagcagt tttaaaaatg tattcaagta catacctaag 47040
atccttgcct tttactctga gtatacctta attttaaaat ctgtttttta aaaagtatta 47100
tgtagatacc ttttattttc ccaatgtctt tattaaatga catctccacg ttttcttctt 47160
tacctctatt tttttttttt tatttctctg tctctcaggc atgcacacac acacacccaa 47220
aaaagtacat atgcataatc cttttggctg aataaaaatca gttgcaactg ttatttgggc 47280
ccttatttgc tccgggtaaa tattcgttag ctgagtggtt tatctgtatc agatatttct 47340
tacatcttca tccagtcaca ccagctggac tgaccagatt gtttttctact tcaagggcag 47400
aatttgtact cactgctgaa tgcttccaaa tgatacgtag aataacaaat ttaagactta 47460
gatttttact ttttcaggtc tttttttttt tttctgtgct gtatagcatt tcctgaaag 47520
cttaacttca tctgtaagtg atgcagtgga tgtgttacta ttggattaat ttatttactc 47580
ttaggttagt ttgtaactg tcatcatgct gttgtttttt tgtgtgggtt tgtttttggt 47640
tttgagacag ggtctcactc tgctgcccag gctggagagg ctgagtgca gtgatgtgtt 47700
tatgggtcac tgcagattca atctctggg ctcaagtgat ctctctgctt caaccccttg 47760
tgtagatgga agcacagggt cacgccacca caccgggcta tttttttaa tgtattgtag 47820
agacgaggca tcattttttt gcccaaggct gatctgaaac tcctgggctc aaacaatcct 47880
cccactctgg ctccaaaagt gctgggatta cagatgtgaa ccaccaactc agctccatca 47940
ttctgttatt agttgttctc tagtatgagt caaaaactct tacctgacct tttacagttt 48000
tataaataag taagcagaat agcagaatgt ggacattttt taaatccaaa ttgaatatgc 48060
acatgactca aggagtcaaa tagtaccgta atcggtttat gataaaatcc agtggtttgg 48120
ctgggtgtcg tggctcacac ttgtaatccc agcaccttgg gaggtgagg cagggtggatc 48180
acctgaagtc aggagtttga gaccagtctg acctacatgg tgaactactc aaaatacaaa 48240
attagctggg catggtgggt catgcctgta atcccagcta cttgggaggc tgaggcagga 48300
gaattgcttc aacccgggag gcagaggttg tggtagccg atatcgatt atttcagaac 48360
aattttccac aagatcagtg agtgctgtcc aatagacata taatacaacc cacatacatg 48420
actttacatt ttctttagc catagtagaa aaggtcaaaa gaagcagatg aaattaatag 48480
cctgggcaac aagagcaaaa ccccatcttt taaaaataa aataaaatat ggtggtttgc 48540
tgcctccacc tcagaccatt tctctggtct ttctcattga ccaccactcc caatctttgt 48600
tctgctgatt gattacagct tgtatatatc tccatatttc taagcaaat gtttatcttt 48660
tttaaattta taaattcttt ttattatttt tcagagacag ggtcttaact ctgtcgecca 48720
ggctggagta cagtggcacc atcgtagctc actgtagcct cgaactcctg ggctcaagca 48780
gtcttctctc ctccgctct caggtagctg agactacgct acaggcacat accaccatgc 48840

-continued

ccagctcaaa atgtttatct tttgatacat tattcgagac cattattaag gtggatgatt 48900
tagttttctt aaacagccat cccctttctt ttoctocct ctgcttcacc gccccattt 48960
tcccaatggt ttaccttttg gttaaatcag tactcattgt ttacattatt tgcctctgca 49020
catagtcaaca gatagtattg tactgtactg tactgtgttt cttttttaa cattatttct 49080
gttgtaata attgactttt taattttttt cctattttgt tttttaaga gatggggct 49140
tactatattg cccaggctag agttcagtgg ctcttcgctg gcatgatccc actgctgatc 49200
agtacaggaa tttccacctg ctccatttcc aacctggacc agttcaccct ttcttaggca 49260
acctgggtgg cccccattcc cgggaggtca gcatattgat gccaaactta gtgcgacac 49320
ccgatcggca taacgcatgc agcccaggac tectggctc aagcagctct cccgggtca 49380
agcagtcctc ccacctaaag ctcccogta gctgagacta cagacacttg ccaccacacc 49440
aggtaattt ttgtgtttt ttagagggtg gggttttgct atgtgtcca gactcatctc 49500
aaacttctca gctcaagtga gctcctgctc tcagcttccc aagtagctgg gattatagac 49560
gcatgccacc acaccccatg ataattgct tttttttaa tttgcataat tttctttgta 49620
gcttttgcta atgttcccat atcttcttat agccttacag aatgatttcc cacaagatca 49680
gtgagtctg tccagtagac atataataca acccacatac atgattttac cttttttgt 49740
agccatagta aaaaaggta aaagaagcag atgaaattaa tagtatcttt tacttaacc 49800
agttcattca aaatgttatt tcaataaatg gtcaatattt aaaatacttg agatattttg 49860
ctttatttta tttctttgt tactaagtct tcaaaatcca atgtgtattt tacacttaca 49920
gaacatctct ttttagactg gccacatgta gctcagggtt actgtattgg acagagtgg 49980
ttcagtttca agtttttctc tggagacatc ctacttgaat tttccattct ccatgtatct 50040
gggtgggttg tctatagact tgccaactcag agctgtcacc ttgagacttt ctttgetttt 50100
cttctctatt ggatattcag tttcctggat ttcaggctct ctcattttcc tctagtagtt 50160
ttgttaggtc atgggttgta tggcatgggt gggatagcgt gttcacacag ctatctcgtg 50220
agtcatactc ctccaatcca gctcctcctc tcccctgctc tgcctatgtag ttgtcaccct 50280
gctatctctc cctccagttt ttgcagaaat ttcctttgct ttcactcttg gcttctctct 50340
cccatcccc atgtatccta tatctttctc tttcttggtt tatttcatca ctcaggtgga 50400
aaagatgctc cagtggatta ctgggaaaag ggggagcag gatgataaag gtattgagac 50460
cttacacgct aggaatttt ttttttttt ttttttgag acggagtttt gctctgtctc 50520
aggttgaggt gcagtggctc caactcggct cactgcaacc tccacctctc gggttcaagt 50580
gattctctct cctcagctc ctgagtagct gggattacag gtgcccgcga ccacgccag 50640
ctaattttt gtatttttaa tagagacgag gtttactgt gttggccagg ctggtcttga 50700
actctactt caggcaatcc acccactcct gaatgtttt attgtccct ctcatttcat 50760
gactgctggg ctaggtagat aatccagaa tcattgttct tagaatctcg aaggcattgc 50820
ttcattgctg gccagcttct agtgttctg caaagtctga agctgtgcta atcacctcat 50880
cctttgaaag tgaactgtt tttcttcca gaaacttaca gaacattctc tttgtccgca 50940
gaattctggg attgcaatta ctgtgcctta gaatgggtct gttttatca ttatgaagag 51000
tactggatgg gtcgggaggt tttcttgaat tacttcttga tgtttcttt ccttgtattt 51060
ttttgttgc taattttcta ttttttttc ttggttact ttcttgggca gggggatttc 51120
ttctacttat atttgattct tcagttgagc ttgtcatttt tgcctatctg tttttaagtt 51180
tcgagagaca tctttgtttt atataacatt ctgttcttaa tacatagatg caagatcttt 51240

-continued

tctttctgag tatattaata tgtatttgaa atctttctat tctctgcagt ttgtttcccc 51300
caagggtttt ttttttttcc tggtttttgt tttttgtttt tatgttagag actttcctgt 51360
tatatctggt catcagtggt acctgcatgt ggtggagagt aggggcttat tggagatga 51420
gaaccttgag cagggtgaag gaggctgtca acaactgcgt ggectcaggg cctctagga 51480
ggctgccagt tgtgcattct gaggatacct tttggttggt ccttttgtct ggtcagatta 51540
tctagagatg ctctgcctcc tacctggagg agaagggtct agctgccagc ggtgtgagt 51600
tctctggggg aaaaggactc gagttcctgg tgtttggctt gtgtatggcc gcttacccca 51660
tttttgggtg agcgcctaca tcttccactg tgccaacagt cttgctgcag ttcatagacc 51720
ttctggttta catttttcca gaaagtatgt ctttagattt ctgcagaagt ctgaggagca 51780
tggaaggagc ttggggaatg agatggcaat ccaggtcttc ccagatggct ctacctttat 51840
cccctgcagg gaatcccact cctccttctt gactgggagc acagccagag ccttgggagg 51900
aatctggagt ggaaatctcg ggcggtctgg ctttcttact gttcactgtt aattttgctt 51960
tctcacaact gccaaccaact aatcagcctg atttccagct tccagaatc tattgctgtt 52020
gtctgctctc ctattcccac cgtaggggat ggggctgtct tttttttttt ttttaatttt 52080
ggtaaaacat acaaaacata aagtgttcca ttttagccat ttttaggtac acagttcagt 52140
ggcagtaagt acattcagct tgtgtgtatt tgttttttta gtaataaaca atataaaatt 52200
ttttaagtaa taaaacacaa ataaaagatt gtttaagtgt attatcgtgg aattttaggt 52260
gtgatcagga gccatggtgt agtcttctgt tgaaacaggg tgataggatt tgtttaccac 52320
ctcctaggaa agcagttgga tagtttgttg gcataaaagt acattttatc tatttttaatt 52380
aatcgtagct ttatagaaat tgcagttgga actcccaggc ctggcattca aggcctctctg 52440
agatctgggc taccacacca tgcctccagc ccgtctgtct cacctcctac tgcccactca 52500
ctgttctctg catgagatgt gatctccagc ccccatgcct ttgctgtgca ggggtgttcca 52560
gagtgaattg tccctcctgt ctgtctctct gccctcttcc tcgtctttcc atcttctctc 52620
cccacatcac tgctcctac ccaaggcctg tgcctcattc tectcggttt tccccatgg 52680
cctggtacat acctctgaat tatcaccttg catttcccat attgcccggc tctctttgat 52740
gtctgtttct ttgctgggtc ttctcagtg tctgacggtc agttaaatgt ctttattctt 52800
ttttgtagga tatccgacat gaagccagtg acttcccatg tagagtggtc aagcttccca 52860
agaacaaaaa ccgaaatagg tacagagagc tcagtcctct taagtatcca cgtggccggt 52920
accagttctg ctcttctttt gctgcaggcc tttttagtca agactccttt cgctcaggg 52980
tttagtataa taataaatca atgtagcaga ggtttatgac gcgattgttt cctatagtaa 53040
aggcattaga gacttatagt aatagetcat ttttccacca ttatagaagg gctcaggttt 53100
cagtttctgg aaaattcagt gaagttcaaa gcacttttct taagctttga ctgtttttgt 53160
gatgaatcat tttctacca gctgaagcag agtatagcag gcataataaa accttttctg 53220
gatgactcag cagcagcgtc attagggcat gagcactgtg ttccgctgta atgaagcccc 53280
gcacaggeat tgggggtggg cactgtctgc cctgcgctg aatatgcaag gcagctctgt 53340
ctggagtccc caccgcctcc acccccgcca acctcatcat ttttctccct ctttctctgt 53400
gttagttctt cctaggattg tcagtgtgct tgctggcctg tggcagccct gtcgccttc 53460
tgagtgattg gctgtcagtc tgccggtagc tgaaaagtaa ataactaac atgttagaat 53520
tgcataaag taaggaaaac tggagctgag tacaggactt gaactgcgcc atctcctca 53580

-continued

```

ggccacagag gccttttga ccccttcca ggtctttaga cattgtcagg cagtgagggg 53640
tcgtagctgc cagtgtctcc atggtagcgt gctctgccag ggatgcagaa gattctccag 53700
tcattctctc agtgggcaact tctgcaggt cctgtgcca tggctgggag tgggtgctgt 53760
cattgttctc tgccagaagg gttagcagtg catcctgacc tgacttatgt ggcgcccaga 53820
ttcctggaag ggggtcaaaa atggacctag acttggtgta gaacgtgtgc ctcttggcct 53880
gccaccatgg ttccctgctt ggttttgtgt gtcagctctg ccgcttaaga actgagtggc 53940
ttcgggcaag ttgttctctc tcataggagt gtgtgaagat gaagcaacat aagctgctta 54000
gccagcgccc cagtacctca cgcagacata agtgctcagt aaatggtgtc tgtggtgggg 54060
atggtgtgca ccaacatctg aagtgcactt ctaggctcgc aggtgacatg attggcgcca 54120
acacatggta ctcttgattt agcacatctc agctgaggca cctcattgat atttgtttaa 54180
aaacaaaaac aaaaaactt ggtgattctg ctgtgaagtc ctggccagaa acctccagac 54240
cgctgatcaa cacgcaacag aaccatcacc gttcacctct ttgacatggt gccaggatac 54300
cctggatctc tagcttttgc tatagttgct ctaattaggg aataatcttg tctttaatat 54360
tcctttgcta cattttttaa catttcttat ctaaaggtt ttatgaatca gttttacaga 54420
gaaaaaaaa cagtatttaa aatattcttc caggggctgg tccaagtaca gtagtgttta 54480
caactatgtg atcacaacca gttacagatt tctttgttcc ttctccatcc ccaactgctt 54540
acttgactag ccaaaaaaaaa aaaaaaaaaa agttattcca gggaaacaat tctccaactt 54600
tttactctcc aatctcactc ctcttatctt cctcccgtae tctatctcct cctccgtaet 54660
cctatctctc tcccctactc ctatctcca gtagaacag tcatttgctg tgaaggttat 54720
gggggagaat gagtcaagg tagaagtcac ctgctgcca gctcacagtg ctgctggtga 54780
tgacagcagt ccacagttac aggcacttgc tgaacgaggg gctctgtata cacctcagct 54840
cattgactct tcccacaacc ctcttgctac ctaccattta gcaaatgaaa aaaccaaggc 54900
tctgaggtga gttgtttgcc cagagtcacc cagtgtctgt tgaacccact cacataacca 54960
accaatacca ttatgtaatt tttgaggtct tttatctctg tgatccactt aaaaattatc 55020
caagtatctt tattgtact aagcctccat aatgagaaac agtgttccag atggtggcta 55080
gttttcaaag acatctctct ttggaattct tctttagaac aaaaagcccc agaccactta 55140
tccccattca tatccctttt ggacctaggg agaaggtact atttataggt gatcacctga 55200
gtttatgtc ccttgctgtg tgccagaaat aaaggtcccc acctgctctt attagctcta 55260
ctaacaggat aaggaaagtg gccctcagag agctactgct tttgtgcaa acaaatgata 55320
caagaaaaaa aaagtggctt ttaatttta gtgacctggg gcaggacttc caaatgaaag 55380
tttatttcta aaaactaaaa ggtaaattta atatacttc agtgtttggg cttaaatctc 55440
ctttcaagtg tctttgtgat atgctctgaa ttttaaaaat ttagaatcat tgaagttcat 55500
tatacttgaa ctttaaaaaa aaaaaacaaa aacctcgtat aaaggtcaag gtatgacttc 55560
atgctgctgt gtacttaggt catttaatct tcaaaccact ggatagaggt taggttgaag 55620
ttcgatctta aatcctacct actgtagctc attgtaccag caacagctgt agggactagg 55680
tggaaatcat ggtgggtttt gttccctttt aaagattgaa gccaccatat tttctgcctt 55740
ctaaaagttt atgtcagcca ggcattgggt gctcacactt gtaatcccag cactttgggg 55800
aggctgaggt ggggtgatca cttgaggcca ggagttcgag accagcctgg ccaacatggt 55860
gaaaccccat ctctactaaa aatagaaaaa ttaggtgagc atggtggcct gcgcctgtaa 55920
tcccagctac tcgggaggtc gaggcaggag aaacatttga atccgggaga tggaggctgc 55980

```

-continued

```

agtgagctga gaacatgcca ctgcactcca gcctgggtga cagagtgaga ctcttgactc 56040
aaaaaaaaa gttatgcatac agagaacaga tcctttgatg ccctcctctg ccctgaaag 56100
tttttggggg agagtaataa gtatcacac aagatatgac ctgagaacag atttcccaga 56160
taggacatga tccatgtttt aatatggctt actgctgttg cttcatagtg tgaagcttca 56220
gacacttctg aaaacccttt cagaaaatcc cagtcgcccc atactgatga ctaatctcaa 56280
ctaaaacagg gcttcagcca gtgtgaatgc cactaatgcc accaactcac ctttgctttt 56340
ctgtagggtg tgcacctgta tgtacacatt cagcttttcc gggattaacc tetgagttct 56400
ggtttgtctt tcagttgacc atagtcggat taaactacat caagaagata atgactatat 56460
caacgctagt ttgataaaaa tggaagaagc ccaaaggagt tacattctta cccaggttaag 56520
cagattgtct gaattttcta tttaatgtca atttaagagt ttgagagtgc tgttatccac 56580
acctcaaata aaatctgcca catcctttag aaggtcagga tttcagcata ccaaaaagca 56640
gcaagggaag gggaaaaatc atccttcaaa ggttcagttt gggtataagg aacgctaatac 56700
ttttctggga agcataagat gacattgctg gaaatgagag cttatagaaa acaacattaa 56760
aatgccagag ttgcctgtgt ggtctgttgg cagagacagc agagccatgg ctggaggagg 56820
gtctgtacct gtgttgcttc cagaagtatt tgtcgtagag cacttgtgat ggcaaatcta 56880
agaacgtag cagtagacca ggaatctctg tccagagcca ttcagagtag ctcagcatgg 56940
ttctcattct ttggccagaa gaaaggcatc attggatcat gtgaacaagc atgaaaaatg 57000
acttaaaatt tctgttggtt tttggcatct ttatggaac aaaatcctga aagtggttta 57060
ataattgagc ctcttgtaaa acaactcagtg gcatgtgacc aaaaggggat ctgggaaaga 57120
ggataaaaag agtttctttt taattaatct tctcaagtct taacttgta cctgtaagtt 57180
ggtctaaaaa gactgggttt cttattttgt ttttcatcat aatttttgtt tctcattcca 57240
tgtcagcttt cagtcttata tggctttagg ccacagggcg attttgaaca tttgtaattt 57300
tgcttaataa ttaggaaatt aaaattctgg ggaagacaga atgctctatg aagaaaggct 57360
gctttgagca aggagctagg tcagggcgcg tcaactgag gcctttcttc actgcctttt 57420
tgtcttctcc cagttctctc ccatttatga ctaaaatcag cccagatgct tctcgtcacc 57480
tgggatgcag agcatcagcc cagctgtgtt cagtcctatg gggccattga gtaagttctt 57540
ggtgcatgga tacagggcag gcctttacca ggcctgagc ccctggctcc cccagcacc 57600
ctggggatt taggggaggc tgatggggga gggggttgat aaggcgggag atgtctgggg 57660
atgaggttga ggcaaaagtg acttcttgag gactttgctt tttggagaag tcaaatctcc 57720
tacttcttga tttcagccct tcaactctgg tatggagtca ggaagccctt taaatacctg 57780
ttgtcgggtg tatcatgtca agtgttgcac tagcaaatga ccatgtatcc ttgtgctact 57840
gtcctgccta ccccgcatcc tagcgtctcc ttgggacatg agaagctctg tctggtttgt 57900
gaggtggcac tggggatggt gagaaactgt ttacacagtt tccctttgcc ctggggattt 57960
actaaaggag tcgaggcagc ctgaccccaa agcatcacc ctagacacta tgaccgaaac 58020
atccccccag tgcccaaac aagaacacc tccccatctt ttttccagtg gtgttcatta 58080
tgtaataata caagtctctc ttctcatttt ttaaaagtca gaagtacaga agagcagaga 58140
ataatgtcca aggggcccctc cttcacctcc cccgtgcagt gtcagctaaag tgtggtgcgt 58200
gtccttgacag atcttagggg attgtgatcc ttcagaccat tctaaaactgg ggtggtgctg 58260
ggagttaggg aaggcatgaa gggagtgtg gagagctgca gtgactgggg tcttcatgcc 58320

```

-continued

```

aggggtggaga atgcaaggcc caggtggcca gccatgtgcc acgggatttc tggctgcca 58380
gagctgttta tctgttact ggggagggaa gagttaaatg tggctgtctt ttctccgagt 58440
cccttcagca cagggagtgc tgacttgtct tgttcaggta gtaagttcaa gatgagctca 58500
ggaaagaaag tgagaggaca ctgagggcta gtggttgagc caagtgtgat gggacttaaa 58560
gggagaagat ttaagaata aggagcttat gggccgggga cgggtggcta cgctgtaat 58620
cccagcactt tgggagctg aagcaggtgg atcacttggg tcaggagttc gaggccagcc 58680
tggccaacat ggtgaaacc cgtctctact aaaaatacag aaattagctg ggtgtggtag 58740
tgtgcacctg taatcccagc tacttgggag gctgagacag gagaatcgct tgagcccag 58800
aggcagaggt tgcagtgagc caggattgcg cccctgtact ccagcctggg tgatggagcg 58860
agactctgoc tcaaaaaaaaa taaaaaaaa ataaagaggt taggtgaaaa tagatgagaa 58920
tggaaacat gagaaagat gatgctggcc aaggacatga caggttctga tgtggaggtg 58980
ataggcaatg tctctccag ccactgctaa taattgagac aaactcaagg cattcatacc 59040
ctgtgtccag taaacatctg tgcccattgc caggtgagct ggattgaaat gggccagctg 59100
ctcagcagac accctcatgc cccagtgact ctgttcccct tgggccacct cattgacat 59160
ttatgtttct acatctccta agtttgttg gccaaagatg gaggtgtct gccgtcaggg 59220
tctcattgc tgatggtagg aatagttgct gatgttcat tggatgtgc tgtattctag 59280
ggactgtgct aagtacttta tagaaatgaa catacttcat ttccacagtt ttatgaatag 59340
ggactattat tagtcaagta agcgtgagg aaactggggc agggagcgt gaagtgactt 59400
gcgcaaggtc acaagatgat gtgattgaa ccaagagaag tgttgtggtt ggccacgccc 59460
ccacactgcc tctcatctgc accaaggagt tttgtccat agcccaaggg ccttggggac 59520
gaatctcagt ggaggccctt agcgggctg cctgagccag aaagcagaat cggcattttt 59580
ctgtccttgg ttggcccagc cctgaaactga gatgcgaaa tcgcttctg ctgctggtta 59640
gaaaatggag ctgcagttac tgaccaccag gcagagagag gtgggtccct gtcccagcct 59700
cagccaccac tctgcctaag ctgtggggac tgagggcgt gtcgttagct gactgcagaa 59760
ggtgagcaca cgctgtagca tgttatgtt cagatgtcac atgttgtgtt attgtgtctt 59820
tgcagggccc tttgcctaac acatgcggtc acttttggga gatggtgtgg gagcagaaaa 59880
gcaggggtgt cgtcatctc aacagagtga tggagaaagg ttcggtaagt ctcggttca 59940
tttctgtgt atgtgatcat gcataccact ccatatagtt accattttcg tccagatttt 60000
taaattattt ttcttgcctt tgtatttct ttacgtagta tttttattta aaaaaattaa 60060
aacagcagca tataaatgca tgttggttgt caaccagtta atgaagtgaa taaaaggag 60120
gaggcgaag aactgcacgg acctcttgc ccccgcttc tctgtgtgg tgcgtgtggc 60180
gctccgcca cctgtgtgc ctgtgaggct ctcacacag tgtggagttg tgtgtggagt 60240
tatggagacc tgettttate ttgaaaagca agttcttagt gcatcttcat ggtgtctgat 60300
tttttggctg gtgagagtgt ggctacctc gcggagctgt gggagcggct gactagatga 60360
gatttgcctc cattcagtac ctgactctt gccctgccac acctcttgg agtgagcatt 60420
gacttcagga tgtgtgctat tctaagttcc tgcaactttt caaacacccc tcgggctagc 60480
gtgtggctgc acggtgtcca tttgtgcagg ccaccactcc tcttgcactc gggcttagcc 60540
acctctcctt cttgacttac catagttcat tttgtacct gctttcagaa tgagctttct 60600
caaatccaag tctcaccag gttcttcca gctgaaaacc cttgtcgggt tccctttgcc 60660
tcacaggata atacatggtg tggcttacgg aacctgcag gtctggccct aggcccttg 60720

```

-continued

acacagacct ctcaccactc ttggaacttt agccaggaca aagttttctg tttttagttt 60780
cttaccatgt tctctgggce gaggagtccc agtgcccacg ttcacccac ttgcaggcac 60840
cctgggacgg ctgccccag ctcccact gectgcattc tcccctgccc tcctcactct 60900
gttggaatag ctgagaatag cegatttctg ggcagccggc ctectgtgta gactgtcctg 60960
tgtagactgt cctgtgtaga ttgtctgtgt agactgtcct gtgtagattg tctgtgtaga 61020
ctgtcctgtg tagactgtcc atgtaaactg tectgtgtag attgtctgtg tagactgtcc 61080
tgtgtagact gtctgtgta gattgtctgt gtagactgtc tctgtagacc gtcgtgtata 61140
gactgtcctg tgtagactgt ctctgtagac cgctgtgtat agactgtcct gtgtagactg 61200
tctctgtaga ccgtcctgtg tagattgtct gtgtagacca tctgtgtgtag accatcccat 61260
ttagaccatc tgctgtgca ggcgcaggcc agtgttcagc agggccacag gctcctcggc 61320
ctccctgccc tcgctgtctc ccaacactgc caaccctgct gcggggtcca ggaggagatg 61380
ggctgaggat cgtggagacc agcaggagcg tgtggcccag gagcaggaa ctgggtgtcc 61440
ttgggccttg ccaggctccag gctcagctag gacacggctc tcacagctgt cctggttgcc 61500
tccggccaca gaagaagggt agggctccag agaggccacc tttccaaaa aagcacagt 61560
atggccctag aatgtaaaaa atccaagtgt taagaaggaa cacatcaaa gaaacttcag 61620
cagtgaaaac ttgaagcatt aaccacgaag cctctgcctc caccacacac aaagaacgg 61680
ctttagttac tcgcagaaag tcttctctt aggcagcgc gtgttataaa tcataggggt 61740
ttggtttggt ttgttttggg gttgggggtt tttgggggtt tttaccctt gcctactttt 61800
taaaaaatga aagtgtttat ttgcccaca ataacagaca gggagcttgc ctaagtgttc 61860
tgttgatgat ataatgtatc ttgtcttaga aaaaaacttt ttcagtgaaa ggtgggtttt 61920
aaatttttc ttcctcctt agtagcttga ttagtaaaat gtgaagtac aaatgtgaag 61980
caaaccccca ccttcacca ctagtacgca attttgagta aagaacaaa gcatcagggt 62040
ctcacagcac aactgtctt agaggaagg ggaagcctgg tggcctgtgg aagcctcag 62100
catagctcca tctgcaggct tctgaccctc agcactactg aacttgggc tggatcattg 62160
tctgttaggg atccgggagc ggagtggtct gtctgggccc gttaggaagt ttagcagcat 62220
ctctggcctc tatccaccag atgccagtag caccctctcc ccagatgtgg cagtccagatg 62280
tgtttctgtc tagactccag actttgtcca acgtcccctg gtaggcaaaa ttgcccccg 62340
ttgagaacca ccgctctaga tggattgag ggttgggaat tttaaatca gacatttatt 62400
cagaaattac cagatatagt agcatttgct tcttatttat tctttgttg ctaagtgtt 62460
ggcaaaaact ctttctgtg agcacaagggt ttgtcttagc aattgtgtc acattacagc 62520
aaggagtggt gtccagcct gttagttatgt atttgagcag tgtccagtgc ttagttatg 62580
tgttccagcc tcaccaggcc ctgtgcttca ttgtctccca ctcaagactg accacaaatg 62640
gcccacagat cactgtgac aaccttccc tttgggttac tgggtggca tcgagaacat 62700
ggctgggttg ctttctgta gtttactgtg ataactgtc cagcagctcc tgetttcctt 62760
tgttaagtat cccattccac tggaggatta cttgggcgtg cagattggca tgaaaagcaa 62820
tgtatggtt gagattgta aagttcttt gggatcaaca tttcaattc tgtatcagca 62880
ttatccctcc cagagggctg gctgggagaa atcatgagaa gttacagtat cttattgtct 62940
cagctaactc aattataaat gatccacaca gcttgtgta aaaccagctt ttggggagtt 63000
tcatttaat gcatactgt cttctgattt ccttcttca ccaaatagtg taggatgctc 63060

-continued

cctcttattt ttggcaaaaca tgcctgttat cttttgggac cctgggcttc ctggaaacca 63120
gttatgcaga agatgattgt gtgtgttaga ctggggatcat ccagatggct agagtctca 63180
ctggttctgt ttaaggattg acttttagaca cctcagtgta ggctgcacca tggcgtaagg 63240
gttgggattg ttgttttagaa gggggaagta agcaaggatga gtttaattgg ccattgcaga 63300
atctcaccog tatctccctc ctgaaatcct cactaaagct gccgtttgct ttcaggtgct 63360
ttcatgcaca agacactgca ttttgatca cagggtccat ataattcatt tttctctctg 63420
acttagttct ctgtgttaag aattacttac ttagttctct gtgttaataa tttttggcga 63480
aaccaaatta cccgtcacag ggttactgta gatgtctttc ataggttttc caaacaccac 63540
ttgcccaact gtttgggaag gcccgaagga ctgtttaaca tctgcctca tggtggaaac 63600
agcaactatg agagatgcta gcatgttggc actgccatgt tcctctggta ccagcccaag 63660
ataggactca atttgaggcc tggatgaagta ctgtgttcta ataaaaatcc atctactttt 63720
catggccgta tataatcaatg taatagggta actggaaatg tgatcttgct ccttttaaaa 63780
atthttgtgtg tttaaaacaa aaatttctat tggaaatgac agagcatagc ttgttgctgt 63840
agacacctga gagtccttaa aaataaatat tgggttattg acacttagtt gcatgcaga 63900
attctcact tgtacagttc caaagtotta gtctttacc agattacaga gggttattaa 63960
gcattaggtt tggttttgaa agtgagtgtc tctgtctctg aggtgagctt taagactcgt 64020
ctgccctgct tatgagatga ggaagggtgg cctcttccct ctgcatttct gttctctgct 64080
tccttctctg tctgctcact ctgtggaatg cccaccccag cacgggtggg gtggaacctg 64140
tcagatcagt ctctgtttc tggggtcttg aggattata agatctagtt gttagaagtg 64200
tgggattaat tcactctttc acattcttct aagttctctg ttttagctgc cacaccact 64260
ttggctaagt ggggtctctg ccatgtaatt agccctcca tgccaagtgg cagaattgct 64320
tcaatggtga cagattgtcc ccattcaaga gttcactttt ggcaactcat cattgatcca 64380
ggaagggtgac atggatgaaa ctggctaaga cttcagacag gcttgtgtcc agactcttga 64440
gaaagctctg ttggctctg gtctggcact gtgaagttg ctgtgatgct ggcaccacaa 64500
cctgggtgtt octaatttgt ttctcccaca ttttctctg gttttgtctt ttgggcagct 64560
tccagctcca gtatagcagg accaataggc atttgtggtt ctatattcac cctcctcagc 64620
tgcttctctg ctctcattg ccccagatg atgccacagc tcctggggcc tgetgccagt 64680
cgtctgtgat ctgggcctct gctggcccct tctccagctg ctctttcag cctcttattt 64740
gcagtcactg cctaggaat cctagtcac cttcaaaacc tgcctcttgc acagagcttt 64800
ctctgatctc tcttttctgt aacctggct gacctgaaac atttccctct tctgaattcc 64860
tgctgcatgt ccgtagcatt tccccctcag cctccccca tagtccacct tgtcactgct 64920
gggcacagca gtgtctctg acagacagct ggcctgaag tggttccctt caccacacc 64980
atcctttgcc ccagaggagg tattgagtgg gtcagtgcac gtgaactgcc agtgtcattt 65040
gccaagagc tgttgacaca cgctgacatt tcttttctg aaaaataa gggctttgag 65100
cttccctctg tccaggcaca tggtcaggct gaccggtag ctctgcccct gctgacctgc 65160
catttttctc cacaacagtt atccatgac agaaacattt gtgtaactga ggcagaaact 65220
tagttcaagt aaaatgtcac taaattcgag tcagttttg tcttagacc taaatgaaac 65280
caaattttca taaattttct tgttttaag aaaaattaa tgagctacat ttaaactgag 65340
aacatcagat agtgtctgag attatcaaaa tagaacatca aaagtatttt tctgaatgaa 65400
ctgaacaaaa ccagaatgaa agggcaagcc ctggggagcc tgtctccaag ccttctctga 65460

-continued

aaggagctct gtatttggtg ataactgctc agcctctcca aagggcctca cctgctgtct 65520
ctcccagttt tatttttaat tgccctgtgag ttttctgtgc agggtaaggc acctacattc 65580
tatgccagca gcctgatcag gtccctgggta atgtttgaaa tggctacaca gaggagtttc 65640
aaagcctttt gttcaatctg gcttcacctc gtagacggtg agaaagcgtc agagccctgc 65700
aggatcccgt tgccacgttt gaccggggag ccgatgggtt tggaaagtctg agccctgtct 65760
gcacaacctg ccccggtcag cagcttctgtg cccccacccc catctcccca tgaggcaggc 65820
atctgtgctg accatggcct ccatgttcag aaacccccag gcctttgagt tatcatgaag 65880
cttgtgggat gtgctccaag cctcctgcca tagaaaaact gccatattgc tcacaataat 65940
tcactattat ttgtttcccc agttaaatag cgcacaatac tggccacaaa aagaagaaaa 66000
agagatgac tttgaagaca caaattgaa attaacattg atctctgaag atatcaagtc 66060
atattataca gtgcgacagc tagaattgga aaaccttaca gtgagtatag cacacacttc 66120
agcacttcag gcggctactg gttcacatgc ctcttccttt atcccttggg tgatattacc 66180
taatgtcagt gttcctggct tttgtatacc ccgagcaaga tgtggtttgg gcaactgtgt 66240
gagcggagct tacttgtgta cctaccaagt gcccaggag ggtggaggcc acagtgtctt 66300
ctctgacctt taacaacagt taacaccagt tcttagggaa aggagagttt cttaccacaaa 66360
agactgggtc ctgcttgtgc agctgcagag ggaactggagc ggcagcctgc aagtcccagt 66420
gaagcatgct gccttctttg tggctctcag tcttcgagtc tgaagagagg gaagaagggg 66480
tataggggct cactccagtt tcatagctag tgaaggtttt ctgggccagg tcttgggttt 66540
ttttgtgtg ggaagagttt ataacaccag ctacttgctt ggtaaaagtt ggtcttgaa 66600
catggcaagg catttgtgca agcagcactg ccgctgaacg cgctgctcct ggggctttgg 66660
aataattccc ctggatccgt aacttggggg tgttcatgct attctgggga acagtggagg 66720
gagtgcgcgg cagcacctgg gggcaccagt gaagagtggc cagccaccaa cctctagaac 66780
ctaactgggg tcgaatcctg gccccacctt actagctcat cacagtgtct ccgtttctct 66840
ttctgtcaaa ctacagtttt gcgagggttc tgggagggtc tatacgggaa gggttagcag 66900
ttaccatggg tgtgtagcac gggctttatc tgaaggggag gtggagccgt aggggagacca 66960
tgtggagtgg ggctccaggg ctgtgtgggt ggggagggat ctgcttctgg gttaccccat 67020
gcctcccctt ctcaagtaact actttttaat catcatggct cctgccattc atttcatagt 67080
tgatgtaagc caggtgctgt ggtcctcagc tttaatccca gcaactgggg aggctgaggc 67140
caggaggatc actcgaggcc aggagttaa gaccagcttg ggcaacatag tgagaccccc 67200
gtctctacaa aaaaaacaaa acagtttagc agacatcgtg gtgctcccct atagtccagc 67260
tactcaggag gctgaggcag gaggattgct tgtgcccggg agttcaaggc tgcagtgagc 67320
tatgcttgca ccaactgcact ctagcctggg tgacagagca agaccctgct tcaaaaataa 67380
ataaataaaa aaaatagtag aagtaagatc tagaatgtag cacaggttac caggacgtag 67440
gcaaggggtt cgggctgctt ggtccttgag gatggtagca gtgcagctga tgtgagtgtc 67500
ttctgccctc tgggtgtgac cgcgcgggag tcaccagccc tgccatagcc ctgatggggc 67560
agagggttct gagtacgggt gatggagggt ctttctggaa gattctcagg agtaacatgg 67620
gcagtgtgtt ggaatgtgct agaggattta tgcagttagc ttttaaaaga atgcttttta 67680
gcatttgcaa gcctgacatt aagagtgact tctgggaaac tatttgcttg ttgagggaaa 67740
ctgaatttca acagagcaga agagctgtgc gctttttgct tggcagagtg aatacagcca 67800

-continued

gctcagaggt tttgatgtta ggatctgttt gctccaacag actttgtttt taaaaggett 67860
ttctcagcca tagctgtctg ttctagcaca aggctggaat gagttccttg tgaagaggt 67920
gagcaggtgt gagggaggtt gtcagtgggc ggtaacccac accttcaagg attaaaggaa 67980
aacttgcaatt tggcatgctt gcttcttatt caattttaa atactttta acggccgggc 68040
acggtggcta acacctgtaa tcccagcact ttgaggggct gaggtgggtg gttcacgagg 68100
ccaggggttc aagaccagcc tggccaagat ggtgaaacct catctctact aaaaatacaa 68160
aaaaaaaa aattagccgg gcgtgggtgc gggcacctgt aatcccagct actcgggagg 68220
ctgaggcaga gaattgcttg aaccaggag gcggaggttg cattgagccg agatcatgcc 68280
actgcattcc agcctgggcg gcagagcaag actctgtctc aaaataata taataatfff 68340
ttaaaatac attttaagtc cttttcttcc ccacctgcct ccaccacca aatagaagag 68400
gtatttcttc ttctttaatg tcattaaggt tatatggata ccattttcta gagaggaaa 68460
aatgatggaa ttgcttagtg tgagtctagc aattatccta acatacacia atttctcctt 68520
gttctgtgcc aagatactgt atttaatat taatgaacat taaatattat ttactagtgt 68580
atftaatggc tgaggcaggg ttaaatatgt attattttca tcccagcaga gttgggggag 68640
gtcctagtaa ctatgccatg agctctgtga gggtgaggtg gtgtctttgc ccccgctcc 68700
ctggcacagt gactggcaca tgattggcat agtgtggaca ttcgtcaagt gaaggaaggc 68760
atcatgagca gatctctggc ctgaatcctt ctgccatcag ctgctcgcca ggtggccctg 68820
gcactgggccc acagggaaac tctccaggtt ggtatggttc ctgtctgtgg ctgtcttccc 68880
gggcccattg taggagactt tcacttccag agccctttcc ctctcagggc cttgcttacc 68940
aagtgactgg ttcccattta ctaggagctc ttaggtcatt gaagatgttg cgtactcccc 69000
ccagtgaggg ctgccttttg atcacagccg ccagaagcct caaggaagga gcagagctgg 69060
aaacagacgc caggccattg cttctgttcc tctggggcag acccagccac ggaagagaca 69120
ttctgggaca agggctgggg tccaccttcc aaacgtgtct gcagcaggct ctcagcatgg 69180
actctctgcc tccaaacatc cacctcctca tcggaaaatg gatgggagtg cctgcctgga 69240
gcagctggtg ggagagcgca gcgccagcac gtaggacaca ctcggttcat gggctgatgc 69300
cgttcgcatt gactgcctct tcagctgggt gttgagccac acctggagt caccagtctt 69360
tgagaccaa gtctgctact tttttctcta aagtgacaat cctctgaaac ctccagatca 69420
tcttgaagcc cccgtctgaa agttgcccag agccagtgcc tcacctgctg ttcttgttc 69480
actttttcac gggaggcctt gcagggcttt atgacaagat tttatgggtg gctgccagc 69540
atcattgtga ctctgagac agagagaaac cagttgtaac catgtagaca gtggaagtga 69600
tagggagaaa agaggtgagg ggactcttca atccgaaggg aaatgaagtc taagcaggcg 69660
cacctgcag gttcagtgtc aagcccaggg cctggcccca ggggtgtgga tttgttgact 69720
gggtgtgtgg acctggggag aaagtctgag aatgaatgtt cctcttagag gtagagagtg 69780
gaagtgact ctgtgtgtac ttggaattag tgattctgt acagatgatt cttttagaat 69840
catcatgagt atttttctct ttcagacca agaaactcga gagatcttac atttccacta 69900
taccacatgg cctgactttg gagtcctga atcaccagcc tcattcttga actttctttt 69960
caaagtccga gagtcagggt cactcagccc ggagcacggg cccgttgttg tgcactgcag 70020
tgcaggcatc ggcaggtctg gaacctctg tctggctgat acctgcctct tgetggtaag 70080
gaggccctcg cgggtgccct ggggagctcc tctacctgct ctgtgtgat gtttttct 70140
aagtagaaac tgaagcgtc ctcttccaaa atacagagac tcaactgtgt agtctgtttt 70200

-continued

tgcgttacta ataaaggcgt acctgagact cggtaatttg taaagaaaag aggtttaact 70260
 ggctccccgt tctgcaggct gtacaagcat ggcaccagca tctgctcggc tctgggggag 70320
 gcctcaggga gcttcocagtc atgggtggaag gtgaagggga gcaggagcaa gagatggggg 70380
 aggtcccaga ctcttaacca gctctcttgt gaatgcattg cctcaggggag ggcaccaagc 70440
 ctttcatgag ggacctgtcc cctgaccca gacacctccc acccagcccc acctccaaca 70500
 ctagggatca catttcagca tgagattggg aggggacaga catctaacgg tgttattaac 70560
 gttgcccctg agaattggac ctggctgact tatatctcct ctctggcttt cagatggaca 70620
 agaggaaaga cccttcttcc gttgatatca agaaagtgtc gttagaaatg aggaagtttc 70680
 ggatggggct gatccagaca gccgaccagc tgcgcttctc ctacctggct gtgatcgaag 70740
 gtgccaaatt catcatgggg gactcttccg tgcaggtcag cattgccttt gtttgaatcc 70800
 aggtgtgacc attttaactt ttttgtctt gaaggaggct gtcagttgta aaagtccaaa 70860
 caccgtctgg tgcagggga aatagctacc cttcatgttt aaaatagcta gaaagtgtc 70920
 aaaatgttca ccattgttga ctttgtgcct ttgaagtgtc cacatagaga gcattgatag 70980
 gaagacgaga ctttattttc aaaagatttc atcttccaag tacatggctg cagccctgag 71040
 aggccgagag cccctcgcga agccgtcacc tctgctcatg caaagggatt tcctgacaaa 71100
 ccagccgaag tgaacactaa taggacttcc tcttctgctc ctttcaagga tcagtggaa 71160
 gagctttccc acgaggacct ggagccccc cccgagcata tccccccacc tccccggcca 71220
 cccaaacgaa tcctggagcc acacaatggg aaatgcaggg agttcttccc aaatcaccag 71280
 tgggtgaagg aagagaccca ggaggataaa gactgcccc tcaaggaaga aaaaggaagc 71340
 cccttaaag cgcacccta cggcatcgaa aggtaatatg attgggtccc agcttgttgg 71400
 ggtgagggga aatgactttc tgttctagaa acacacgctg gtactgaaac cctgtggatg 71460
 cagcctcctg ttggcaagca gcgcttccgc atccttgggg aacagggcgc gtggaccaca 71520
 gccactccac tcctggctgc tggaggtccg gtattgggca cagggtggcc gcaggacatg 71580
 agccacttct gtgggcttct agtgccacct tgtggtgctt gttggaatga ggggctcggg 71640
 gccaccgagt agggtttttc tgccccccct gacgacagcg ccctccccc ggtttccgga 71700
 cagtccgaa atgtgatgtc caggctgag tgccctcagt cccacagtg gtccttggg 71760
 gaatgtaacc ttttttatgt ggtcttgatt aaatccatt ttacttctt gcaggttaac 71820
 aaccattatt gagtacctat tgatatgtgt ggtgtactga gttactaga acatgtcccc 71880
 tggctctgt tctagaccat cttgctggga aaaaggcaga cccaaagcat attttgggtg 71940
 gggcccatgg acagtgatgt gatagaggtg tccgctgagg tggtcaggga aggctgcttg 72000
 cagtaggtgg ccgtgcacgg aaagtttga gaatgagcag gtgttagttc cagctggaga 72060
 tgactgcccg ctgtgccctt ggtacctgct ttctggaggg aagttttaag acgtgtgcat 72120
 acttgacca gcagtgttat acatggagaa atttactttg cagcaactct caaaacaagc 72180
 gtgtaaagat gtgtataggt agttgtgtt gttgtggcat tgtttgtagt agtgaanaat 72240
 tagagacagg ccaatgatat aaccagggac ctgatcaatt atgttctctc ccggtgttgg 72300
 gatattctgt agctcttaaa gaatgagatc tgggtgtact gatgtggcca gacattgcaa 72360
 ttgcagtaca tgagaaggca aatcatacag tagtgtgtac accagtgagt cctccagcca 72420
 gataaatcct cacagtgacc agtcgcccag gcacctgtg aaccctaccc tgggtgtggg 72480
 tgctatctga agtacctggg ggaggggggtg acaagtggac ttcaggctga tgtgggccct 72540

-continued

```

ggcctggccc tccctccaag cagagggggc tggctcgtg gaaggttaac atcatccaac 72600
tctgtotaca cgtggcttgt ttttctctag aattcctgcc acaatagcag catccttgcc 72660
attcattttc tccaaagtga gtaaccctc tctgcctct gattoctcag catgagtcaa 72720
gacactgaag ttagaagtgc ggtcgtgggg ggaagtcttc gaggtgcccc ggctgcctcc 72780
ccagccaaag gggagccgtc actgcccag aaggacgagg accatgcact gagttactgg 72840
aagcccttcc tggtaacat gtgcgtggct acggctctca cggccggcgc ttacctctgc 72900
tacagggtat gtttccactg acagacgcgc tggcgagatg ctctgtgca gagagcactg 72960
gccgctagcc cgatggtagg attcagttct gtggtgcctc tgagccagtc tcagaagaaa 73020
cagatcaaag gtttttaag tctggaactg tgggaaggct aacaagagaa ttaaggatcg 73080
atgcactggg gttttaagga gccctctggt cccaagaata taagagtcta atctcagggc 73140
cttaacctat tcaggagtaa gtagagaaaa tgccaaatc gtctgtttct ctctctcttt 73200
ttttttttat tctttgttt ttgaaaaaaa atagagttac aacacattgt tgtttttaac 73260
ctttataaaa agcagctttt tgttatttct ggaacaaaa aaaacaaagt aggcacttat 73320
gaaactttct cataccctta ggtgatgtaa tcagccatat aatttatatt tgatttccca 73380
gggaaggaat cccaaacttt tacgaatgta aactccctg gagaagaggg ttaggacgct 73440
gttgcgctca agccccctc agctgtgtgc aactgagcc aggacagggt ctttgagctt 73500
tcccactata agaagaacag caacaaaagg ccgtctagaa aaacagaacc tgctctgct 73560
tctgtcagg gtgtccccgc tgggtttcca ttgtccttc tccattgctc cctcctgtga 73620
cagccatctt gctcatgtac cagccctcat cccccatcc ccataaatgg gtgtcctcga 73680
ggcctctgcc tgggggctcag aggtcaccac aggggtggcca ttggcatgct aaccctctgt 73740
taattcagag aagtgggctc cacctcattg ggagaagtgc catttcagca gaaattcaca 73800
cgttagacgt gtgttctgt taagtaaggg gaagagagag gactagcctc agagctctgg 73860
ccatggaaat gacctcctaa gactttttcg tggttttaa tattttacct ctttccaggt 73920
ggcatctgag tacatcagat ggttttgcaa aatgcaaaaa atttttctc tggggatgat 73980
ttttggggag agggggctac tgtaaaaaat aaaacaaaa cccctttgc tccctcggag 74040
gttgaagtgt ccgggggggt tggccgggggt catgcatgag gcgacagctc tgcaggtgct 74100
ggctctgggt catctgaact gtttggttc attccagttc ctgttcaaca gcaacacata 74160
gcctgacct cctccactcc acctccacc actgtccgc tctgcccga gagcccagc 74220
ccgactagca ggcagtcgc ggtaggtgag ggcgcggga ccgctagag agccggggcc 74280
cggacggaag ttggttctgc actaaaaacc atcttccccg gatgtgtgct tcacctctca 74340
tccctttact ttttgcctc tccacttga gtaccaaatc cacaagccat tttttgagga 74400
gagtgaaga gagtaccatg ctggcgggc agaggggagg ggcctacacc cgtcttgggg 74460
ctgccccac ccagggtct cctctggagc atcccaggcg ggcggcacgc caacagcccc 74520
cccctgaaat ctgcaggag caactctca ctccatattt atttaacaa tttttcccc 74580
aaaggcatcc atagtgcact agcattttct tgaaccaata atgtattaaa atttttgat 74640
gtcagccttg catcaagggc tttatcaaaa agtacaataa taaatcctca ggtagtactg 74700
ggaatggaag gctttgcat gggcctgctg cgtcagacca gtactgggaa ggaggacggt 74760
tgtaagcagt tgttatttag tgatattgtg ggtaacgtga gaagatagaa caatgctata 74820
atatataatg aacacgtggg tatttaataa gaaacatgat gtgagattac tttgtcccgc 74880
ttattctct cctgttctc tgctagatct agttctcaat cactgctccc ccgtgtgtat 74940

```

-continued

tagaatgcat	gtaaggtcct	cttgtgtcct	gatgaaaaat	atgtgcttga	aatgagaaac	75000
tttgatctct	gcttactaat	gtgccccatg	tccaagtcca	acctgectgt	gcatgacctg	75060
atcattacat	ggctgtgggt	cctaagcctg	ttgctgaagt	cattgtcgct	cagcaatag	75120
gtgcagtttt	ccaggaatag	gcatttgcct	aattcctggc	atgacactct	agtgacttcc	75180
tggtagagcc	cagcctgtcc	tggtacagca	gggtcttgc	gtaactcaga	cattccaagg	75240
gtatgggaag	ccatattcac	acctcacgct	ctggacatga	tttagggaag	cagggacacc	75300
ccccgcccc	caccttggg	atcagcctcc	gccattccaa	gtcaaacctc	ttcttgagca	75360
gacctgatt	tggaagagag	gcacctgctg	gaaaccacac	ttctgaaac	agcctgggtg	75420
acggctcctt	aggcagcctg	ccgcccgtct	tgtcccgggt	caccttgccg	agagaggcgc	75480
gtctgcccc	ccctcaaacc	ctgtggggcc	tgatggtgct	cacgactctt	cctgcaaagg	75540
gaactgaaga	cctccacatt	aagtggcttt	ttaacatgaa	aaacacggca	gctgtagctc	75600
ccgagctact	ctcttgccag	cattttcaca	ttttgccttt	ctcgtggtag	aagccagtac	75660
agagaaatc	tgtggtggga	acattcgagg	tgtcaccctg	cagagctatg	gtgaggtgtg	75720
gataaggctt	aggtgccagg	ctgtaagcat	tctgagctgg	gcttgttgtt	tttaagtctt	75780
gtatatgtat	gtagtagttt	gggtgtgtat	atatagtagc	atttcaaaat	ggacgtactg	75840
gtttaacctc	ctatccttgg	agagcagctg	gctctccacc	ttgttacaca	ttatgttaga	75900
gaggtagcga	gctgctctgc	tatatgcctt	aagccaatat	ttactcatca	ggtcattatt	75960
ttttacaatg	gccatggaat	aaaccatttt	tacaaaaata	aaaacaaaaa	aagcaagggtg	76020
ttttggtata	ataccttttc	aggtgtgtgt	ggatacgtgg	ctgcatgacc	gggtgggtgg	76080
gggggagtg	ctcaggtctt	tctgtgacct	cacagaactg	tcagactgta	cagttttcca	76140
acttgccata	ttcatgatgg	gtttgcattt	tagctgcaac	aataaaat	ttttctaag	76200
aacatgaatt	tgggggtgct	cccatttttt	tctttgctta	atagagctaa	accaggatga	76260
gtaactcctg	tttctttota	tccctgctga	tgtgaaacag	atgttgtcaa	tcagctgggg	76320
ttagagtttt	ccacttctaa	gaattaacct	cagcatcctt	gcattgcccag	caccctcagg	76380
ctggagcgc	ttccttgact	gtgagcttgt	tgaacacctt	aggcctcagc	ccatttctct	76440
cccaaattga	cgctttgctt	gtgtagggcc	ctcagataac	ttaacaaact	taccagtgtt	76500
gtttgaagaa	cagtgttttg	agttgtaatc	tcaaaacct	atcccttacc	caattacctg	76560
taagacacaa	tggttaccac	atctcagtag	gtaaagtcca	cttgatatag	aattgactta	76620
gaaataagac	agattagtag	agtttttcat	ttgtgtacaa	aattaacaaa	tgtaaatcc	76680
ccccaaagt	atttttttga	ctttttgaag	taattttgga	cttgcaaaat	gttgccaana	76740
tagtacgaag	agttccccag	taccctcgaa	gtttctcga	ctgtttcaaa	gctggctgca	76800
ggcccagcct	catgagactg	ggaagaggac	aggctgtggt	catgtggacc	cacaggggcc	76860
tggggctgca	gaagtctag	tggcttccac	catttcagg	ataaaaaagg	gcatctaagc	76920
tttcaagaag	aggaggatg	ctctagggca	gcggtoceca	accttttctg	gcaccaggaa	76980
ccggttccat	ggaagacaat	tttttcacag	gcctgggggt	ggtaggggat	ggttttggga	77040
tagaaacttc	cacctcagat	catcaggcat	cagattctca	taaggagctt	gcaacctgat	77100
ctcttgaca	cattcagttc	acaatagggt	tcacgctcct	aagagaacct	gatgctgcag	77160
ctgatctaac	aggagatgga	gctcaggtgg	tcatgctcag	tcgctcgcca	ctcacctcct	77220
gccatgcagt	ccagttccta	acaggcctca	gaccagtacc	ggctctggtg	ctgggggttg	77280

-continued

```

aggaccctg ctctaggctg gtactgctga tgcttaaaaa gagagggtt gccagaaatc 77340
agatgggaca aaagggcaaa ggccgtgcca cagagtgcc atatagggga gagcacgcct 77400
ggagccttcg agagcatgca gagaagcctg gagactgcat ttaccggagc tgctgcctga 77460
ggccaccctc caagtgtccc cacagcgcac cacaagacca caggagtgc ctcctcactg 77520
gcaggtatct ggggaaacaa ctgctgtcta ctcttttggg taaaaagtga aacaccaata 77580
gtttaattga aatttcagaa aattgaacat atgaacaagg caaataaata ctaagtaagt 77640
taaaaacaca aaatatgtcc aggaagtatc gatgagaatg ttcaagttaa agttctccaa 77700
tgccattgct acagcaacct caaacctag gttctctctg cactattaac acagacatct 77760
caggacatgg tttgcttttt ttttaagactt aaataggaaa ctaatttttc tttctttaa 77820
gcaattgctg tcttcagtga actctttctt taggccagtt gatggcttct tagcagtta 77880
ttgacgagat cctagggtag cttccgaagc tgggttgatt gattgcattt gggtgcgat 77940
ggccaaagtg agtggcccta ctgcctgtgc tgctcagggc tcctgggctg atgtggtggc 78000
t 78001

```

<210> SEQ ID NO 3

<211> LENGTH: 4522

<212> TYPE: DNA

<213> ORGANISM: Macaca mulatta

<400> SEQUENCE: 3

```

gcggtgctga gttccggctg ccggttgaca tgaagaagcc gcggcgctga gggcgcggt 60
agcggcagga gtcggtgctt gctgaggacc tcagggctaa gagcgcgacg cggcctagag 120
cggcggactg cgcagtgggc cgagaaggag gcgcagcagc cgccctggcc cgctcatggag 180
atggaaaagg agttcgagca gatcgacaag tccgggagct gggcggccat ttaccaggat 240
atccgacacg aagccagtga cttcccatgt agagtggcca agcttcctaa gaacaaaaac 300
cgaaataggt acagagacgt cagtcccttt gaccatagtc ggattaaact acatcaagaa 360
gataacgact atatcaacgc tagtttgata aaaatggaag aagccaaaag gagttacatc 420
cttaccaggg gccctttgcc taacacatgc ggtcactttt gggagatggt gtgggaacag 480
aaaagcaggg gtgtcgtcat gctcaacaga gtgatggaga aaggttcggt aaaatgcgca 540
cagtactggc cacaaaaaga agaaaaagaa atgatctttg aagacacaaa cttgaaatta 600
acattgatct ctgaagatat caaatcatat tatacagtgc gacagctaga attgaaaaac 660
cttacaaccc aagaaactcg agagatctta catttccact ataccacatg gcctgacttt 720
ggagtccccg aatcgccagc ctcatctctg aactttcttt tcaaagtccg agagtccagg 780
tcaactcagc cggagcatgg gcccgctgtg gtgcaactgca gtgcgggtat cggcaggtct 840
gggaccttct gtctggtgta tacctgcctc ttgctgatgg acaagaggaa agacccttct 900
tccgttgata tcaagaaagt gctattagaa atgaggaagt ttcggatggg gctgatccag 960
acagcagacc agctgcgctt ctctacttg gctgtgatcg aaggtgcca attcatcatg 1020
gggactcct ctgtgcagga tcagtggaag gagctttccc acgaggacct ggagccccc 1080
cccagcacg tccccccacc tccccggcca cccaaacgaa tcctggagcc acacaatggg 1140
aatgcaggg agttcttccc aaatcaccag tgggtgaagg atgagaccca ggaggataaa 1200
gactgcccc tcaaggaaga aacaggaagc cccttaaatg ccgcacccta cagcatggaa 1260
agcatgagtc aagacactga agttagaagt cgggtcgtgg ggggaagtct tcgaggtgcc 1320
caggctgcct ccctagccaa aggggagccg tcaccgccta agaaggagga ggaccatgca 1380

```

-continued

ctgagtcact	ggaagccctt	cctggtaaac	atgtgtgtgg	ctacggtoct	cacggccggc	1440
gcgtacctct	gctacaggg	atgtttccac	tgacagacgc	gctggcgaga	tgctcgtgtg	1500
cagagagcac	tggccgctag	cccgatggta	ggattcagtt	ctgtggcgca	tctgagccag	1560
tctcagaaga	aacagatcaa	aggtttttaa	agtctggaac	tgtggaaggg	ctaacgagaa	1620
ttaaggatcg	atgcactggg	gttttaagga	gccctctggt	cccaagaata	taagagtcta	1680
atctcagggc	cttaacctat	tcaggagtaa	gtagagaaaa	tgccaaatac	gtctgtctct	1740
ctctctctct	ctttttttta	tccctttgtt	tttgaaaaaa	aatagaatta	caacacattg	1800
ttgtttttaa	cctttataaa	aagcagcttt	ttgttatttc	tggaaaaaaa	acaaactagg	1860
cacttaatga	aactttctcg	tacccttagg	tgatgtaatt	agctataata	tttatatttg	1920
atttcccagg	gaaggaatcc	caaactttta	cgaatgtaa	ctcccttggg	gaagaggggt	1980
aggacgctct	tgcgctcaag	ccccctcag	ctgtgtgcac	actgagccag	gacagggctct	2040
ttgagctttc	ccactgtaag	aacagcaaca	caaggccgtc	tagagaaaca	gaacctgcct	2100
ctgcttctgc	tcagggtgtc	cgttgtcctt	tctccattgc	tccctcctgt	gacagccatc	2160
ttgctcatgt	accagccctc	atcaccocat	tcccataaaa	gagtgtcctc	gaggcctctc	2220
cctgggggtc	agaggteacc	acaggggtgg	cctcagcatg	tcagccctct	gttaattcag	2280
aggagtgggc	tccacctcat	tgggagaagt	gccatttcag	cagaaatcca	cacgttagac	2340
gtgtgttctg	gttaagtaag	gggaagagag	gactagcctc	agagctctgg	ccatggaaat	2400
gacctcctga	gactttttca	tcgttttaaa	tattttacct	cttttcaggt	ggccatctga	2460
gtacatcaga	tggttttgca	aaatgcaaac	aattttttcc	ttgggggtga	tttttgggga	2520
gaaggggcta	ctgtaaaaaa	taaaaccaa	accccccttg	ctccctcgga	ggttgaagtt	2580
gccggggggg	gtggccgggg	tcgtgcatga	ggcgacagct	ctgcgggtgc	gggtctgggg	2640
tcctctgaac	tgtttggttt	cattccagtt	cctgttcaac	agcaacacat	agcctgacce	2700
tccctcactc	cacctccacc	cactgtccgc	ctctgcccgc	agagcccacg	cccgactagc	2760
aggcatgccg	cggtaggtaa	gggcccggg	accgcgtaga	gagccgggcc	ccggacggac	2820
gttggttctg	cactaaaaac	catcttcccc	ggatgtgtgt	ctcaccctc	atccttttac	2880
tttttgcccc	ttccactttg	agtaccaaat	ccacaagcca	tttttgagg	agagtgaaag	2940
agtaccatgc	tggcggcgca	gagggagggg	gcctgcacct	gtctggaggg	tcgccccacc	3000
cagggctccc	tcctggagca	tcccaggcag	gtggtacacc	aacagcccc	ttgactcgca	3060
gggagcaact	ctccactcca	tatttattta	aacaattttt	ccccaaaggt	gtccatagtg	3120
cactagcatt	ttcttgaacc	aataatgtat	taaaaatttt	tgatgtcagc	cttgcatcaa	3180
gggctttatc	aaaaagtaca	ataataaatc	ctcaggtagt	actgggaatg	gaagactttg	3240
ccatgggcct	gctgcgtcag	accagtactg	ggaaggagga	cggttgtaag	gcagtcgtta	3300
tttagtgata	ttgtgggtaa	cgtgagaaga	tagaacaatg	ctataatata	taatgaacac	3360
gtgggtattt	aataagaaac	atgatgtgag	attactttgt	cccgttatt	ctctccctg	3420
ttatctgeta	gatctagttc	tcaaatcact	gtccccctgt	gtgtactaga	atgcatgtaa	3480
ggctctcttg	tgtcctgatg	aaaaatatgt	gcttgaaatg	agaaactttg	atctctgctt	3540
actaatgtgc	cccatgtcca	agtccaacct	gcctgtgcat	gacctgatca	ttacatggct	3600
gtggttccta	agcctgttgc	tgaagtogtt	gtcactcagc	aataggggtc	agttttccag	3660
gaataggcat	ttgcctcatt	cctggcctga	cactctagtg	acttccctgt	gagaccggc	3720

-continued

```

ctgtcctggt gcagcagggt ctcgctgtaa ctcagacatt ccaagggtat ggaagccat 3780
attcacacct cacgctctgg acattattta ggcaagcagg gacaccccc gccccacc 3840
tttgggatca gcctctgcca ttccaagtca gcaactctct tgagcagact gtgatttga 3900
agagaggcaa ctgctgga aa ccacacttct tgaaacagcc tgggtgacgg tcctttagc 3960
agcctgccgc cgtctccgtc tgggttcacc ttgccgagag aggcgcgtct gccccaccct 4020
cgaaccctgt ggggcctgat ggtgctcag actcttctcg caaagggaa tgaagacct 4080
cacattaagt ggctttttaa caagaaaaac acggcagctg tagctcccga gctactctct 4140
tgccagcatt ttcacatttt gcctttctcg tggtagaagc cagtacagag aaattctgtc 4200
gtgggaacat tcgaggcatc accccataga gctgtggtga ggtgtggata aggcttaggt 4260
gccaggctgt aagcattctg agctgggctt gttgttttta agtcctgtat atgtatgtag 4320
tagtttgggt gtgtatatat agtagcattt caaaatggac gtactggttt aacctctat 4380
cctcggagag cagctggctc tccacctgt tacacgtatg ttagagaggt agcgagctgc 4440
tctgctatat gccttaagcc aatatttact catcaggtca ttatttttta caatggccat 4500
ggaataaacc atttttacaa aa 4522

```

```

<210> SEQ ID NO 4
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 4

```

```

ttgtcgatct gctcgaactc 20

```

```

<210> SEQ ID NO 5
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 5

```

```

gacttgcga tctgctcga 20

```

```

<210> SEQ ID NO 6
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 6

```

```

cccggacttg tcgatctgct 20

```

```

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 7

```

```

gtcctccggac ttgtcgatct 20

```

```

<210> SEQ ID NO 8
<211> LENGTH: 20

```

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 8

ccagctcccg gacttgctga 20

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 9

ggcaccttcg atcacagcca 20

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 10

gtctcttcca ctgatectgc 20

<210> SEQ ID NO 11
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 11

ggtcatgcac aggcaggttg 20

<210> SEQ ID NO 12
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 12

aggtcatgca caggcaggtt 20

<210> SEQ ID NO 13
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 13

gatcaggtca tgcacaggca 20

<210> SEQ ID NO 14
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 14

-continued

tgatcaggtc atgcacaggc 20

<210> SEQ ID NO 15
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 15

acccttgaa tgtctgagtt 20

<210> SEQ ID NO 16
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 16

cccataccct tggatgtct 20

<210> SEQ ID NO 17
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 17

tcccataccc ttggaatgtc 20

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 18

ttccataacc cttggaatgt 20

<210> SEQ ID NO 19
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 19

tattccatgg ccattgtaa 20

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 20

ttattccatg gccattgtaa 20

<210> SEQ ID NO 21
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 21

tttattccat ggccattgta 20

<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 22

gtttattcca tggccattgt 20

<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 23

ggtttattcc atggccattg 20

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 24

tggtttattc catggccatt 20

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 25

atggtttatt ccatggccat 20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 26

aatggtttat tccatggcca 20

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 27

aaatggttta ttccatggcc 20

-continued

<210> SEQ ID NO 28
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 28

aaaatggttt attccatggc 20

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 29

aaaaatggtt tattccatgg 20

<210> SEQ ID NO 30
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 30

aggaggtcat ttccatggcc 20

<210> SEQ ID NO 31
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 31

ggtcatttcc atggccagag 20

<210> SEQ ID NO 32
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 32

ggaggtcatt tccatggcca 20

<210> SEQ ID NO 33
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 33

ctggtttaac ctcctatcct tgga 24

<210> SEQ ID NO 34
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 34
cagagcagct cgctacctct ct 22

<210> SEQ ID NO 35
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 35
cagctggctc tccacctgtg tacacattat gt 32

<210> SEQ ID NO 36
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 36
ggagttcgag cagatcgaca a 21

<210> SEQ ID NO 37
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 37
ggccactcta catgggaagt c 21

<210> SEQ ID NO 38
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 38
agctgggcgg ccattacca ggat 24

<210> SEQ ID NO 39
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 39
tattccatgg ccattgta 18

<210> SEQ ID NO 40
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 40
ttattccatg gccattgt 18

<210> SEQ ID NO 41

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 41

tttattccat ggccattg 18

<210> SEQ ID NO 42
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 42

gtttattcca tggccatt 18

<210> SEQ ID NO 43
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 43

ggtttattcc atggccat 18

<210> SEQ ID NO 44
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 44

tggtttattc catggcca 18

<210> SEQ ID NO 45
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 45

atggtttatt ccatggcc 18

<210> SEQ ID NO 46
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 46

aatggtttat tccatggc 18

<210> SEQ ID NO 47
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 47

-continued

aaatggttta ttccatgg 18

<210> SEQ ID NO 48
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 48

atggtttatt ccatgg 16

<210> SEQ ID NO 49
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 49

tttattccat ggccat 16

<210> SEQ ID NO 50
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 50

gcggttgctc ttctctctgc gtttttt 27

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 51

gaccagctgc gcttctccta 20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Primer

<400> SEQUENCE: 52

cagaggagtc ccccatgatg 20

<210> SEQ ID NO 53
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 53

ttggctgtga tcgaaggctgc caaa 24

<210> SEQ ID NO 54
<211> LENGTH: 19
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 54

gggccctttg cctaacaca

19

<210> SEQ ID NO 55
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 55

cgacaccctt gcttttctg

19

<210> SEQ ID NO 56
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Probe

<400> SEQUENCE: 56

cggtcacttt tgggatgg tgtgg

25

What is claimed is:

1. A method of treating diabetes in a subject comprising administering to the subject a pharmaceutical composition suitable for parenteral administration to an animal comprising an aqueous solution, said aqueous solution comprising:

- a pharmaceutically acceptable carrier or diluent; and
- a single stranded modified oligonucleotide targeted to PTP1B consisting of 20 linked nucleosides [having] consisting of a nucleobase sequence consisting of SEQ ID NO: 26, or salt thereof,

wherein the carrier or diluent is sterile and the aqueous solution is suitably viscous for parenteral administration and wherein the composition is administered parenterally, thereby treating diabetes in the subject.

2. The method of claim 1, wherein the aqueous solution suitably viscous for parenteral administration has a viscosity level less than 40 centipoise (cP).

3. The method of claim 2, wherein the parenteral administration is subcutaneous injection.

4. The method of claim 2, wherein the parenteral administration is intravenous infusion.

5. The method of claim 1, wherein the 20 linked nucleosides of the single stranded modified oligonucleotide [comprises] consist of:

- a gap segment consisting of ten linked deoxynucleosides;
- a 5' wing segment consisting of five linked nucleosides; and
- a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine of the single stranded modified oligonucleotide is a 5-methylcytosine.

6. The method of claim 5, wherein the aqueous solution suitably viscous for parenteral administration has a viscosity level less than 40 centipoise (cP).

7. The method of claim 6, wherein the aqueous solution comprises the single stranded modified oligonucleotide targeted to PTP1B at a concentration of about 165-185 mg/mL.

8. The method of claim 7, wherein the aqueous solution has a temperature of about 25° C.

9. The method of claim 8, wherein the parenteral administration is subcutaneous injection.

10. The method of claim 8, wherein the parenteral administration is intravenous infusion.

11. The method of claim 1, wherein the pharmaceutically acceptable carrier or diluent is water.

12. The method of claim [5] 11, wherein the 20 linked nucleosides of the single stranded modified oligonucleotide [comprises] consist of:

- a gap segment consisting of ten linked deoxynucleosides;
- a 5' wing segment consisting of five linked nucleosides; and
- a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine of the single stranded modified oligonucleotide is a 5-methylcytosine.

13. The method of claim 12, wherein the aqueous solution suitably viscous for parenteral administration has a viscosity level less than 40 centipoise (cP).

14. The method of claim 13, wherein the aqueous solution comprises the single stranded modified oligonucleotide targeted to PTP1B at a concentration of about 165-185 mg/mL.

15. The method of claim 14, wherein the aqueous solution has a temperature of about 25° C.

16. The method of claim 15, wherein the parenteral administration is subcutaneous injection.

17. The method of claim 16, wherein the parenteral administration is intravenous infusion.

193

18. The method of claim 1, wherein the subject is human.
19. The method of claim 18, wherein the diabetes is Type II diabetes.
20. The method of claim 19, wherein administering the [compound] *composition* decreases blood glucose levels in the human.
21. The method of claim 12, wherein the subject is human.
22. The method of claim 21, wherein the diabetes is Type II diabetes.
23. The method of claim 22, wherein administering the [compound] *composition* decreases blood glucose levels in the human.
24. The method of claim 13, wherein the subject is human.
25. The method of claim 24, wherein the diabetes is Type II diabetes.
26. The method of claim 25, wherein administering the [compound] *composition* decreases blood glucose levels in the human.
27. A method of decreasing blood glucose levels in a subject comprising administering to the subject a compound consisting of a single stranded modified oligonucleotide targeted to PTP1B consisting of 20 linked nucleosides [having] *consisting of* a nucleobase sequence consisting of SEQ ID NO: 26, wherein the 20 linked nucleosides of the single stranded modified oligonucleotide [comprises] *consist of*:
- a gap segment consisting of ten linked deoxynucleosides;
 - a 5' wing segment consisting of five linked nucleosides; and
 - a 3' wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine of the *single stranded* modified oligonucleotide is a 5-methylcytosine; and wherein the compound is administered to the subject parenterally, thereby decreasing blood glucose levels in the subject.
28. The method of claim 27, wherein the subject is human.
29. The method of claim 28, wherein the human has diabetes.
30. The method of claim 29, wherein the diabetes is Type II diabetes.
31. The method of claim 29, wherein administering the compound treats diabetes.
32. The method of claim 30, wherein administering the compound treats diabetes.
33. A single stranded modified oligonucleotide consisting of 20 linked nucleosides [having] *consisting of* a nucleobase sequence consisting of SEQ ID NO: 26 [and comprising],

194

- wherein the 20 linked nucleosides of the single stranded modified oligonucleotide consist of:
- a gap segment consisting of ten linked deoxynucleosides;
 - a 5' wing segment consisting of five linked nucleosides; and
 - a 3' wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine of the *single stranded* modified oligonucleotide is a 5-methylcytosine.
34. A compound [consisting of] *comprising* a pharmaceutically acceptable salt of [the single-stranded] *a single stranded* oligonucleotide [of claim 33] *consisting of* 20 linked nucleosides consisting of a nucleobase sequence consisting of SEQ ID NO: 26, wherein the 20 linked nucleosides of the single stranded modified oligonucleotide consist of:
- a gap segment consisting of ten linked deoxynucleosides;
 - a 5' wing segment consisting of five linked nucleosides; and
 - a 3' wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine of the *single stranded* modified oligonucleotide is a 5-methylcytosine.
35. The compound of claim 34, wherein the pharmaceutically acceptable salt is a sodium salt.
36. The compound of claim 34, wherein the pharmaceutically acceptable salt is a potassium salt.
37. A compound consisting of a sodium salt of a single stranded modified oligonucleotide consisting of 20 linked nucleosides [having] *consisting of* a nucleobase sequence consisting of SEQ ID NO: 26 [and comprising], wherein the 20 linked nucleosides of the single stranded modified oligonucleotide consist of:
- a gap segment consisting of ten linked deoxynucleosides;
 - a 5' wing segment consisting of five linked nucleosides; and
 - a 3' wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine of the *single stranded* modified oligonucleotide is a 5-methylcytosine.

* * * * *